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 Abstract 
Studies on RNA Regulation: From Enhancer RNAs to RBBP6 Isoform3 
Yaqiong Chen 
 
This dissertation contains two separate yet interconnected pieces of work, which shed light 
on the complicated RNA regulatory mechanism. The first part, as the main focus of the thesis, 
characterizes a large pool of human polyadenylated enhancer RNA under deficient nuclear 
surveillance conditions, and investigates their metabolism mechanisms.  The second part 
elucidates the dynamic localization mechanism of RBBP6 isoform3, which inhibits pre-mRNA 3’ 
processing by completing with RBBP6 isoform1.  
Despite being composed of approximately 3 billion base pairs, only 1 to 2% of the human 
genome codes for proteins. The non-coding DNA regions can however function as transcription 
units and generate non-coding RNAs such as enhancer-derived RNAs, or eRNAs, that play crucial 
roles in gene expression regulation, cell differentiation, development, and diseases. Previous 
studies have suggested that most eRNAs are transcribed by RNA polymerase II (RNAP II), but 
not polyadenylated. In Chapter 3, I identify a large fraction of polyadenylated enhancer RNAs 
under deficient nuclear surveillance conditions via genome-wide analyses, and explore their 
biogenesis and degradation mechanisms. I find that the Integrator complex plays an important role 
in polyadenylated eRNA biogenesis, and that their exosome-dependent degradation requires two 
cofactor complexes containing the RNA helicase Mtr4: the PAXT/PPC complex and the NEXT 
complex. Additionally, the canonical poly(A) polymerases PAP-α and PAP-γ play a major role in 
the 3’ end processing of pA+ eRNA. Finally, I show that under deficient nuclear surveillance 
  
conditions, pA+ eRNAs accumulate in the cytoplasm and associate with polysomes, suggesting 
that at least some might have translation potential.  
I also contributed to the discovery of two novel complexes both containing the RNA 
helicase Mtr4, which is a master player of the nuclear surveillance system. Mtr4 and ZFC3H1 form 
the PAXT/PPC complex, which facilitates the turnover of polyadenylated nuclear RNAs, including 
prematurely terminated RNAs (ptRNAs), upstream antisense RNAs (uaRNAs), and eRNAs (see 
the paper in Appendix II). Mtr4 also associates with NRDE2 to form a complex, functioning in the 
DNA damage response pathway (see the paper in Appendix III). These works provide additional 
insights into the complexity and significance of the RNA helicase Mtr4. 
In the second part of the thesis, presented in Chapter 4, I studied a polyadenylation factor 
known as Retinoblastoma-binding protein 6 (RBBP6). RBBP6 was initially identified as a large 
multidomain protein, interacting with tumor suppressors p53 and Rb. Later, its diverse roles were 
uncovered in cell cycle progression, apoptosis, nucleic acid metabolism, differentiation, and 
mRNA processing. RBBP6 protein has four isoforms, among which the shortest isoform, iso3, has 
only one domain: the DWNN (Domain With No Name) domain. The DWNN domain displays 
high similarities with ubiquitin, implying its function as a novel ubiquitin-like modifier. However, 
I show that the DWNN domain is actually not a ubiquitin-like modifier, but is itself ubiquitinated. 
Moreover, the monoubiquitylation of iso3 can facilitate its localization at chromatin. Additionally, 
I find that the C-terminal tail of iso3 also plays a role in iso3 chromatin localization, presumably 
by interacting with other factors of the polyadenylation machinery. Pulldown experiments of iso3 
followed by mass spectrometry identified Importin7 as an iso3-interacting factor that assists its 
cytoplasmic retention. Our results identified novel mechanisms for the dynamic localization of 
RBBP6 iso3, which shed light on the role of iso3 in mRNA 3’ processing and disease. 
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This thesis is divided into five chapters. Chapter 1 is a general introduction including the 
recent progress and the future perspectives of the enhancer RNA research, a brief summary of all 
Mtr4-containing complexes with a focus on the exosome adaptor complexes, as well as an 
overview of the functional significance of the RBBP6 protein. Chapter 2 is a published review 
article I co-authored, summarizes the current knowledge of the nuclear RNA surveillance system 
and discusses the physiological significance of the nuclear RNA exosome in mammalian 
biological processes. Chapter 3 is a manuscript about the identification of a large pool of human 
polyadenylated enhancer RNAs as well as the characterization of their metabolism mechanisms. 
Chapter 4 is a manuscript, elucidating the dynamic subcellular localization mechanism of RBBP6 
isoform3. Chapter 5 provides a general discussion as well as future directions of the works 
presented in the thesis. Appendix I shows the protein sequences of two RBBP6 derivatives, whose 
peptide cleavage merits further study, as discussed in Chapter 5. Appendix II and III are two 
published articles I co-authored, about the discovery and function characterization of the 















This Chapter presents a general introduction of three parts: Part I summarizes the discovery 
and recent progress of enhancer RNA research; Part II introduces the key Mtr4-containing 
complexes in the nuclear surveillance pathway; those two parts, together with Chapter 2, provide 
comprehensive background knowledge for the works in Chapter 3. Finally, Part III reviews the 
functional studies and physiological significance of the RBBP6 protein, whose isoform 3 
subcellular localization mechanism is scrutinized in Chapter 4. 
 
Part I. Enhancer RNAs 
The advent of deep-sequencing techniques has largely expanded our knowledge about the 
transcriptome in cell. Numerous nonprotein-coding DNA elements in the genome is found to be 
transcribed, which create a much larger RNA repertoire than mRNAs. In this thesis, I study an 
abundant class of unstable RNAs transcribed by RNA polymerase II (RNAP II) from 
transcriptional enhancers, known as enhancer RNAs, or eRNAs. Here, I briefly summarize our 
current understanding of eRNAs and their biological functions. 
 
The Characterization of Enhancers 
Enhancers were originally defined as DNA elements that activate promoter transcription, 
characterized by a lack of orientation and distance requirements from target genes (Serfling et al., 
1985). The first enhancer was discovered in SV40 viral DNA, as a tandem 72bp DNA fragment. 
It can enhance the transcription of a reporter gene by ~200-fold, irrespective of its orientation or 
distance from the gene (Banerji et al., 1981; Moreau et al., 1981). Later, with the remarkable 
development of next-generation sequencing technology, scientists were able to annotate putative 
enhancers on a genome-wide scale, based on the classic features of enhancers: DNase I 
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hypersensitivity; related histone modification such as higher H3K4me1/H3K4me3 ratio and 
histone acetylation; high binding density of transcriptional co-activators (e.g. CBP/p300) as well 
as multiple transcription factors (TFs) (reviewed by Calo and Wysocka, 2013; Kleftogiannis et al., 
2016; Shlyueva et al., 2014). The use of epigenomic markers in enhancer annotation has greatly 
expanded the pool of putative enhancers in humans, whose number varies between 400,000 to 1 
million, almost ten-fold of the number of coding genes (Calo and Wysocka, 2013; Rivera and Ren, 
2013; Shlyueva et al., 2014). However, only epigenomic markers alone were far from accurate in 
terms of annotating functional enhancers. For example, the DNase I hypersensitive sites also enrich 
in other regulatory DNA regions such as promoters; TFs bind to a variety of regulatory elements 
besides enhancers (Buecker and Wysocka, 2012); the H3K4me1/H3K4me3 ratio failed to identify 
highly transcribed enhancers(Core et al., 2014; Dao et al., 2017). I discuss the transcripts derived 
from enhancers regions, which can be used as another criterion to predict active enhancers in the 
next section.   
It’s noteworthy that there is a group of enhancers, named as “super enhancers” particularly 
interesting. They are defined by unusually high level of TF and mediator binding, and often cluster 
in close genomic proximity (Whyte et al., 2013). Those enhancers not only boost the expression 
of target genes, but also exhibit robust eRNA transcription (Hah et al., 2015; Liu et al., 2014). 
Many important findings about eRNA were revealed through studying super enhancer, which are 
elaborated below.   
 
Enhancer as non-coding RNA transcription units  
The human genome consists of approximately 3 billion base pairs, but only 1 to 2 % of it 
are coding genes. Nevertheless, non-coding DNA can be transcribed and generates non-coding 
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RNAs, including for example enhancer-derived RNAs, or eRNAs. Early studies showed sporadic 
examples of extragenic and intergenic transcription (Ashe et al., 1997; Masternak et al., 2003; 
Rogan et al., 2004; Tuan et al., 1992). Nevertheless, not until the advent of large-scale 
transcriptome profiling and RNA polymeras II (RNAP II) ChIP-seq analyses, were scientists able 
to obtain genome-wide evidence that enhancers are widespreadly transcribed, and generates 
largely non-polyadenylated and bidirectional eRNAs (De Santa et al., 2010; Kim et al., 2010). 
Further studies using the cap analysis of gene expression (CAGE) technique, which analyze m7G 
capped RNA in a transcriptome, showed that eRNAs are generally capped on their 5’ end, and 
estimated the number of eRNA-producing enhancers in humans to be ~40,000-65,000 (Andersson 
et al., 2014a; Arner et al., 2015). Notably, a recent pan-cancer analysis using the TCGA database 
found that the maximum number of eRNAs detected in any given cancer type is less than 10,000 
(Chen et al., 2018), which is less than 1/4 of the total enhancers defined by CAGE. This implies 
that despite over 40,000 enhancers can generate transcripts, only a fraction of enhancers is actually 
active in a given cancer. This is no surprising, given that one typical feature of enhancer expression 
is its high spatio-temporal and tissue specificity. 
Studies have found that eRNAs can serve as a signature of functional enhancers, given the 
finding that enhancers that generate eRNAs, display a higher affinity of transcriptional co-
activators, greater chromatin accessibility, and higher enrichment of active histone markers (Hah 
et al., 2013; Kim et al., 2010; Zhu et al., 2013). It is possible that some non-transcribing enhancers 
might produce eRNA, whose level either is too low to be detected, or is degraded rapidly. 
Intriguing, the nascent RNA sequencing analyses were able to identify enhancers merely based on 
their transcription level, instead of epigenetic markers (Core et al., 2014; Henriques et al., 2018). 
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An intriguing question is: are eRNAs just transcriptional noise after enhancer activation, 
or do they exert regulatory functions to instruct the activation of promoter? It’s possible that at 
least some eRNAs might be byproducts of unspecific transcription of RNAP II: On the one hand, 
RNAP II has been found to constantly scans the genome randomly (Struhl, 2007); on the other 
hand, the high chromatic accessibility of active enhancers allows RNAP II to load conveniently. 
Moreover, the low expression level of eRNAs can be another evidence of non-productive 
“scanning” of RNAP II.  Nevertheless, a genome-wide analysis of both human and mouse covering 
a wide range of tissues and biological stimuli, discovered that eRNAs, temporally preceding the 
mRNAs, respond to the stimuli. In other words, enhancer transcription represents the earliest 
transcription event, when stimuli or differentiation cues are given (Arner et al., 2015). This result 
indicates that RNAP II transcriptional machinery might first load on the enhancer regions, rather 
than promoters, and subsequently produces eRNAs as the earliest responses to stimuli. It is very 
likely that eRNAs play a role in transcriptional machinery recruiting or promoter activation. 
Next, I discuss how enhancer regulates promoters, by looking into the well-established 
enhancer-promoter looping model. 
 
Enhancer-promoter looping model 
A number of studies have shed light on the intriguing architectural and functional 
similarities  between enhancers and promoters, such as enrichment of general TFs (e.g., TATA-
binding protein) and serine 5-phosphorylated RNAP II, DNase I hypersensitivity, related histone 
modification patterns, and bidirectional transcription (Core et al., 2014; Furlong and Levine, 2018; 
Kim et al., 2010; Kim and Shiekhattar, 2015; Whalen et al., 2016). Those similarities further 
backed the enhancer-promoter looping model, which has been a widely accepted mechanism for 
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enhancers to regulate promoters. As shown in Figure 1-1, enhancer and promoter regions are in 
direct contact with each other. This reflects association of TFs bound to enhancers (Levine, 2010) 
with factors at the promoter, with this association facilitating gene activation (Bulger and Groudine, 
2011; Furlong and Levine, 2018) and allowing bidirectional exchange of components of the 
transcriptional machinery (Lam et al., 2014; Li et al., 2016). Moreover, a recent study found that 
some bidirectional enhancer can act as weak promoters, while bidirectional promoters act as strong 
enhancers during Drosophila embryogenesis (Mikhaylichenko et al., 2018). This observation 
further demonstrated the architectural and functional similarities between promoters and enhancers. 
Despite the remarkable similarities between those two DNA elements, we also note that 
there are distinct sets of TFs preferentially associates with enhancers and promoters (Consortium, 
2012; Core et al., 2014). For example, enhancers show preferences to recruit certain lineage-
determining and signal-regulated TFs, such as oestrogen receptors (reviewed by Spitz and Furlong, 
2012). This echoes the high spatio-temporal specificity of enhancer activation. 
Another evidence for the enhancer-promoter interaction is made possible by the 
chromosome conformation capture (3C) techniques, which analyzes the contact frequencies 
between selected genomic sites using biochemical crosslinking (de Wit and de Laat, 2012; Denker 
and de Laat, 2016). Studies using 3C have confirmed the existence of long-range interactions 
between enhancers and promoters (Lee et al., 2015; Sanyal et al., 2012; Zhang et al., 2013). 
Nevertheless, we note that the results of 3C and its modified versions are not always consistent 
with direct observation under microscopy using fluorescence in situ hybridization (Williamson et 
al., 2014), which might be due to the technical limitations of different methods, and the highly 
dynamic interaction between enhancers and promoters (Drissen et al., 2004; Vakoc et al., 2005). 
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Although the mechanism of enhancer-mediated gene activation is not completely resolved, 
more and more evidence indicate that enhancers activate gene expression by stimulating RNAP II 
from pausing to productive transcriptional elongation at the target gene promoter by recruiting the 
positive transcription elongation factor, P-TEFb, a subunit of the super elongation complex 
(Bradner et al., 2017; Kim and Shiekhattar, 2015; Schaukowitch et al., 2014; Smith and Shilatifard, 
2014). The enhancer-promoter looping structure would allow efficient exchange of those factors 
and facilitate the escape of paused RNAP II.  
 
Figure 1-1. Model for enhancer-promoter looping.  
Enhancers and promoters are able to engage in long-range interactions by forming “loops”, where components of the 
transcriptional machinery might be exchanged between enhancers and promoters. 
 
Next, I would like to discuss the potential role of eRNAs in enhancer-promoter loop 
formation. Several studies have shown that after eRNA knockdown, the corresponding enhancer-
promoter looping was impaired (Hsieh et al., 2014; Lai et al., 2013; Li et al., 2013; Pnueli et al., 
2015). These studies indicated a potential role of eRNAs in the proper formation of enhancer-
promoter loops. Nevertheless, other evidence showed that knockdown of functional eRNAs 
through chemical inhibition of RNAP II, didn’t affect the looping (Hah et al., 2013; Schaukowitch 
et al., 2014). Collectively, at least some eRNAs contribute to the formation of enhancer-promoter 




In Chapter 3, I provide additional evidence of the enhancer-promoter looping, by 
characterizing novel regulators shared between enhancers and promoters, as well as the similar 3’ 
end processing mechanism between polyadenylated eRNAs and mRNAs.  
 
Polyadenylation of eRNAs 
After being transcribed from genomic DNA, RNAs that either encode proteins or execute 
non-coding functions undergo a series of processing steps, such as splicing, 5’ capping, and 3’ 
polyadenylation. A natural question would be whether eRNAs also undergo these processing steps? 
As mentioned above, results of CAGE analyses have showed that eRNAs, similar to mRNAs, are 
generally 5’ capped (Andersson et al., 2014a; Arner et al., 2015). Nevertheless, only ~5% of 
eRNAs are spliced, whereas ~80% of mRNAs show splicing (Andersson et al., 2014a). This is 
consistent with the finding that enhancer regions lack U1 splice sites (Andersson et al., 2014b; 
Core et al., 2014). Lastly, although bioinformatic analyses showed that Polyadenylation Signals 
(PASs) are highly enriched in enhancer regions (Andersson et al., 2014a; Core et al., 2014), eRNAs 
have been thought to be large non-polyadenylated: one study failed to detect any eRNA in poly(A)- 
RNA fractions (Kim et al., 2010), whereas another estimated that approximately 90% of eRNAs 
were non-polyadenylated (Andersson et al., 2014a). However, all those studies were conducted 
under intact nuclear surveillance conditions, and thus may have failed to capture fast-turnover 
nuclear RNA species. Considering the low stability and abundance of eRNAs in cells, we 
suspected that previous studies might be biased, overlooking a fraction of eRNAs with rapid 
turnover and extremely short half-lives. Indeed, we identified a large pool of polyadenylated 
eRNAs under nuclear surveillance system in Chapter 3. Our findings shed light on the 3’ 
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processing mechanism of eRNAs, and provide new insights on the enhancer-promoter looping 
model.   
The biological functions of enhancer RNAs 
The functional significance of enhancers as DNA elements has been extensively studied in 
the past. However, the genome-wide transcription of enhancers was not discovered until 2010 (De 
Santa et al., 2010; Kim et al., 2010). Here, I summarize the biological functions of enhancer RNAs 
from four different aspects: R-loop formation, diseases, development, and evolution. 
• Enhancer RNAs and R-loops 
 R-loops, three-stranded nucleic acid structures consisting of an RNA-DNA hybrid and a 
non-template single-stranded DNA occurs in organisms from bacteria to human. Although studies 
have found that R-loops are essential for many normal and physiological processes, at the same 
time R-loops also can cause single- or double-stranded DNA breaks, and subsequently lead to 
genomic instability and replication stress (Aguilera and Garcia-Muse, 2012; Santos-Pereira and 
Aguilera, 2015). Since R-loops are frequently formed during transcription in the genome, enhancer 
transcription might also serve as a source of R-loops. Indeed, a study showed that the accumulation 
of eRNAs after RNA exosome depletion is accompanied with increased level of R-loops at some 
specific enhancer regions in mouse stem cells and B cells (Pefanis et al., 2015). Consistent with 
this, a genome-scale computational analysis also revealed that the preferential colocalization 
regions for R-loop forming sequence include enhancers, promoters, and gene ends (Kuznetsov et 
al., 2018). Given that the genome instability caused by R-loops can be a hallmark of cancer 
(Macheret and Halazonetis, 2015), enhancer transcription might be also involved in tumorigenesis, 




• Enhancer RNAs in disease 
As we mentioned above, enhancer transcription might cause the accumulation of R-loops, 
and subsequently contributes to tumorigenesis (reviewed by Rothschild and Basu, 2017). Indeed, 
Evidence has been provided by studying activation-induced cytidine deaminase (AID), a B cell-
specific protein, which initiates both somatic hypermutations and class switch recombination of 
immunoglobulin genes in human B cells. Although AID is mainly specific for immunoglobulin 
genes, it can also damage oncogenes and consequently causes tumorigenesis. Studies have shown 
that transcribed intragenic super-enhancers facilitate AID mis-trageting and consequently induce 
genomic instability and tumorigenesis (Laffleur et al., 2017; Meng et al., 2014; Qian et al., 2014).  
The dysregulation of enhancer transcription has been reported to play a crucial role in 
Huntington’s disease (HD), a progressive neurodegenerative disease. In HD mouse striatum, a 
subset of eRNAs with neuronal signatures was downregulated, and some of them also lost their 
RNAPII binding sites, which in turn led to further downregulation of those eRNAs (Le Gras et al., 
2017).  
Another interesting finding was provided by computational integration of high-throughput 
sequencing data. Just like disease-causing variants in coding genes, a great number of genomic 
variants were found in enhancers, which are linked to human diseases (Epstein, 2009; Hnisz et al., 
2013; Mathelier et al., 2015; Parker et al., 2013). Intriguingly, a high enrichment of autoimmune 
disease-associated single nucleotide polymorphisms (SNPs) was observed in a subset of 
transcribed enhancers (Farh et al., 2015; Vahedi et al., 2015). Additionally, another systematic 
genome analysis also found that a great number of disease-associated SNPs are indeed over-
represented in transcribed enhancers (Andersson et al., 2014a). However, the precise function of 
those eRNAs, transcribed from enhancers carrying disease-associated SNPs, remain to be revealed.  
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• Enhancer RNAs in development 
 Metazoan development requires precise spatio-temporal regulation of gene expression, 
which requires the orchestration of a mass of enhancers (Bulger and Groudine, 2010; Rickels and 
Shilatifard, 2018). Despite the extensive researches on enhancers, as DNA elements, in metazoan 
development (reviewed by Buecker and Wysocka, 2012; Rickels and Shilatifard, 2018), we have 
limited knowledge about the functional significance of enhancer transcription in this process. A 
systematic analysis of enhancer transcripts in a variety of human cell types and tissues has showed 
that consistent with enhancers, the majority of eRNAs are also cell-type and tissue specific 
(Andersson et al., 2014a). Additionally, the expression level of eRNAs correlates closely with their 
target gene expression (Kim et al., 2010). Nowadays, more and more studies have indicated the 
involvement of eRNAs during differentiation and development processes. For example, three 
eRNAs were found to control the expression of certain key TFs for myogenesis (Mousavi et al., 
2013).  In another study, a set of eRNAs was identified in multiple stages of B-cell development 
and activation (Brazao et al., 2016).  Additionally, some erythrocyte-specific eRNAs were 
revealed to regulate red blood cell maturation (Alvarez-Dominguez et al., 2014). Nevertheless, the 
ubiquitous mechanism to elucidate the role of all eRNAs in differentiation and development 
remain obscure. 
• Enhancer RNAs and evolution 
Enhancers lack sequence conservation, and undergo rapid evolution across mammalian 
species (Villar et al., 2015). Several studies have indicated that such rapid-evolving non-coding 
DNA regions help species to gain adaptive advantages by producing de novo genes from the 
perspective of evolution (Tautz and Domazet-Loso, 2011; Young et al., 2015). Especially 
considering the vast number of enhancers and the widespread transcription on enhancer regions, 
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eRNAs can be an ideal reservoir for the translation of de novo micropeptide. In Chapter 3, we 
show that some polyadenylated eRNAs can accumulate in the cytoplasm and associate with 
monosome/polysomes when the nuclear surveillance pathway is compromised. Our finding 
implies that some polyadenylated eRNAs might have translation potential to produce de novo 
micropeptides. Nevertheless, further studies are necessary to prove the existence of de novo 
micropeptides from eRNAs. 
 
Part II. Mtr4-containing complexes 
The nuclear surveillance system guarantees transcriptional fidelity and efficient RNA 
turnover by regulating the maturation and degradation of a vast array of RNA species. The central 
role in nuclear surveillance is played by the nuclear RNA exosome, which degrades both coding 
and noncoding RNAs produced by all three major RNA polymerases (Mitchell, 2014; Schmid and 
Jensen, 2018; Zinder and Lima, 2017). Nevertheless, the exosome requires the facilitation of 
additional protein complexes, to recognize selective RNA substrates. Recent studies have 
identified a number of nuclear exosome-adaptor complexes, which are largely conserved across 
species. Remarkably, all of those complexes contain the RNA helicase Mtr4, responsible for 
unwinding RNA substrates. The published review in Chapter 2 provides a comprehensive 
overview of our current knowledge of the nuclear surveillance system. Nevertheless, here I briefly 
summarize the key Mtr4-containing complexes presented in this thesis (Figure 1-2). 
 
NEXT complex 
The RNA helicase Mtr4, together with the RNA binding protein RBM7 and the Zn-knuckle 
protein ZCCHC8, constitute the Nuclear Exosome Targeting (NEXT) complex (Lubas et al., 2011). 
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The NEXT complex has been found to be involved in the degradation of a large repertoire of RNAs, 
including replication-dependent histone mRNAs (Andersen et al., 2013), PROMPTs/uaRNAs 
(Lubas et al., 2011), eRNAs (Lubas et al., 2015). In Chapter 3, I show that the NEXT complex 
regulates a subset of novel polyadenylated eRNAs, half of which are also regulated by the 
PAXT/PPC complex mentioned below. 
 
PAXT/PPC complex 
The interaction between Mtr4 and ZFC3H1, a Zinc finger protein, was discovered by two 
independent studies (Meola et al., 2016; Ogami et al., 2017). The previous study in our lab showed 
Mtr4/ZFC3H1 facilitate the turnover of unstable nuclear RNAs. Depletion of Mtr4/ZFC3H1 led 
to the cytoplasmic accumulation of prematurely terminated RNAs (ptRNAs) and upstream 
antisense RNAs (uaRNAs), and consequently polysome association with those RNAs. Therefore, 
the Mtr4/ZFC3H1 was named as Polysome Protection Complex (PPC). Consistent with this, a 
recent study showed that ZFC3H1 indeed acts as a central nuclear retention factor for nuclear 
polyadenylated transcripts. Depletion of ZFC3H1 resulted in nuclear export of its polyadenylated 
RNA substrates (Silla et al., 2018). I contributed to the discovery of PPC complex, and the paper 
is available in Appendix II.  
 Meanwhile, another group also identified the interaction between Mtr4 and ZFC3H1. 
Besides, their study showed that PABPN1 also interacts with Mtr4/ZFC3H1 complex, although 
this interaction is more transient and likely to be RNA dependent (Meola et al., 2016). PABPN1 
has been found to promote the exosome-mediated degradation of nuclear polyadenylated RNAs 
(Beaulieu et al., 2012; Bresson and Conrad, 2013; Bresson et al., 2015), and share a subgroup of 
RNA substrates with Mtr4/ZFC3H1(Meola et al., 2016; Ogami et al., 2017). Given that this 
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complex preferentially regulates transcripts with long poly(A) tails, Mtr4/ZFC3H1/PABPN1 was 
referred as Poly(A) Exosome Targeting (PAXT) complex (Meola et al., 2016). 
 In Chapter 3, I show that depletion of PAXT/PPC complex results in substantial 
accumulation of polyadenylated eRNAs, and its “polysome protection” role also applies to those 
polyadenylated eRNAs. Additionally, I reveal a novel role of ZFC3H1 in RNA biogenesis, besides 
its known function in RNA degradation and nuclear retention. 
 
Mtr4/NRDE2 complex 
Mtr4 interacts with NRED2, a protein mainly localizing in nuclear speckles, in human cells 
(Jiao et al., 2019; Lubas et al., 2011; Ogami et al., 2017; Richard et al., 2018; Wang et al., 2019). 
Such interaction is highly conserved, as studies showed that the Mtr4 homolog Mtl1 and the 
NRDE2 homolog Nrl1 in S. pombe also interacts with each other (Lee et al., 2013; Yamanaka et 
al., 2013). A published work in our lab discovered that the both Mtr4 and NRDE2 depletion causes 
DNA double-strand break, surprisingly, in a R-loop independent way. Nevertheless, the R-loop 
formation in a subset of genes was indeed regulated by the Mtr4/NRDE2 complex. These results 
indicate a novel role of Mtr4/NRDE2 in DNA damage response. My contribution to this work is 
listed in Appendix III. Additionally, a recent study showed that NRDE2 actually is a negative 
regulator of the nuclear surveillance system, by inhibiting the interaction between Mtr4 and the 
nuclear RNA exosome (Wang et al., 2019). This study has shed light on the connection between 





Figure 1-2. The Mtr4-containing complexes in human cells. Four Mtr4-containing complexes are listed: the NEXT 
complex (Mtr4/RBM7/ZCCHC8), the PPC (Mtr4/ZFC3H1) or PAXT (Mtr4/ZFC3H1/PABPN1) complex, the 
Mtr4/NRDE2 complex, and the TRAMP complex (Mtr4/ZCCHC7/PAPD5). Only TRAMP complex is in the 
nucleolus, while other three all locate in the nucleoplasm.  
 
TRAMP complex 
The human TRAMP complex is composed of the RNA helicase Mtr4, a zinc knuckle 
protein ZCCHC7, and a noncanonical poly(A) polymerase PAPD5. The TRAMP complex is 
believed to be restricted in nucleoli, since one of its subunit ZCCHC7 can only be observed in 
nucleoli (Lubas et al., 2011). The other two subunits are also enriched in nucleoli (Lubas et al., 
2011; Ogami et al., 2013; Rammelt et al., 2011). Consequently, the substrates of TRAMP 
substrates are believed to be restricted to nucleolar RNA species (Lubas et al., 2011). Since 
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TRAMP complex has been shown to participate eRNA degradation, I didn’t knockdown any 
TRAMP subunits in the eRNA study presented in Chapter 3. 
 
Part III. Retinoblastoma-binding protein 6 
The retinoblastoma-binding protein 6 (RBBP6) was initially discovered as a large 
multidomain protein, interacting with tumor suppressor protein p53 and Rb (Saijo et al., 1995; 
Sakai et al., 1995; Simons et al., 1997). Later, studies found that RBBP6 participates in diverse 
biological processes, such as cell cycle control, apoptosis, embryonic development, and pre-
mRNA processing (Di Giammartino et al., 2014; Gao and Scott, 2003; Li et al., 2007; Miotto et 
al., 2014). The complexity of RBBP6 isoforms echo their versatile roles in cell. Here I review the 
key studies of RBBP6, to provide a comprehensive background for the work in Chapter 4. 
 
The complexity of RBBP6 isoforms 
The RBBP6 gene contains 17 introns and generates four isoforms by alternative splicing 
(Figure 1-3) in human.  All four isoforms contain a domain named DWNN (Domian With No 
Name) at the very N terminus. The DWNN domain, with a ubiquitin-like structure (Mather et al., 
2005; Pugh et al., 2006), can be expressed as a single domain protein, RBBP6 isoform3, or iso3. 
Given the high similarities between DWNN and ubiquitin, an intriguing question would be 
whether RBBP6 iso3 itself may function as a novel ubiquitin-like modifier of other protein 
substrates (Pugh et al., 2006). This question is answered in Chapter 6, where I show that the 
DWNN domain is not a ubiquitin-like modifier, instead, itself is ubiquitinated.  
The other three isoforms (isoform 1, 2 and 4) all contain a Zinc finger, a RING domain, 
besides the N-terminal DWNN domain. These three highly conserved domains are also shared by 
16
  
all RBBP6 homologs across species. In contrast, the p53- and Rb-binding domains only present in 
vertebrate RBBP6 protein, suggesting that RBBP6 interacting with p53 and Rb was the result of 
evolution, which provides more specific or diverse regulatory mechanisms of RBBP6. We also 
note that the RING domain is a signature domain for E3 ubiquitin ligases. Indeed, RBBP6 possess 
E3 ligase activity and catalyse ubiquitination for several proteins including YB-1, ZBTB38, and 
p53 (Chibi et al., 2008; Li et al., 2007; Miotto et al., 2014). Most studies to date have been focusing 
on the longest and shortest isoforms of RBBP6, iso1 and iso3, respectively. Intriguingly, these two 
isoforms, though generated from a single gene, seem to exert opposing functions in mRNA 
processing and carcinogenesis Consequently, the overall function of RBBP6 can be tuned by 
adjusting the iso1/iso3 protein ratio in cell (Chen et al., 2013; Di Giammartino et al., 2014; Moela 
and Motadi, 2016; Motadi et al., 2011; Motadi et al., 2018; Yoshitake et al., 2004). 
The complexity of RBBP6 isoforms has been reflected in its multifaceted roles in many 
biological processes. Next, I summarize the key functions of RBBP6 from three aspects: mRNA 
processing, embryonic development, and its implication in disease.  
 
Figure 1-3. The domain organization of RBBP6 isoforms.  
RBBP6 isoform1, 2 and 4 represent the long-form RBBP6, whereas isoform3 is the short-form RBBP6, only 
containing a DWNN domain. The only difference between isoform1 and 2 is a short coiled-coil structure (colored in 
light yellow) before RS domain. There are in total eight domains listed above, the DWNN domain, the Zinc finger 
domain, the RING domain, the coiled-coil motif, the arginine and serine (RS) domain, the p53-binding domain, the 
Rb-binding domain, and the nuclear localization signal (NLS). The total amino acid (AA) numbers of each isoforms 




RBBP6 in pre-mRNA processing 
Despite the diverse roles of RBBP6 revealed in numerous studies, mRNA 3’ processing 
has been one of the most  conserved function of RBBP6, from human (Di Giammartino et al., 2014) 
to yeast (Lee and Moore, 2014; Vo et al., 2001). This function can be reconstituted by the three 
domains at the N terminus: the DWNN domain, the Zinc finger, and the RING domain, in human, 
regardless of the long C-terminal fragment in RBBP6 iso1 (Di Giammartino et al., 2014). 
Consistent with this and as mentioned above, these three domains are highly conserved across 
species in RBBP6 homologs (Pugh et al., 2006), further confirming that mRNA processing is the 
most conserved function of RBBP6.  
Studies in human cells and yeasts have shown consistent results: The Zinc finger and RING 
domain are required for efficient RNA binding, whereas the DWNN appears most critical for 
interaction with Cleavage and Polyadenylation Specificity factors, CPSFs (Di Giammartino et al., 
2014; Lee and Moore, 2014). Moreover, a previous study in our lab found that RBBP6 iso3, the 
single DWNN domain protein, can compete with the long-form RBBP6 for binding to CstF64, a 
component of the core 3’ processing machinery. Moreover, by adjusting the ratio between the 
promoting iso1 and inhibitory iso3, the alternative polyadenylation (APA) pattern and global gene 
expression can be modulated. As shown in Figure 1-4, low iso1/iso3 ratio leads to 3’UTR 
lengthening in genes with more than one APA sites, as well as defective pre-mRNA cleavage for 
genes with only one poly(A) site (Di Giammartino et al., 2014). High iso1/iso3 ratio, which is the 
case in many cancers (Chen et al., 2013; Mbita et al., 2012; Moela and Motadi, 2016; Motadi et 
al., 2011; Motadi et al., 2018; Yoshitake et al., 2004), corresponds with more efficient 3’processing 




Figure 1-4. Model for pre-mRNA 3’ processing mechanism modulated by RBBP6 iso1/iso3 protein ratio.  
RBBP6 iso1 High iso1/iso3 ratio guarantees efficient pre-mRNA 3’ processing and leads to global 3’UTR shortening, 
which is also observed in many cancers. Low iso1/iso3 ratio inhibits pre-mRNA 3’ processing, and results in the use 
of the strongest poly(A) sites, which are usually more distal. Eventually it will lead to global 3’UTR lengthening.  
 
In Chapter 6, I show that the dynamic nuclear localization of RBBP6 iso3 is regulated by 
monoubiquitylation and Importin7. This finding provides another way to regulate the iso1/iso3 
ratio in nucleus, which is by transporting iso3 in and out of the nucleus. 
 
RBBP6 in embryonic development 
In this section, I discuss the key function of long-form RBBP6 in embryonic development. 
Studies have found that null mutants of RBBP6 are embryonic lethal in both mice and flies (Li et 
al., 2007; Mather et al., 2005). Homozygous deletion of RBBP6 genes in mice resulted in early 
embryonic death on embryonic day 7.5 (E7.5), which can be prolonged to E11.5, by simultaneous 
deletion of p53. This partial rescue is likely mediated by Mdm2, a key negative regulator of p53: 
RBBP6 promotes p53 ubiquitination and degradation in a Mdm2 dependent manner. Moreover, 
knockdown of RBBP6 results in accumulated p53 and induces p53-denpendent apoptosis, which 
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has been observed in mouse embryos (Li et al., 2007). Consistent with this, disruption of SNAMA, 
the RBBP6 homolog of Drosophila, also leads to apoptosis during embryogenesis and throughout 
the gastrula. Nevertheless, unlike human RBBP6, SNAMA doesn’t possess p53- or Rb-binding 
domain, which indicates that RBBP6 might also regulate apoptosis in a p53-independent pathway. 
The roles of RBBP6 in embryonic development still remains to be elucidated.  
 
RBBP6 and disease 
RBBP6 has been implicated in various diseases. For example, RBBP6 iso1 has been found 
to be overexpressed in many types of cancer, such as breast, cervical, lung, colon, and esophagus 
carcinoma (Chen et al., 2013; Moela and Motadi, 2016; Motadi et al., 2011; Motadi et al., 2018; 
Yoshitake et al., 2004). In contrast, RBBP6 iso3 is downregulated (Mbita et al., 2012). As 
discussed in the previous section “RBBP6 in pre-mRNA processing”, the high iso1/iso3 ratio in 
cancer is consistent with the finding that cancer cells typically display global 3’UTR shortening, 
which often contribute to oncogene activation (Mayr and Bartel, 2009).  
Besides modulating global 3’UTR, RBBP6 can also contribute to cancer development 
througth another mechanism, as it is also found to play a role in cell cycle and apoptosis: The 
overexpression of near full length RBBP6 leads to cell cyle arrest at prometaphase as well as 
mitotic apoptosis (Gao and Scott, 2002). Lastly, we note that several studies have shown that the 
expression level of RBBP6 can used as a predictive or prognostic parameter for several cancers 
(Chen et al., 2013; Morisaki et al., 2014). 
Another example is that five germline RBBP6 mutations in/adjacent its p53-binding 
domain display predisposition to myeloproliferative neoplasms, which suggests a p53-dependent 
pathway of RBBP6 in pathogenesis (Harutyunyan et al., 2016). Also, a recent study identified 
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RBBP6 as a negative regulator of Ebola virus replication by systematically mapping the interaction 
between Ebola virus proteins and human proteins (Batra et al., 2018). Moreover, a 23 amino acid 
region (549-571 amino acid regions of RBBP6 iso1) was characterized to bind the viral 
transcription regulator VP30 by X-ray crystallography, which can serve as a potential therapeutic 
target. Surprisingly, this region was outside of all the defined domains in RBBP6, instead, it locates 
between the RING domain and the RS domain. It’s noteworthy that only iso1 but not iso3, binds 
VP30 and exhibits an inhibitory effect on viral replication.  
The functional significance of RBBP6 has been backed by more and more evidence in 
recent years. Expectantly, my work on the nuclear localization mechanism of RBBP6 iso3, 
presented in Chapter 6, would contribute to a better understanding of this multifaceted protein. 
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Abstract: The nuclear RNA exosome is an essential and versatile machinery that regulates maturation
and degradation of a huge plethora of RNA species. The past two decades have witnessed remarkable
progress in understanding the whole picture of its RNA substrates and the structural basis of its
functions. In addition to the exosome itself, recent studies focusing on associated co-factors have been
elucidating how the exosome is directed towards specific substrates. Moreover, it has been gradually
realized that loss-of-function of exosome subunits affect multiple biological processes, such as the
DNA damage response, R-loop resolution, maintenance of genome integrity, RNA export, translation,
and cell differentiation. In this review, we summarize the current knowledge of the mechanisms of
nuclear exosome-mediated RNA metabolism and discuss their physiological significance.
Keywords: exosome; RNA surveillance; RNA processing; RNA degradation
1. Introduction
Regulation of RNA maturation and degradation is a crucial step in gene expression. The nuclear
RNA exosome has a central role in monitoring nearly every type of transcript produced by RNA
polymerase I, II, and III (Pol I, II, and III). The exosome guarantees fidelity of the mature 30 ends
of certain stable RNA species, such as ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), telomeric
RNAs, small nuclear and nucleolar RNAs (snRNAs and snoRNAs), not only by catalyzing 30 end
trimming, but also by degrading transcripts containing an incomplete 30 end [1–3]. Besides, processing
of messenger RNA precursors (pre-mRNAs), such as by splicing and 30 end formation, is also under
the surveillance of the exosome (Figure 1) [4–13].
Intriguingly, recent advances in RNA sequencing techniques have enabled detection of novel Pol
II transcripts (Figure 1), which are expressed at extremely low levels because of rapid RNA turnover
by the exosome. A large fraction of these RNAs can be categorized as long non-coding RNA (lncRNA).
The most well-known lncRNA substrates for the exosome are cryptic unstable transcripts (CUTs) in
yeast [14–16], and their human counterparts, promoter upstream transcripts (PROMPTs) or upstream
antisense RNAs (uaRNAs) [17,18], which arise due to antisense transcription from divergent gene
promoters. The exosome removes sense non-coding transcripts, such as prematurely terminated
RNAs (ptRNAs) [19], which are prematurely terminated and polyadenylated at a poly(A) signal (PAS)
typically located in an intron of a protein-coding gene [20], and transcription start site (TSS)-associated
RNAs (tssRNAs), which are infrequent short non-coding RNAs (ncRNA) (20–65 nt) generated as
a result of promoter-proximal termination of sense transcription [21]. Transcriptional enhancers are
also transcribed bi-directionally, and produce a class of lncRNA called enhancer RNAs (eRNAs). It was
reported that exosome-sensitive eRNAs emerge from virtually all active enhancer regions, determined
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by comprehensive cap analysis of gene expression (CAGE) analyses [22]. Furthermore, long intergenic
RNAs (lincRNAs) are also exosome targets [23], although they are generally more stable than uaRNA
and eRNA [24].
Strikingly, recent studies have been gradually revealing that the exosome is involved in multiple
important biological processes. Those include the DNA damage response (DDR), R-loop resolution,
maintenance of genome integrity, RNA export, translation, and cell differentiation. In this work,
we review and update our current understanding regarding structural insights into RNA degradation
by the exosome and its associated co-factors. We also summarize how abrogation of the functions of
the exosome impacts cellular processes in mammals.
 
Figure 1. Schematic depiction of Polymerase II transcripts generated from enhancers and gene
promoters. Both enhancers and promoters are transcribed bi-directionally and produce various types of
transcripts, including messenger RNA precursors (pre-mRNA), transcription start site-associated RNA
(tssRNA), prematurely terminated RNA (ptRNA), upstream antisense RNA (uaRNA) or promoter
upstream transcript (PROMPT), and enhancer RNA (eRNA). The exosome functions in nuclear RNA
surveillance to degrade these RNAs, as well as misprocessed messenger RNA (mRNA) precursors, such
as intron-retained and poly(A) signal-mediated cleavage, and polyadenylation-defective pre-mRNAs.
2. The Nuclear RNA Exosome: Structure and RNA Degradation Mechanisms
The eukaryotic nuclear RNA exosome is a 30–50 exonuclease complex, consisting of a 9-protein
catalytically inactive core complex (EXO-9) and two catalytic subunits, Rrp6 (also known as PM/Scl-100
or EXOSC10), and Dis3 (also known as Rrp44 or EXOSC11). EXO-9 forms a double-layered barrel-like
structure that comprises six ribonuclease (RNase) pleckstrin homology (PH)-like proteins (Rrp41,
Rrp42, Rrp43, Rrp45, Rrp46, and Mtr3) and three S1/K homology (KH) “cap” proteins (Rrp4, Rrp40,
and Csl4) [3]. The two catalytic subunits occupy opposite ends of EXO-9 to constitute EXO-11. Rrp6
is placed at the top of the S1/KH cap ring near the RNA entry pore, and Dis3 is tethered to the
bottom of EXO-9 near the RNA exit pore [25–27]. Both Rrp6 and Dis3 are 30–50 exonucleases, but
the latter also has endonucleolytic activity [28–30]. Rrp6 widens the central channel of core EXO-9
and allosterically stimulates Dis3 activity [26]. Recently, a study focused on the last 100 amino acids
of Rrp6, referred to as a “lasso,” and revealed that the lasso binds RNA proximal to the EXO-9
33
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channel and enhances RNA decay [31]. In humans, both Rrp6 and Dis3 are mostly nuclear, but Rrp6
shows significant nucleolar enrichment [32,33], whereas Dis3 is excluded from the nucleoli [33,34].
In contrast to humans, yeast Rrp6 is restricted to the nucleus, but Rrp6 and Dis3 are both present in the
nucleoplasm and nucleolus [32,35].
Three additional co-factors, Mtr4 (in humans, also known as SKIV2L2 or MTREX (nomenclature
recently suggested by HUGO)), Rrp47 (also known as C1D), and Mpp6, are required for maximal
activity of the nuclear exosome. Rrp47 interacts with Rrp6 to provide a binding platform for Mtr4,
an essential DExH-box RNA helicase [36]. Mpp6 binds to the cap subunit Rrp40, and enhances Mtr4
helicase activity [37,38]. This activity is required to unwind secondary structures formed at the 30 end
of RNA substrates, so that the resultant single-stranded RNA substrates can be threaded into the
central channel of the core complex in a 30 to 50 orientation [39]. Dis3 degrades RNAs threaded
through the entire central channel (Figure 2a), whereas Rrp6 degrades or trims the RNA that enters
into the S1/KH cap ring, and then traverses the cap to reach the Rrp6 active site (Figure 2b) [26,40,41].
In addition, there is an alternative path by which the RNA can directly access the Dis3 active site
(Figure 2c) [42]. The RNA channeling, but not the direct route, induces a conformational change in
Dis3 [42]. The estimated path lengths of the threading and direct access in vitro are ~30 nt and ~10 nt,
respectively [42–45]. Recent studies in Saccharomyces cerevisiae have revealed that RNA substrates show
preferences for a specific path to Dis3 [46,47]. Notably, identification of transcriptome-wide interactions
of RNAs with individual exosome subunits using the ultraviolet (UV) crosslinking and analysis of
cDNA (CRAC) technique in growing budding yeast cells showed that RNA substrates produced by all
three RNA polymerases (Pol I, II, and III) exhibit preferences [47]. Interestingly, whichever the route is,
Mtr4 is required for RNA degradation [47]. In addition to these two paths, a potential new route to
Dis3 was recently suggested [48]: by assessing the average length of RNAs protected by the exosome
in living budding yeast using CRAC analysis, it was found that there are not only ~10 nt (reflecting
direct access) and 39 and 44 nt (likely reflecting RNAs threaded through the channel and also protected
by co-factors) peaks, but also a ~20 nt broad peak that was not described in in vitro studies.
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Figure 2. Structure of the RNA exosome and paths for RNA substrates to the catalytic subunits.
(a) Threading route: RNA enters the central channel of the core exosome and reaches the active site of
Dis3. (b) Route to Rrp6: RNA traverses the cap structure and reaches the active site of Rrp6. (c) Direct
access to Dis3. RNA bypasses the central channel and directly accesses Dis3.
3. Molecular Apparatus for RNA Targeting of the Exosome in Yeasts and Humans
The fact that the exo ome t rgets a wide variety of transcripts raises an important qu tion: how
is the exosome specifically recruited t particular RNA substrates? Recent studies have ide tified
a number of nuclear exosome–adaptor complexes, which help the exosome load onto selective
RNAs [2,3,49]. The components of the adaptors are largely conserved, especially between fission
yeast and humans (Table 1). Importantly, Mtr4 is contained in all of the adaptor complexes, indicating
that Mtr4 is a central and essential factor for formation of the complexes and for their functions
(Figure 3).
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Figure 3. Overview of Mtr4-containing exosome adaptor complexes in yeasts and humans. The RNA
helicaseMtr4 participates inmultiple distinct exosome adaptor complexes to complete degradation and/or
processing of specific RNA substrates. Mtr4-containing complexes identified in Saccharomyces cerevisiae
(upper-left), Schizosaccharomyces pombe (extbflower left) and Homo sapiens (right) are shown.
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3.1. Saccharomyces cerevisiae
The Trf4/5-Air1/2-Mtr4 polyadenylation complex (TRAMP) was first described in S. cerevisiae,
and now is the most well-characterized co-factor that assists exosome-mediated RNA degradation
and processing in budding yeast nuclei. Soon after recognizing the importance of polyadenylation of
hypomodified methyonyl initiator transfer RNA (tRNAiMet) by the non-canonical poly(A) polymerase
Trf4 for exosome-dependent tRNA quality control [50], the full composition of the responsible
protein complex, TRAMP (Mtr4, Trf4, and the Zn-knuckle RNA-binding protein Air1 or Air2), was
determined [14,51,52]. Later, another TRAMP complex containing Trf5, a close homolog of Trf4, was
identified [53]. Air1/2 provides RNA-binding capability and is also critical for TRAMP assembly [54–56].
TRAMP recognizes a variety of transcripts [12], such as tRNAs [50,52,57–59], rRNAs [59–61],
sn/snoRNAs [59,62,63], telomeric RNAs [64], CUTs [14,59,64], and pre-mRNAs [59,65–67], and these
substrates are commonly polyadenylated by Trf4/5. In TRAMP, Mtr4 plays roles in RNA unwinding
and modulation of poly(A)-tail length of RNA substrates [57,68–73]. Although TRAMP itself has
an RNA-binding capacity, its efficient recruitment to RNA substrates is further assisted by the
Nrd1–Nab3–Sen1 (NNS) complex [74]. Nrd1 and Nab3 are RNA-binding proteins that recognize
specific sequence elements [59,75,76], whereas Sen1 has DNA/RNA helicase activity, which promotes
dissociation of Pol II from the template DNA [77–79]. Importantly, NNS travels with a transcribing
Pol II by interacting with the C-terminal domain of the Pol II largest subunit (CTD) and terminates
transcription when the sequence elements emerge on the nascent RNAs [78,80–85]. NNS-dependent
transcription termination is further promoted by the cleavage/polyadenylation factor Pcf11 [86].
Nrd1 interacts with the CTD-containing heptapeptide repeats (YSPTSPS) phosphorylated on Ser5
(Ser5P) through its CTD interaction domain (CID) [83,87,88]. The Nrd1 CID also binds to a CTD
mimic motif in Trf4 [89]. The Nrd1 CID interacts with Trf4 and Pol II in a mutually exclusive
manner, and therefore, NNS-mediated transcription termination and TRAMP/exosome-mediated
RNA degradation are coordinated [89]. Notably, proteins homologous to the NNS components were
found in Schizosaccharomyces pombe and humans (Table 1). Both S. pombe and humans have Sen1
homologs, Sen1 and Senataxin (SETX), respectively. S. pombe has the Nrd1 homolog Seb1 [90], which
has Ser5P-CTD- and RNA-binding abilities [91,92]. However, although Seb1 is involved in transcription
termination and alternative polyadenylation, no NNS-like function was observed [91,93,94]. Functions
of the human CID-containing homolog of Nrd1, SCAF8 [95], remain unexplored, except that SCAF8
can bind to the elongating phosphorylated CTD [96,97]. Also, human RALY protein is somewhat
similar to Nab3; the RNA recognition motif (RRM) in RALY shares 31% amino acid identity with
the Nab3 RRM [98]. However, there is currently no evidence that these putative homologs of NNS
subunits form an NNS-like complex and regulate human TRAMP functions.
Several other exosome partners exist in budding yeast. Utp18 and Nop53, an early and late
associating small subunit processome factor, respectively, were shown to interact with the exosome
to regulate ribosomal RNA precursor (pre-rRNA) processing [99]. Both proteins contain a conserved
motif termed an arch-interacting motif (AIM), which directly dock to the arch domain of Mtr4. Recent
X-ray crystallography and NMR analyses revealed the structural basis of Mtr4–Nop53 interaction
and showed that the Mtr4 arch can bind Nop53 and RNA simultaneously [100]. The G-patch protein
Sqs1/Pfa1 also contains a perfect AIM consensus sequence, and thus binds to the Mtr4 arch domain;
however, the roles of the interaction remain elusive [99]. In addition, Babour et al. reported that the
chromatin remodeling complex ISW1 physically interacts with the exosome in an RNase-insensitive
manner [101]. Interestingly, this interaction is enhanced in the export-incompetent thermo-sensitive
npl3-1mutant strain. ISW1 is required to retain export-defective poly(A)-tailed RNAs on chromatin
and remove them by recruiting the exosome. This finding implies that ISW1/exosome participates in
a messenger ribonucleoprotein (mRNP) nuclear export surveillance system.
36
Non-coding RNA 2018, 4, 8 6 of 21
3.2. Schizosaccharomyces pombe
The fission yeast S. pombe has a complex similar to S. cerevisiae TRAMP, consisting of Mtr4,
Air1 and the Trf4/5 family of poly(A) polymerase Cid14 [102]. It functions in heterochromatic gene
silencing at centromeric repeats [102–104] and polyadenylation-dependent decay of centromeric
RNAs [105,106], snoRNA precursors [107], and Argonaute-bound small RNAs [108]. The precise
mechanism of TRAMP recruitment to target transcripts remains unclear; however, Mlo3, the S. pombe
homolog of mRNA export factor Yra1 or ALYREF, was shown to interact with TRAMP to silence
centromeric transcripts [103,104]. Besides, the THO complex, which coordinates the steps from
transcription to RNA export, is required to maintain TRAMP at snoRNA genes, and these complexes
cooperate in the control of snoRNA expression, thus linking transcription and nuclear surveillance
machineries [107]. Notably, Yra1 physically associates with the THO complex in S. cerevisiae [109,110],
and therefore, it is possible that both Mlo3 and the THO complex work in the same pathway for
TRAMP-mediated RNA metabolism.
S. pombe has a second Mtr4 homologue protein named Mtl1 (Mtr4-like protein 1), which is
independent of TRAMP. Mtl1 interacts with the zinc-finger protein Red1 and various other proteins to
form a complex called Mtl1–Red1 core (MTREC) or nuclear RNA silencing (NURS) [111,112]. MTREC
interacts with the exosome, presumably through Red1 but not Mtl1 [113]. In agreement with this, Mtl1
lacks the N-terminal motif that mediates the interaction of Mtr4 with Rrp6 and Rrp41 [36]. MTREC
further associates with several sub-modules such as Iss10-Mmi1, Red5-Pab2-Rmn1, Ars2-Cbc1-Cbc2,
and the canonical poly(A) polymerase Pla1 [111–113]. All of these sub-modules can bind to MTREC
simultaneously, forming a large 11 subunit complex [113]. However, since the sub-modules show
different stoichiometry for MTREC-binding, there might be various forms of the MTREC complex.
The sub-modules enable MTREC to direct specific RNA targets for exosome-mediated decay. The YTH
protein Mmi1 is a well-characterized regulator of meiotic gene expression [114–116]. Mmi1 programs
meiotic transcripts for co-transcriptional decay by recognizing repeats of a short nucleotide motif
termed determinant of selective removal (DSR), which are found within introns in some target
genes [116–119]. Iss10 is required for stable interaction between Mmi1 and Red1, and thus, involved in
meiotic gene regulation [120]. Red5 and Pab2 contribute to degradation of meiotic mRNAs [121,122]
and CUTs [113], whereas depletion of the associating factor Rmn1 does not affect the amount of
either meiotic mRNA or CUTs [112,113]. The cap-associated complex Ars2–Cbc1–Cbc2 is responsible
for efficient CUT degradation [113], which is reminiscent of the function of the human cap-binding
complex (CBC)–ARS2 (CBCA) complex. The human CBCA complex is required for degradation of
PROMPTs/uaRNAs [123], which are comparable to yeast CUTs [17] (discussed below).
Mtl1 also forms a Red1-independent protein complex with the Caenorhabditis elegans NRDE-2
homologue Nrl1 and the coiled-coil- and DUF4078 domain-containing protein Ctr1 [111,113].
The Mtl1–Ctr1–Nrl1 complex further associates with splicing factors, and is suggested to degrade
unspliced pre-mRNA [111,113].
3.3. Homo sapiens
In addition to Mtr4, factors homologous to the yeast TRAMP subunits are present in humans;
the closest orthologues of Air1/Air2 and Trf4/Trf5 are the zinc-knuckle protein ZCCHC7 and the
non-canonical poly(A) polymerase PAPD5 (also known as Trf4-2), respectively. These three proteins
form the TRAMP-like complex [124]. Functions of TRAMP-like are thought to be restricted to
nucleoli under normal cellular conditions, due to the strict nucleolar localization of ZCCHC7 [124].
The other subunits Mtr4 and PAPD5 are restricted to the nucleus with nucleolar enrichment [124–126].
Interestingly, it was recently shown that viral infection induces cytoplasmic translocalization of
ZCCHC7 and Mtr4 to facilitate exosome-mediated viral RNA decay in the cytoplasm [127]. It has
been shown that PAPD5 is responsible for poly- or oligo-adenylation of nucleolar RNAs, such as
snoRNAs [128] and aberrant pre-rRNA species [124,129], suggesting that polyadenylation assists
RNA 30 processing and/or degradation by TRAMP-like. Of note, PAPD5 has a close paralog, PAPD7
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(also known as Trf4-1), that has been suggested to interact with ZCCHC7 [56]. However, roles of
PAPD7 in TRAMP-like remain unclear; PAPD7 is excluded from nucleoli [126], and in agreement
with this, PAPD7 is dispensable for polyadenylation of aberrant pre-rRNA species [129]. In addition,
there is no evidence of an interaction between PAPD7 and Mtr4 in several independent proteomics
analyses [20,124,130].
Human TRAMP-like interacts with several additional proteins. It has been shown that
TRAMP-like-mediated pre-rRNA processing is modulated by the AAA-ATPase NVL2 [131,132]
and its regulatory factor tryptophan-aspartic acid (WD) repeat-containing protein WDR74 [133–135].
Moreover, splicing factors such as U4/U6·U5 tri-snRNP subunits and hnRNPs are found to associate
with TRAMP-like complex [20,124,130]. The function of the interaction with splicing factors awaits
further investigation. The nucleolar exosome can interact with the double-stranded RNA-binding
protein DGCR8, which is well known as a microprocessor subunit, to degrade mature snoRNAs and
telomerase RNA (hTR) [136]. It is noteworthy that although the physical interaction between DGCR8
and TRAMP-like has not been reported, both snoRNAs and hTR are targeted by the TRAMP-like
complex [136–139].
In the nucleoplasm, at least two distinct exosome adaptors are present. One is Mtr4–ZFC3H1 or
poly(A) tail exosome targeting complex (PAXT), which brings the exosome to various kinds of lncRNAs,
including snoRNA host gene (SNHG) transcripts, eRNAs [49], uaRNAs [20,49], and ptRNAs [20].
Another is nuclear exosome targeting complex (NEXT) [124], comprising Mtr4, the RNA binding
protein RBM7 and the Zn-knuckle protein ZCCHC8, which degrades PROMPTs/uaRNAs [124],
replication-dependent histone mRNAs [123], eRNAs [140], snRNAs [123,141], and snoRNAs [140].
Of note, ZFC3H1 is a close homolog of S. pombe Red1, and therefore, Mtr4–ZFC3H1 is the
human MTREC. Although RNA substrates of Mtr4–ZFC3H1 and NEXT partly overlap, there are
clear differences in their features; Mtr4–ZFC3H1 substrates are longer in RNA body size and
have a long poly(A)-tail [20,49]. The precise molecular fundamentals of substrate recognition
by Mtr4–ZFC3H1 await further characterization. However, Meola et al. suggested the transient
and partially RNA-dependent interaction between Mtr4–ZFC3H1 and the nuclear poly(A)-binding
protein PABPN1 [49]. It has been shown that PABPN1 promotes exosome-dependent decay of
nuclear poly(A)-tailed transcripts [142–144]. PABPN1-mediated RNA decay is dependent on RNA
polyadenylation, which requires the canonical poly(A) polymerases PAP↵/ , but not the TRAMP
subunit PAPD5 [142–144], and is thus termed PABPN1- and PAP↵/ -mediated RNA decay pathway
(PPD) [143]. Notably, subsets of the PABPN1 substrates overlap with those of Mtr4–ZFC3H1 [20,49].
Yet, the fact that co-depletion of Mtr4 and PABPN1 resulted in synergistic accumulation of target
transcripts suggests that Mtr4–ZFC3H1 and PABPN1 may work in both the same and redundant
pathways [144]. It will be interesting to investigate if and how Mtr4–ZFC3H1 participates in
the PPD pathway. RNA recognition by NEXT involves the connection with the ARS2-associated
cap-binding complex CBCA [123], U-rich RNA binding capacity of RBM7 [140,141], and possibly
the pre-mRNA 30 processing complex [145]. CBCA and NEXT further associate with the zinc-finger
CCCH domain-containing protein ZC3H18 (also known as NHN1) [123,146], and this interaction
is important for cap-proximal Pol II stalling, transcription termination, 30 end formation, and RNA
decay [123,146,147]. The significance of the interaction between NEXT and the pre-mRNA 30 processing
complex remains undetermined.
A nucleoplasmic protein NRDE2, which is the homolog of S. pombe Nrl1, also interacts with Mtr4.
However, in contrast to the S. pombe counterpart, it is unlikely that Mtr4/NRDE2 associates with the
whole exosome, since analysis using size-exclusion chromatography-coupled mass spectrometry (MS)
revealed that Mtr4/NRDE2 elutes around 440 kDa, which is smaller than the exosome/Mtr4 complex
(>600 kDa) [20]. In agreement with this, our recent MS analysis of NRDE2-interacting proteins did not
detect any exosome subunits [148].
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4. Significance of the Nuclear RNA Exosome in Mammalian Biological Processes
Loss-of-function of the exosome due to mutation or depletion of its subunits and co-factors can
cause alterations in various biological processes [2], and ultimately contribute to human disease, such
as multiple myeloma [149–151]. Despite various interesting phenotypes in yeast, such as altered
chromatin modifications in exosome-deficient cells, we restrict discussion here to evidence provided
using mammalian cells.
4.1. DNA Damage Response
The activity of the nuclear exosome is altered during the cellular DDR. The change is triggered by
phosphorylation of the NEXT subunit RBM7 by the stress-related kinase p38 MAPK/MK2 [152,153].
Phosphorylated RBM7 is bound by the phosphoserine-binding protein 14-3-3, and loses its RNA-
binding ability, which consequently leads to stabilization and accumulation of NEXT substrates such
as PROMPTs [152]. Interestingly, cells become hypersensitive to a DNA damaging reagent when RBM7
is depleted, and cells lacking RBM7 exhibit poor survival after drug treatment [152]. Although it is still
largely unclear how these changes in the DDR affect cell physiology, there are interesting suggestions
that a fraction of promoter-associated lncRNAs can modulate transcription of neighboring genes.
For example, cyclin D1 (CCND1) PROMPTs upregulated in response to DNA damage by ionizing
irradiation provide a binding platform for the RNA-binding protein FUS/TLS. FUS/TLS recruited to
the CCND1 promoter through PROMPTs represses the histone acetyltransferase activity of CBP/p300,
which results in decreased CCND1 transcription [154]. However, it seems that PROMPT-mediated
gene regulation is not widespread, since no correlation was observed between altered expression
of the downstream gene and increased PROMPT levels in DNA damage or Rrp40 depletion [155].
This might possibly indicate that most PROMPTs lack sequence elements necessary for recruiting
specific RNA-binding proteins, and the action of only a small fraction of PROMPTs may be required
for the DDR.
4.2. R-Loop Resolution and Genomic Integrity
R loops are three-stranded structures composed of the nascent RNAhybridizedwith DNA template
and the resultant displaced single-strandedDNA (ssDNA). R-loop resolution is a critical step tomaintain
genome integrity, since the displaced ssDNA is vulnerable to DNAdamage [156–159]. Moreover, R loops
are associated with human disease (reviewed in [160–163]). Intriguingly, multiple studies have reported
the involvement of the exosome in R-loop resolution and genome integrity. In yeast, depletion of Rrp6
or Trf4 leads to R loop-mediated genomic instability and hyperrecombination [164,165], as well as
accumulation of aberrant truncated RNA products released from an R loop [166]. These factors also
promote the loading of ssDNA binding protein RPA to double-strand breaks (DSBs), and activate the
checkpoint kinase Mec1/ATR, which facilitates the formation of continuous Rad51 filaments to initiate
homologous recombination [167]. Strikingly, overexpression of RNase H, which removes R loops by
digesting the RNA strand of RNA/DNA hybrids, dramatically rescued the rate of genome instability
in TRAMP-depleted cells [168]. In human cells, the DNA/RNA helicase SETX (Senataxin), which
plays a key role in R-loop resolution [169], directly interacts with the exosome subunit Rrp45 [170].
The interaction requires sumoylation of SETX, which interestingly, is blocked by certain SETXmutations
in ataxia oculomotor apraxia 2 (AOA2) patients. It is speculated that SETX recruits the exosome to R
loops to promote degradation of the RNA unwound and released by SETX, and thus prevents possible
rehybridization and the resultant DNA damage.
Over the last decade, the concept has emerged that exosome-mediated R-loop prevention is
a critical step in immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM)
in B lymphocytes [171]. To initiate CSR and SHM, activation-induced cytidine deaminase (AID)
deaminates cytidines on both template and non-template DNA strands of transcribing switch regions.
However, the template DNA strand hybridized with a nascent transcript cannot be modified by AID
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because of limited access to the template strand. Basu et al. identified the core RNA exosome EXO-9 as
a key factor that promotes AID access to the template strand in the context of RNA/DNA hybrids,
and thus, CSR and SHM [172]. The interaction between AID and the RNA exosome is promoted by
the E3 ubiquitin ligase NEDD4, which regulates clearance of Pol II from the immunoglobulin switch
region [173]. In mouse B cells and embryonic stem cells (ESCs) containing a conditional inversion
allele of Exosc3 (Rrp40) or Exosc10 (Rrp6), which allows conditional ablation of the exosome by drug
treatment, loss of the exosome results in enhanced R-loop formation and genomic instability, due to
an increase of ncRNAs associated with TSS and superenhancers [174–176]. More recently, it was shown
that Mtr4 has an RNA/DNA hybrid unwinding activity, and Mt4-deficient B cells exhibited greater
R-loop formation at the immunoglobulin heavy chain locus [177].
4.3. RNA Export and Translation
In addition to its role in NEXT loading to nascent transcript 50 ends, the CBC is required to
initiate nuclear RNA export by recruiting various proteins. The TREX mRNA export complex is
recruited to the 50 end of mRNAs through the export adaptor proteins ALYREF and THO associating
with CBC [178–180]. While splicing enhances TREX recruitment [181], the interaction of ALYREF
with the cap-binding protein CBP20 was shown to stimulate nuclear export of capped intronless
mRNAs [180]. CBC-associating factor ZC3H18 can also enhance export of intronless mRNAs [182].
Recently, Fan et al. showed that Mtr4 competes with the export adaptor protein ALYREF for binding
to ARS2, and thus inhibits nuclear export, providing an important checkpoint to prevent undesired
transport of aberrant RNAs into the cytoplasm [183]. Intriguingly, CBCA (CBC–ARS2) and ZC3H18
are also found in the ZFC3H1 interactomes [49], suggesting that Mtr4–ZFC3H1 can also be recruited to
CBCA assembled on the 50 cap structure. Therefore, it is possible that both NEXT and Mtr4–ZFC3H1
can antagonize ALYREF binding to CBCA. This competition, as well as the rapid RNA degradation of
poly(A)-tailed lncRNAs by Mtr4–ZFC3H1, is particularly important, since normally unstable lncRNAs
are exported to the cytoplasm in cells lacking Mtr4–ZFC3H1 [20,184]. Of note, there is a link between
RNA 30 end cleavage/polyadenylation and export. Several 30 cleavage and polyadenylation factors
interact with RNA export factors. For example, Pcf11 directly interacts with the yeast homolog
of ALYREF, Yra1 [185]; CFIm68 directly binds to the mRNA export receptor NXF1 [186]; CPSF100
and CFIm proteins associate with the THO subunit THOC5 [187,188]; and CstF64 and PABPN1
help ALYREF-binding to mRNA 30 ends [189]. Therefore, effective recruitment of RNA export
complex, including ALYREF, is mediated not only by CBC, but also the 30 processing machinery
and a poly(A)-tail. Recent remarkable progress in ribosome profiling technologies [190] has led to the
realization that ribosome binding or even translation of lncRNAs is pervasive in mammals [191–197].
Concordantly, exported lncRNAs in Mtr4–ZFC3H1 deficient cells become ribosome-associated and
likely translated. Because of the translatability of lncRNAs, as well as the more mRNA-like structures
of Mtr4–ZFC3H1 substrates (presence of the cap and a poly(A)-tail) than those of NEXT substrates [49],
the aberrantly exported Mtr4–ZFC3H1 substrates appear to overwhelm translation machinery and
disrupt the quantitative balance between ribosomes and translatable RNAs, which leads to global
reduction in heavy polysomes and translation [20,184].
Recently, Sinturel et al. reported intriguing findings that diurnal oscillations in liver mass and
hepatocyte size are regulated by rhythmic changes in ribosome biogenesis, in which the nuclear
exosome plays a role [198]. In this study, using mice, they demonstrated that these changes are
controlled by feeding time: diurnal changes were observed only in mice fed during night and ad
libitum, but not in day-fed mice. Importantly, they found that the number of ribosomes also exhibited
diurnal fluctuations. In the active/dark phase, translation of ribosomal protein mRNAs was found to
be significantly enhanced, and thus, protein synthesis rates increased, while in the resting/light phase,
ribosomal protein synthesis was decreased, leading to an imbalance between ribosomal proteins and
rRNAs. TRAMP functions to rebalance the amount of these factors by polyadenylating and degrading
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excess rRNAs in incomplete ribosomal subunits. These events contribute to a daily rhythm of mouse
liver protein content.
4.4. Stem Cell Self-Renewal and Differentiation
Precise regulation of the activity and maintenance of the fidelity of gene expression is vital for
stem cell self-renewal, differentiation, and development. Studies have suggested that the nuclear RNA
exosome is essential for maintaining progenitor cell function and preventing premature differentiation.
A defective exosome pathway can lead to aberrant accumulation of RNAs, among which are mRNAs
encoding differentiation-specific transcription factors, and ultimately break the balance between
proliferation and differentiation. For example, the nuclear exosome directly degradesGRHL3 transcripts,
which encode a transcription factor critical for epidermal differentiation [199]. Depletion of the
exosome subunit Rrp45 (EXOSC9) leads to loss of progenitor cells from the basal epidermal layer
and premature differentiation. More recently, Skamagki et al. suggested that the exosome plays
an important role in maintaining pluripotent stem cell redox status in mice [200]. They found that
the transcription factor ZSCAN10, which activates transcription of EXOSC1/2/5 genes, is expressed
at a low level in induced pluripotent stem cell clones generated from aged tissue donors, and the
decreased expression of RNA exosome subunits causes the accumulation of AU-rich element-containing
RNAs, including glutathione peroxidase 2 (Gpx2). Overexpression of GPX2 increases the reduced form
of glutathione, thus scavenging glutathione-mediated reactive oxygen species, which consequently
blunts the DDR and reduces apoptosis. Similar defects were observed following knockdown (KD)
of exosome subunits EXOSC2 and/or EXOSC8 in ESCs. Mtr4 is also important in cell proliferation
and differentiation. On the one hand, Mtr4 expression is highly upregulated when the self-renewal
state of ESCs is induced by inhibitors of kinases, known as 2 inhibitors (2i) [201]. On the other hand,
KD of Mtr4 resulted in moderate to severe mouse ESC death [202]. Additionally, depletion of Mtr4
impairs mitosis and induces cell differentiation in the murine cancer cell lines Neuro2A and P19 [203].
All the above indicates that levels of the exosome subunits correlates with cell differentiation. Indeed,
Rrp4/Rrp40/Rrp42/Rrp45 (EXOSC2/3/7/9) expression is enriched in progenitor cells, but decreased
upon epidermal differentiation in humans [199]. These observations strongly suggest that an abundance
of the exosome is a critical prerequisite to maintain stem and progenitor cells in an undifferentiated state.
4.5. Influenza A Virus (IAV) Ribogenesis and Infectivity
A recent study revealed the significance of the exosome in influenza A virus (IAV) ribogenesis and
growth [204]. In this study, Rialdi et al. analyzed the proteome of viral polymerase complex-interacting
proteins, and identified the core exosome subunits. Intriguingly, they found that viral polymerase
activity is attenuated in cells transfected with siRNAs against exosome subunits and in patient-derived
cells harboring an EXOSC3 (Rrp40) mutation. Importantly, viral growth was suppressed in these
cells, indicating the essential role of the exosome in viral biogenesis. NEXT-assisted exosome seems to
be co-opted by the viral RNA polymerase, since similar results were obtained following RBM7 KD.
Moreover, synthesis of host/viral chimeric transcripts generated as a result of “cap snatching”, in which
initiation of viral transcription is primed using 50 ends of host transcripts (cap with 10–20 downstream
nucleotides), is decreased upon exosome-depletion. Collectively, these results suggest that the nuclear
exosome coordinates with viral polymerase during the initial steps of viral transcription with Pol II at
host promoters to enhance influenza A virus ribogenesis and infectivity. From the evolutionary point
of view, viruses need to integrate their biological activities into hosts by recycling regulatory RNAs
generated by hosts. The exosome, as the hub of RNA surveillance system, can be co-opted by viruses
to facilitate the efficient formation of cellular/viral hybrid RNAs and cap-snatching.
5. Conclusions and Perspectives
The RNA exosome and its co-factors monitor the versatility and specificity of a huge variety of
RNA substrates, and thus plays a crucial role in regulating the activity and maintaining the fidelity of
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gene expression. Numerous studies have revealed that an impaired RNA surveillance system can break
RNA homeostasis, and thus cause detrimental consequences in multiple biological processes leading
to human diseases (reviewed by Morton et al. [149]). However, there are still many unanswered
questions about both the fundamental and the pathological mechanisms of the nuclear exosome:
how are both specificity and versatility of RNA substrates guaranteed at the same time in the RNA
surveillance system? What is the comprehensive mechanism of the nuclear exosome in multiple
biological processes, including maintenance of genome integrity and cell differentiation? Deeper
understanding of the complexities of the RNA surveillance system has the potential to lead to novel
therapeutic remedies to fight human disease.
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 Abstract  
The human genome consists of approximately 3 billion base pairs, but only 1 to 2 % of it codes 
for proteins. Much of the non-coding DNA is however transcribed and generates non-coding RNAs, 
including for example enhancer-derived RNAs, or eRNAs. Previous studies have suggested that 
most eRNAs are transcribed by RNA polymerase II (RNAP II), but not polyadenylated. We now 
describe a genome-wide analysis of eRNAs in which the nuclear surveillance machinery has been 
compromised, and our analyses indicate that a large fraction of eRNAs are in fact polyadenylated. 
Assessing the mechanisms involved, we found that the Integrator complex plays an important role 
in polyadenylated (pA+) eRNA biogenesis, and that their exosome-dependent degradation requires 
two cofactor complexes containing the RNA helicase Mtr4. We also show that the canonical 
poly(A) polymerases PAP-α and PAP-γ play a major role in the 3’ end processing of pA+ eRNA. 
Additionally, we find that under deficient nuclear surveillance conditions, pA+ eRNAs accumulate 
in the cytoplasm and associate with polysomes, suggesting that at least some are translated. Our 
findings not only identified an unexpected large pool of unstable polyadenylated eRNAs, but also 






Continuing improvements in deep-sequencing techniques have revealed that a large 
portion of the nonprotein-coding human genome is transcribed. Amongst the transcripts produced 
are an abundant class of unstable RNAs transcribed by RNA polymerase II (RNAP II) from 
transcriptional enhancers known as enhancer (e) RNAs (ENCODE Project Consortium, 2012). 
Enhancers were originally defined as DNA elements that activate transcription of nearby protein-
coding genes, characterized by a lack of orientation and distance requirements from target 
promoters (Banerji et al., 1981; Bulger and Groudine, 2011; Moreau et al., 1981; Schaffner, 2015). 
Enhancers can be located upstream, downstream, or in the coding region of genes, but are 
frequently hundreds if not many thousands of base pairs distant from target promoters (Bulger and 
Groudine, 2011).  
The current view of how enhancers function involves chromatin “looping,” such that 
enhancer and promoter regions are in direct contact with each other. This reflects association of 
transcription factors bound to enhancers (Levine, 2010) with factors at the promoter, with this 
association facilitating gene activation (Bulger and Groudine, 2011; (Furlong and Levine, 2018) 
and allowing bidirectional exchange of components of the transcriptional machinery (Lam et al., 
2014; Li et al., 2016). Consistent with this, RNAP II has been shown to localize to enhancers 
(Heintzman et al., 2007; Koch et al., 2008; Kim et al., 2010). While this may reflect part of the 
gene activation mechanism, it is consistent with the fact that enhancers are frequently transcribed 
(De Santa et al., 2010; Kim et al., 2010; Masternak et al., 2003; Rogan et al., 2004; Tuan et al., 
1992). Indeed, a number of studies have illustrated architectural and functional similarities 
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 between enhancers and promoters: enrichment of general transcription factors (e.g. TATA-binding 
protein, TBP) and serine 5-phosphorylated RNAP II, DNase I hypersensitivity, related histone 
modification patterns, and bidirectional transcription (Core et al., 2014; Furlong and Levine, 2018; 
Kim et al., 2010; Kim and Shiekhattar, 2015; Whalen et al., 2016).  
Active enhancers are characterized by specific chromatin modifications and by 
bidirectional transcription originating from the enhancer region. When an enhancer is activated, 
typically by binding a “pioneer” transcription factor (Schaffner, 2015), it undergoes histone 
modifications leading to a looser chromatin structure, enabling transcription factor binding and 
RNAP II recruitment to initiate bidirectional transcription (Heinz et al., 2015; Li et al., 2016). 
eRNA expression can thus be a signature of enhancer activation. Recent genome-wide profiling 
has annotated 40,000-65,000 active enhancers, based on epigenetic makers, binding of 
transcriptional co-activators and detection of 5’ capped RNAs (Andersson et al., 2014; Djebali et 
al., 2012; Li et al., 2016). Another genome-wide study of nearly 9,000 cancer patient samples 
using TCGA RNA-seq data further validated the existence of these enhancers and detected on 
average approximately 4,500 active enhancers in any given cancer type (Chen et al., 2018).  
Enhancer RNAs are exceptionally unstable due to the constant degradation by nuclear 
RNA exosome complex. The RNA helicase Mtr4 is an essential co-factor for the eukaryotic nuclear 
exosome, and functions by unwinding RNA substrates and delivering them to the exosome core 
(Johnson and Jackson, 2013; Ogami et al., 2018). Three Mtr4-containing exosome adaptor 
complexes have been identified so far in human nuclei, known as hTRAMP, NEXT and 
PAXT/PPC. The hTRAMP complex consists of the non-canonical poly(A) polymerase TRF4-
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 2/PAPD5, the zinc-knuckle protein ZCCHC7 and Mtr4, and is mainly responsible for rRNA 
processing and decay (Lubas et al., 2011). The Nuclear Exosome Targeting (NEXT) complex 
facilitates the turnover of various short-lived nuclear RNA substrates, including eRNAs, upstream 
antisense RNAs (uaRNAs, also known as promoter upstream transcripts, PROMPTs), and 3’ 
extended products from snRNA and histone genes (Lubas et al., 2015; Lubas et al., 2011). Later, 
the Poly(A) tail Exosome Targeting (PAXT) or Polysome Protector Complex (PPC) was found to 
be involved in the degradation of more extensively polyadenylated nuclear RNAs, including a 
small fraction of eRNAs, prematurely terminated RNAs produced from many protein coding genes 
(ptRNAs), and uaRNAs (Meola et al., 2016; Ogami et al., 2017). Besides the shared subunit Mtr4, 
NEXT contains the Zn-finger protein ZCCHC8 and the RNA-binding protein RBM7, while the 
Zn-knuckle protein ZFC3H1, and perhaps the nuclear poly(A)-binding protein PABPN1, are part 
of the PAXT/PPC complex. The complex was dubbed the PPC because depletion of either subunit 
results in stabilization, cytoplasmic transport and association of normally unstable, nuclear 
restricted RNAs with polysomes, and inhibition of mRNA translation (Ogami et al., 2017).  
While the above studies are making inroads in understanding eRNA turnover, many 
aspects of eRNA biogenesis remain unclear. However, one important factor is the Integrator 
complex. The Integrator was originally discovered to be crucial for 3’ processing of certain 
snRNAs (Baillat et al., 2005). Additionally, Integrator is necessary for productive transcriptional 
elongation of EGF target genes following activation (Gardini et al., 2014). Another study on EGF-
induced eRNAs found that depletion of Integrator subunits led to increased level of RNAP II on 
enhancer regions, and faulty termination and extended transcription of EGF-induced eRNAs, 
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 providing strong evidence that Integrator functions in eRNA biogenesis, specifically 3’ processing. 
Notably, this study also found a significant increase of polyadenylated eRNAs derived from the 
EGF-responsive enhancers under the depletion of Integrator (Lai et al., 2015). Two Integrator 
subunits, INTS9 and INTS11, constitute the catalytic core, and show sequence homology with the 
pre-mRNA 3’ processing factors CPSF100 and CPSF73, respectively, while INTS4 associates with 
INTS9/11 as a “Symplekin-like” scaffold, to form the Integrator cleavage module (Albrecht et al., 
2018). Interestingly, multiple Integrator subunits were detected in our previous proteomics analysis 
of the purified pre-mRNA 3’ processing complex (Shi et al., 2009), suggesting their possible 
involvement in mRNA processing. eRNAs, however, have been thought to be largely non-
polyadenylated, with previous studies suggesting that ~90% of eRNAs lack a poly(A) tail 
(Andersson et al., 2014; Li et al., 2016).  
Here we have further investigated eRNA biogenesis, especially how their 3’ ends are 
fashioned. By impairing the nuclear exosome degradation system, we show that a large fraction of 
eRNAs are indeed polyadenylated (pA+ eRNAs). Consistent with this, pA+ eRNAs typically 
contain AAUAAA-like and G/U-rich signal sequences near their 3’ ends. However, we found that 
the Integrator functions in the biosynthesis of pA+ eRNAs as well as ptRNAs, and that both the 
NEXT and PAXT/PPC complexes are required for pA+ eRNA degradation. Moreover, we provide 
evidence that the canonical poly(A) polymerases, PAP-α/γ, are crucial for assuring the proper 3’ 
cleavage of pA+ eRNAs. We also find that pA+ eRNAs, under nuclear surveillance deficient 
conditions, can be transported to cytoplasm and associate with polysomes. Our findings have 
provided new insights into eRNA biogenesis and degradation mechanism, and suggest novel 
60
 similarities between eRNAs and other RNAP II transcribed RNAs.  
 
Results 
A large fraction of eRNAs detected under nuclear surveillance deficient conditions are 
polyadenylated 
As described above, previous work has indicated that depletion of exosome cofactors 
such as Mtr4 results in increased accumulation of otherwise unstable nuclear polyadenylated 
RNAs. To extend these findings, we set out to examine whether under such conditions there might 
be a significant accumulation of polyadenylated eRNAs (pA+ eRNAs). In our previous study using 
3’ region extraction and deep sequencing (3’READS; Hoque et al., 2013), we detected significant 
accumulation of polyadenylated ua- and pt- RNAs following depletion of Mtr4, but not other 
NEXT subunits (Ogami et al., 2017). To extend this analysis to eRNAs, we reanalyzed the data by 
mapping the reads to enhancer regions characterized in the ENCODE project (ENCODE Project 
Consortium, 2012). To reduce false detection, each pA+ eRNA was annotated only when >= 2 
reads were assigned to an enhancer region in >= 2 samples. We detected 3919 pA+ eRNAs in total 
under NEXT subunit depletion conditions (KD of Mtr4, ZCCHC8 or RBM7), while only 1761 
pA+ eRNAs under control conditions (Figure 1A). Thus, blocking the nuclear surveillance 
pathway allowed us to capture more pA+ eRNAs. Additionally, we found that 32% of detected 
pA+ eRNAs were transcribed bidirectionally, whereas 68% were unidirectional. Unidirectional 
eRNAs were also refered as 1d-eRNAs, whereas bidirectional as 2d-eRNAs in previous studies. 
Consistent with our results, 1d-eRNAs have been found to be often polyadenylated (Koch et al., 
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 2011; Natoli and Andrau, 2012). 
Next, we classified the 3919 pA+ eRNAs into three groups based on their genomic 
locations, and dubbed them the intergenic group, the intragenic group, and the ua group (Figure 
S1A). The definition of these three groups is illustrated in Figure S1A: Intergenic eRNAs are 
eRNAs generated from enhancers located between genes; the intragenic group includes eRNAs 
generated from enhancers located within genes; and the ua group is defined as eRNAs produced 
from regions within 4 kb upstream of transcription start sites of genes. These overlap with, and 
can be difficult to distinguish from, uaRNAs; hence the name.  
 There were 1457 (37% of the total pA+ eRNAs detected) pA+ eRNAs in the intergenic 
group, 1843 (47%) in the intragenic group, and 619 (16%) in the ua group (Figure S1B, C). We 
also compared our 3’READS data with published RNA-seq data under NEXT complex depletion 
conditions, and found that Mtr4 depletion can indeed capture eRNAs with poly(A) tails, which 
were sometimes absent in these previous RNA-seq experiments (Meola et al., 2016). For example, 
novel poly(A) tail peaks were detected under Mtr4 KD conditions on enhancer EN515 and 
EN27780 RNAs in 3’READS but not RNA-seq analysis (Figure S1D). For other eRNAs, such as 
EN29068 and EN70250, reads were consistent between 3’READS and RNA-seq data (Figure 
S1D). These results raise the possibility that polyadenylation of eRNAs may be more prevalent 
than previously thought. 
 We next wished both to confirm directly that select eRNAs identified in the above 
analysis were polyadenylated and also analyze the length of the added poly(A) tails. To this end, 
we performed an RNA ligation-mediated poly(A) test (RL-PAT) assay to characterize the poly(A) 
62
 tail length of several pA+ eRNAs that we detected (see Figure S2 for a schematic illustration of 
the RL-PAT assay) (Rassa et al., 2000). siRNA knockdown (KD) of Mtr4, as well as PABPN1, a 
subunit of the PAXT complex (Meola et al., 2016), led to accumulation of pA+ eRNAs (originating 
from both plus (+) and minus (-) strands) with complicated polyadenylation patterns that slightly 
differed between Mtr4 and PABPN1 KDs (Figure 1B). All three eRNAs tested (EN11/14/17) had 
poly(A) tails of various lengths, from ~100 nts to, remarkably, ~1000 nts. Treatment with RNase 
H and oligo(dT) confirmed that these were indeed polyadenylated eRNAs. We next performed RT-
qPCR (oligo(dT)-primed RT) of bidirectional pA+ eRNAs EN11/14/17 following Mtr4, ZFC3H1 
or PABPN1 depletion. All the pA+ eRNAs examined accumulated after siRNA KDs compared to 
control (Figure 1C). Noticeably, EN11+/- and EN14+/- were more sensitive to Mtr4 depletion than 
ZFC3H1/PABPN1 KDs, indicating a minor role of PAXT/PPC complex in their degradation. In 
contrast, EN17+/- eRNAs were very sensitive to both Mtr4 and PAXT subunit depletion, revealing 
a more significant role of the PAXT/PPC complex in EN17 degradation. This data indicates that 
pA+ eRNA transcripts are targeted by various exosome-targeting pathways.  
 
PAXT/PPC and NEXT complexes share half of the pA+ eRNA substrates, most of which are 
sensitive to the depletion of the Integrator complex  
The above data suggest that a substantial fraction of eRNAs are polyadenylated. Given 
that this was unexpected, we decided to investigate this using a more sensitive and accurate version 
of the 3’READS technique, 3’READS+ (Zheng and Tian, 2017). We performed 3’READS+ 
analysis of RNA extracted from control HeLa cells or cells depleted of the following three eRNA 
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 regulators: ZCCHC8 (NEXT), ZFC3H1 (PAXT/PPC) or INTS4 (Integrator) (Figure 2A). INTS4 
KD most likely disrupts the structural core of the Integrator complex since studies have shown that 
INTS4 functions as a “Symplekin-like” scaffold for the association of the catalytic module 
INTS9/11 (Albrecht et al., 2018). INTS4 depletion thus allowed us to examine the role of 
Integrator in pA+ eRNA biogenesis, while KD of subunits of the NEXT and PAXT/PPC complex 
should stabilize pA+ eRNAs, as above. We mapped the 3’READS+ signals obtained in each 
condition to ENCODE annotated enhancer regions, and found a total of 6453 pA+ eRNAs (Figure 
2B). While the ENCODE project has generated large-scale annotation of ~53,000 enhancers 
expressed in the human genome across multiple tissues and samples (Djebali et al., 2012), a recent 
genome-wide study of nearly 9,000 cancer patient samples using TCGA RNA-seq data has shown 
that approximately 4,500 enhancers on average were active in a given cancer type (Chen et al., 
2018). The numbers of active enhancers in cancer patients (~4,500) is comparable with the number 
of pA+ eRNAs detected by 3’READS+ (6,453), indicating that polyadenylation of eRNAs is in 
fact a prevalent phenomenon.  
We next classified the pA+ eRNAs based on their genomic locations into the three 
categories described above, intergenic, intragenic, and ua-like (Figure 2B, C). While a subset of 
enhancer regions overlap with other known transcribed elements, including for example introns, 
ncRNAs and uaRNAs, they all have been characterized with classic enhancer-specific chromatin 
status, including DNase hypersensitivity, p300 binding, H3K27Ac, and H3K4Me1 in the 
ENCODE project, reflecting their functions as typical enhancers. However, to eliminate any 
potential signal contamination, further analysis of the intergenic and intragenic eRNAs was 
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 conducted by only considering eRNAs that do not overlap with any other known transcribed 
elements, such as 5’UTR, 3’UTR, CDS, and ncRNAs. We analyzed the ua group as well, which 
was also named as ua/eRNAs. This generated 1,859 pA+ eRNAs in the intergenic group, 1,421 in 
the intragenic group, and 619 in the ua group. Among these 3,899 pA+ eRNAs, 2,875 were 
significantly upregulated (>2 fold increase as compared to siCtrl) under KD conditions (Figure 
2D), while 518 were downregulated (>2 fold decrease as compared to siCtrl) (Figure S3).  
To understand the target specificity of NEXT, PAXT/PPC and Integrator complexes, we 
also classified the pA+ eRNAs according to the identity of the factor depleted (Figure 2D). We 
found that regardless of genomic annotations, depletion of both NEXT and PAXT/PPC subunits 
led to significant accumulation of pA+ eRNAs, with substantial overlap (Figure 2D). However, 
ZFC3H1 depletion affected a larger number of pA+ eRNAs compared to ZCCHC8 depletion. A 
total of 1190 intergenic pA+ eRNAs were detected under ZCCHC8 and ZFC3H1 deficient 
conditions, with 587 (~49%) overlapping. Additionally, we observed ~50% overlap (486) for 
intragenic eRNAs, and ~55% (425) for ua/eRNAs. Thus PAXT/PPC and NEXT complexes both 
control pA+ eRNA accumulation, and share approximately half of the pA+ eRNAs we detected. 
Interestingly, INTS4 KD also resulted in enhanced pA+ eRNA accumulation. In fact, there was 
considerable overlap with ZCCHC8 and ZFC3H1 KDs (see the overlapping areas of the three 
factor KD in Figure 2D). Only a very small fraction of INTS4-depletion sensitive pA+ eRNAs 
were not also affected by ZCCHC8 and ZFC3H1 KD (81 (~6.8%) for intragenic eRNAs, 44 
(~4.5%) for the intergenic eRNAs, and 16 (~2.1%) for ua/eRNAs). These results suggest that 
depletion of INTS4, and presumably inactivation of the Integrator complex, actually enhanced 
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 synthesis of pA+ eRNAs, and that these eRNAs were largely the same as those subject to NEXT- 
or PAXT/PPC-mediated decay. We discuss the mechanistic implications of these findings below. 
We validated our 3’READS+ analysis by performing oligo(dT) primed RT-qPCR and 
RL-PAT assays on six select pA+ eRNAs. We confirmed the bidirectional expression of the pA+ 
eRNAs tested and their sensitivities towards the KD subunit (Figure 2E). Additionally, the RL-
PAT assay results were consistent with our 3’READS+ analysis, again revealing long poly (A) tails 
(from 50 nt up to 1000 nt) (Figure S4). Thus, our combined results indicate that a large fraction of 
eRNAs are indeed polyadenylated, and that these poly(A) tails can be unusually long. 
 
Alternative polyadenylation is rare in eRNAs 
The 3’READS+ analysis allowed us to thoroughly examine the global effect of ZCCHC8, 
ZFC3H1 and INTS4 KD on various polyadenylated RNA substrates. It is widely known that 
alternative polyadenylation (APA) is a very common mechanism of gene control found in a 
majority of mRNAs across all eukaryotic species (reviewed by Tian and Manley, 2017). Given the 
large number of pA+ eRNAs detected in our study, we were curious whether APA also occurs in 
those eRNAs, and if so are they regulated by any of these factors? 
 To investigate APA in eRNAs, we reanalyzed the 3’READS+ data described above. As 
shown in Figure 3A (upper panels), APA events are rare in pA+ eRNAs (less than 70 APA events 
detected out of 3,919 pA+ eRNAs). Additionally, APA of these eRNAs was not affected by 
ZFC3H1, INTS4, or ZCCHC8 KD. For comparison, we also examined the APA events in mRNAs, 
and found that ZFC3H1 and INTS4 depletion led to a global shift of poly(A) site usage, from distal 
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 to proximal, whereas depletion of ZCCHC8 had only minimal effects (although a few affected 
genes also showed RNA length shortening) (Figure 3A, lower panels). Furthermore, we found that 
ZFC3H1 KD resulted in preferential accumulation of two types of transcripts: ptRNAs and 
uaRNAs, while INTS4 KD only caused ptRNA upregulation (Figure 3B).  
 
Poly(A) signals are highly enriched in enhancer regions and actively utilized in pA+ eRNA 
production 
Our data indicate that a large fraction of eRNAs are polyadenylated at their 3’ ends. 
Especially in light of previous studies suggesting that most 3’ ends were nonpolyadenylated and 
formed by the Integrator (Andersson et al., 2014; Kim et al., 2010; Lai et al., 2015), it seemed 
possible that the mechanism might be more analogous to that employed to form certain U snRNA 
3’ ends (Baillat et al., 2005). While previous work showed that poly(A) signal sequences are 
enriched in enhancer regions (Wang et al., 2018), we wished to extend these results and determine 
if such signals were located in the proximity of the 3’ ends we detected in our analysis. To this end, 
we first searched for the most abundantly used AAUAAA canonical PAS motif and/or the 
AUUAAA motif, in the pA+ eRNAs detected by 3’READS+, and found a ~70% enrichment of 
AAUAAA and a higher enrichment (76.2%-88.6%) of both PAS motifs (Figure 4A, B). Known 
PAS motifs including AAUAAA and its variants were found in 79% of human mRNA (Beaudoing 
et al., 2000). Therefore, the abundance of PAS motifs in pA+ eRNAs is at least comparable with 
mRNA. Most functional PAS motifs are known to be located approximately -20 nt upstream of the 
cleavage and poly(A) sites (Tian et al., 2005). Importantly, we found that pA+ eRNAs displayed a 
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 significant enrichment of PAS motifs within 20-40 nt upstream of the 3’ cleavage site, regardless 
of their direction (+ strand vs. - strand) and genomic locations (Figure 4C). Localization of the 
AUUAAA motif in pA+ eRNAs also showed similar patterns (Figure S5). These data strongly 
suggest that AAUAAA motifs are utilized in generation of pA+ eRNA 3’ ends. 
Another sequence element commonly found in active polyadenylation sites is the 
downstream GU-rich sequences. GU-rich sequences are usually located 10-40 nt downstream of 
the cleavage site, and lack a clear consensus sequence (Colgan and Manley, 1997; Tian and Manley, 
2017). To determine whether pA+ eRNAs utilize GU-rich elements similar to mRNAs, we 
conducted a motif search of the pA+ eRNAs detected in our 3’READS analysis. To simplify the 
algorithm, we searched for eight GU-rich elements that have been previously characterized (Perez 
Canadillas and Varani, 2003). As shown in Figure S6, both pA+ eRNAs and mRNAs showed an 
enrichment of these GU-rich sequences downstream of the cleavage sites. However, a GU-rich 
peak was also detected in the region upstream of the cleavage sites in mRNAs, while such a peak 
was absent in pA+ eRNAs. This likely corresponds to U-rich sequences in mRNAs that have been 
described previously (Neve et al., 2017; Tian and Manley, 2013, 2017). These U-rich elements 
often correspond to UGUA motifs that bind the cleavage/polyadenylation factor Cleavage Factor 
I (Brown and Gilmartin, 2003; Yang et al., 2011), and its absence suggests that this factor may not 
function in pA+ eRNA 3’ end formation.  
The absence of an upstream GU-rich peak raises the possibility that there may be 
differences between the polyadenylation machinery that acts to generate the 3’ ends of pA+ eRNAs 
and mRNAs. However, the enrichment of upstream PAS and downstream GU-rich elements in 
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 pA+ eRNAs suggests that pA+ eRNAs might employ a polyadenylation machinery similar to the 
one that functions on mRNAs. To test this hypothesis, we depleted with siRNAs two 
Cleavage/Polyadenylation Specificity Factor (CPSF) subunits: CPSF30 (also known as CPSF4) 
and CPSF73 (also known as CPSF3), together with Mtr4 (to achieve higher accumulation of 
eRNAs), and examined whether the cleavage efficiency of pA+ eRNAs was affected (Figure S7A). 
For this, we used RT-qPCR with primers either spanning or downstream the poly(A) site (detecting 
uncleaved product of pA+ eRNAs specifically), normalized by primers upstream of the poly(A) 
site, to detect possible 3’ cleavage defects in both pA+ eRNAs after CPSF-30/-73 KD. We found 
that 3’ cleavage of all the mRNAs tested (gapdh, β-actin, fos, fn1) was as expected impaired after 
the depletion of CPSF-30/-73, corresponding with an accumulation of uncleaved products (Figure 
S7B). However, 3’ cleavage of pA+ eRNAs (EN11+/-, EN14+/-, EN17+/-) was not affected by 
CPSF-30/-73 KD (Figure S7C). Given the presence of canonical PASs in these pA+ eRNAs, these 
results were unexpected and suggest that pA+ eRNA 3’ end formation might employ a distinct 
mechanism from that used by mRNAs. 
 
Canonical poly(A) polymerases PAP-α/γ function in eRNA polyadenylation 
The above data indicate that a large fraction of eRNAs are polyadenylated, and in a PAS-
dependent manner. This suggested the involvement of the canonical 3’ processing machinery, but 
the above data question this idea. In light of this, an intriguing question is the identity of the 
poly(A) polymerase(s) (PAPs) responsible for poly(A) tail synthesis. Two types of PAPs have been 
described, dubbed canonical and noncanonical. The canonical PAPs, PAP-α and PAP-γ, are known 
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 to polyadenylate most mRNAs (Laishram, 2014), and polyadenylation is crucial for mRNA 
stabilization, export and efficient translation (Colgan and Manley, 1997). Also, more recent studies 
have shown that addition of a long poly(A) tail (100-500 A residues) by the canonical PAPs 
promotes degradation of intron-less nuclear RNAs by the nuclear exosome (Beaulieu et al., 2012; 
Bresson and Conrad, 2013; Bresson et al., 2015).  
We therefore wanted to identify whether the canonical PAP(s) are responsible for eRNA 
polyadenylation. To this end, we KDed PAP-α/γ under Mtr4-depleted conditions in HeLa cells 
(Figure 5A). We then performed RL-PAT assays of specific eRNAs (EN11 is shown in Figure 5B, 
EN14 and EN17 in Figure S8) and sequenced the gel purified PCR products to identify the exact 
position of the RNA 3’ end. Interestingly, we found that depletion of PAP-α/γ led to defective 
eRNA 3’-end cleavage, and consequently transcript readthrough and polyadenylation at 
downstream sites. Occasionally, we failed to identify the downstream cleavage sites due to 
extremely long readthrough (new 3’-end sites are denoted by green triangles on the genomic 
sequences). We also note that there was some apparent variability in precise cleavage sites and 
poly(A) status and tail length of individual eRNAs from experiment to experiment (e.g., EN11; 
Figure 5C), perhaps reflecting the unusual features of eRNA 3’ processing. Nonetheless, our data 
indicate that the canonical poly(A) polymerases PAP-α/γ both are crucial for the proper 3’ 
processing of pA+ eRNA. 
 
pA+ eRNAs are transported to the cytoplasm and associate with active polysomes following 
Mtr4 KD  
Several studies have found that certain unstable nuclear polyadenylated RNAs are 
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 transported to the cytoplasm when Mtr4 or ZFC3H1 are depleted (Fan et al., 2017; Ogami et al., 
2017; Silla et al., 2018). To determine whether pA+ eRNAs behave similarly, we analyzed their 
localization by subcellular fractionation followed by RT-PCR under control and Mtr4 KD 
conditions. Analyzing the same fractions we used in our previous study (Ogami et al., 2017), we 
indeed detected substantial accumulation of pA+ eRNAs (EN11/14/17 bidirectional transcripts) in 
the cytoplasmic fraction after Mtr4 depletion (Figure 6A, cf. lane 2) compared to control cells, 
which show a higher pA+ eRNA abundance in the chromatin fraction (Figure 6A, cf. lanes 1, 3, 
and 5). This phenomenon is consistent with our previous finding of cytoplasmic accumulation of 
pt/ua-RNAs following Mtr4 KD (Ogami et al., 2017). 
We next asked if some of the cytoplasmic pA+ eRNAs might associate with ribosomes 
and be translated. Indeed, we previously observed that pt- and ua-RNAs that escaped from the 
nucleus following Mtr4 KD became polysome associated (Ogami et al., 2017). Interestingly, open 
reading frames (ORFs) of various lengths were identified in several of the eRNAs analyzed above 
(for example, the longest ORF for EN11+ is 465 nt, EN11- 291nt, EN14+ 204 nt, EN14- 222 nt; 
see Figure S9A). To examine whether these eRNAs associated with active ribosomes, we 
conducted polysomes fractionation to evaluate the distribution of the EN11 and EN14 bidirectional 
transcripts, as well as GAPDH mRNA for comparison, in both siCtrl- and siMtr4- treated cells. 
This analysis revealed an increased association of both EN11 and EN14 transcripts with polysomes 
after Mtr4 KD. Consistent with our previous analysis (Ogami et al., 2017), GAPDH mRNA 
polysome association was diminished (Figure 6B; quantitation in Figure S9B). We showed 
previously that Mtr4 KD led to a global reduction of mRNA translation, and proposed that this 
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 reflects competition for the translation machinery by cytoplasmic accumulation of normally 
unstable nuclear pA+ RNAs (Ogami and Manley, 2017; Ogami et al., 2017). It is very likely that 
the stabilized pA+ eRNAs participate in the same process. 
 
Discussion 
In this study, we have explored degradation and biogenesis mechanisms of eRNAs. Our 
results revealed that a large fraction of eRNAs that accumulate under nuclear surveillance deficient 
conditions are polyadenylated. This contrasts with previous studies suggesting a lack of 
polyadenylation in eRNAs. We further identified and examined the roles of three important 
complexes in pA+ eRNA accumulation, the PAXT/PPC, NEXT Integrator complexes. We found 
that both the PAXT/PPC and NEXT are required for pA+ eRNA degradation. The Integrator, 
whose role has been highlighted in mRNA 3’-end cleavage and eRNA biogenesis, functions in the 
biosynthesis of pA+ eRNAs, as well as ptRNAs. Additionally, we found that the detected pA+ 
eRNAs typically contain AAUAAA-like and GU-rich signal sequences near their 3’ cleavage sites. 
We also provide evidence that the canonical poly(A) polymerases, PAP-α/γ, function in pA+ eRNA 
cleavage and polyadenylation, and can lead to production of exceptionally long poly(A) tails. 
Importantly, stabilized pA+ eRNAs accumulate in the cytoplasm and appear to be translated. Our 
findings have provided new insights into eRNA metabolism, and also suggest a novel model 
connecting the roles of the Integrator in mRNA and eRNA synthesis. 
Previous studies have identified a large pool of putative enhancers and defined 
bidirectional transcription from the enhancer region as a feature of enhancer activation. Although 
transcribed by RNAP II, eRNAs have been thought to be largely nonpolyadenylated. One study 
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 was unable to detect any eRNAs in poly(A)- RNA fractions (Kim et al., 2010), whereas another 
estimated that approximately 90% of eRNAs were non-polyadenylated (Andersson et al., 2014). 
In sum, all studies reached the consensus that most eRNAs lack poly(A) tails (reviewed by Lam 
et al., 2014; Li et al., 2016). However, those studies were conducted under intact nuclear 
surveillance conditions, and thus may have failed to capture fast-turnover nuclear RNA species. 
By blocking the nuclear surveillance pathway, we found that a large number of eRNAs (~6500) 
are in fact polyadenylated. Notably, pan-cancer analyses using the TCGA database found that the 
maximum number of eRNAs detected in any given cancer type is less than 10,000, while the 
average number is around 4,500 (Chen et al., 2018). By comparing these numbers, we conclude 
that eRNA polyadenylation is a far more prevalent mechanism than previously thought. Given that 
highly similar molecular features and shared transcriptional machinery of enhancers and promoters 
have been revealed in many studies (Core et al., 2014; Furlong and Levine, 2018; Kim et al., 2010; 
Kim and Shiekhattar, 2015; Whalen et al., 2016), it was in fact somewhat surprising that enhancer-
derived RNAs appeared to lack poly(A) tails, especially since promoter-derived non-mRNA 
transcripts (e.g. ptRNAs and uaRNAs) are all polyadenylated (Kaida et al., 2010; Preker et al., 
2008). Our characterization of pA+ eRNAs provides new examples of the similarities between 
enhancers and promoters.  
Over the past decades, increasing evidence has supported the enhancer-promoter 
interaction model, where the exchange of transcriptional machinery between enhancer and 
promoter may occur from both directions (Hatzis and Talianidis, 2002; Wang et al., 2005). 
Moreover, similar features between enhancers and promoters have been revealed in recent years, 
73
 such as their sequence motifs, chromatin architectures, transcription machineries, as well as 
regulation mechanism (Core et al., 2014; Scruggs et al., 2015; Vihervaara et al., 2017). Further 
extending these similarities, our results showed that both enhancer- and coding gene- derived 
transcripts are controlled by ZFC3H1 (a subunit of the PAXT complex) and INTS4 (a subunit of 
the Integrator complex). 
We first consider the role of INTS4. On the one hand, depletion of INTS4 led to 
accumulation of ptRNAs but not uaRNAs. This can be explained by the previous finding that the 
Integrator complex is important for productive transcription elongation, functioning by recruiting 
the super elongation complex (Gardini et al., 2014). Consequently, defective transcription 
elongation in INTS4-depleted cells led to a decrease in full-length mRNA and an increase in 
ptRNAs or shorter coding transcripts. Expression of transcription elongation-independent uaRNAs 
was not affected by Integrator subunit depletion (Preker et al., 2011). On the other hand, we also 
found that Ints4 depletion caused a significant increase in pA+ eRNA accumulation. Based on 
these findings, we propose a model for the role of Integrator in mRNA/eRNA synthesis. As 
indicated in Figure 7A, active enhancer and promoter regions are in direct contact with each other 
to form a chromatin loop, with transcription machinery at both regions. When a transcription 
complex is in elongation status on the coding gene, depletion of the Integrator complex leads to 
RNAP II stalling (Gardini et al., 2014; Skaar et al., 2015; Stadelmayer et al., 2014), and 
consequently early termination and generation of ptRNAs. Alternatively, when RNAP II is at the 
at the promoter, we propose that depletion of Integrator causes transcription machinery switch to 
enhancer regions, leading to increased level of eRNA synthesis.  
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 We note that another study found that Integrator depletion led to accumulation of extended 
eRNAs following EGF induction (Lai et al., 2015). However, we did not observe any significant 
change of pA+ eRNA length after INTS4 KD. A possible explanation is that the eRNAs in our 
study were all stimulus-independent, thus representing a different group of eRNAs compared with 
EGF-induced eRNAs. This study also observed an increased level of polyadenylated eRNAs on 
EGF-responsive enhancer regions under the depletion of Integrator (Lai et al., 2015), which is 
consistent with and expanded by our finding: the accumulation of polyadenylated eRNAs after 
depleting Integrator subunits, doesn’t limit to EGF-responsive enhancers, but occurs without EGF 
stimulus. 
How might ZFC3H1 function in production of mRNA? Previous studies in our lab showed 
that depletion of ZFC3H1 (and Mtr4) caused increased accumulation of both ptRNA and uaRNAs  
and transport to the cytoplasm, indicating the involvement of ZFC3H1/Mtr4 in turnover and 
nuclear retention of these RNAs. Later, another study confirmed the central role of ZFC3H1 as a 
nuclear pA+ RNA retention factor (Silla et al., 2018). In the current study, we not only detected 
significant accumulation of pA+ eRNAs, but also observed a significant increase of pt/ua-RNAs. 
Importantly, this was accompanied by a proportional decrease of full-length mRNA transcripts 
after ZFC3H1depletion. In contrast, Mtr4 depletion only led to accumulation of pt/ua-RNAs, but 
did not affect abundance of full-length transcripts, indicating an Mtr4-independent function for 
ZFC3H1. Given the finding that the upregulation of ptRNAs and uaRNAs in both ZFC3H1 and 
INTS4 depleted cells is accompanied by a proportional downregulation of the corresponding full-
length RNAs, we believe that ZFC3H1 also plays a role in RNA biogenesis, besides its known 
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 function in RNA degradation and nuclear retention (Meola et al., 2016; Ogami et al., 2017; Silla 
et al., 2018). Future studies will be required to elucidate its precise role. 
Our analyses of the poly(A) signals and G/U-rich regions of pA+ eRNAs indicate that pA+ 
eRNAs utilize AAUAAA-like and G/U-rich signal sequences to direct their polyadenylation and 
cleavage, just like mRNAs. It is well known that such elements are critical for 3’-end formation of 
most mRNAs (Gil and Proudfoot, 1987; McLauchlan et al., 1985). Therefore, we suspected that 
those pA+ eRNA might share a similar 3’-end processing mechanism with mRNAs. However, 
when we depleted two key cleavage and polyadenylation specificity factors, CPSF- 30 and -73, 
which recognize PAS signals and promote mRNA cleavage (Colgan and Manley, 1997; Mandel et 
al., 2008; Millevoi and Vagner, 2010), unlike mRNAs, pA+ eRNA cleavage was not affected, 
indicating that a distinct mechanism of 3’ end cleavage might be employed in pA+ eRNA. 
Consistent with this, the coexistence of both pA+ and pA- eRNAs, which is not observed with 
mRNAs, suggests differences in mechanism. The detailed mechanism of pA+ eRNA 3’ end 
cleavage remains to be elucidated. 
Our analyses of individual eRNAs have discovered that the canonical poly(A) polymerases, 
PAP-α/γ, are crucial for the proper 3’ end processing of pA+ eRNA. Depletion of PAP-α/γ led to 
read-through of normal cleavage sites. Nevertheless, those eRNAs were still polyadenylated, since 
they can be observed in RL-PAT assays, which only detect polyadenylated RNA species. It is 
possible that these eRNAs were polyadenylated by other noncanonical poly(A) polymerases under 
the depletion of PAP-α/γ. Consistent with this, early in vitro studies from our lab provided evidence 
that PAP is frequently required for cleavage as well as poly(A) tail synthesis (Ryner et al., 1989; 
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 Takagaki et al., 1988). Confirming whether the PAP-α/γ involved polyadenylation mechanism 
applies globally to eRNAs will require a genome-wide study. 
Addition of a poly(A) tail can be sufficient for mRNA nuclear export (Brodsky and Silver, 
2000; Fuke and Ohno, 2008). Indeed, our subcellular fractionation experiments showed that pA+ 
eRNAs were exported into the cytoplasm when the nuclear surveillance system has been 
compromised. Additionally, our RL-PAT assays showed that pA+ eRNAs had poly(A) tails of 
various lengths, from ~100 nts to, remarkably, ~1000 nts. In contrast, mammalian mRNAs 
typically have poly(A) tails of ~250 nucleotides (reviewed by Weill et al., 2012). We are 
particularly interested in the exceptionally long poly(A) tails. Previous studies have found that 
PAP by itself is unable to generate poly(A) tails with defined lengths, instead, PABPN1 measures 
the length of poly(A) tails and guarantees the poly(A) extension no longer than ~250 nt (Bienroth 
et al., 1993; Wahle, 1995). It is possible that those pA+ eRNAs with exceptionally long poly(A) 
tails are not regulated by PABPN1. Additionally, it has been found that the longer the poly(A) tail 
is, the more stabile the mRNA is: on the one hand, poly(A) tails of mRNAs are gradually shortened 
in the cytoplasm; on the other hand, mRNAs will only be degraded after removing the long poly(A) 
tails (reviewed by Eckmann et al., 2011; Weill et al., 2012). Therefore, the exceptionally long 
poly(A) tails might indicate longer half-life of pA+ eRNAs in the cytoplasm.   
A previous study in our lab found that excessive polyadenylated RNA species in the 
nucleus “leak” into the cytoplasm under nuclear surveillance deficient conditions, thus disrupting 
the translational system by competing with mRNAs to bind ribosomes (Ogami et al., 2017). 
Consistent with this, our polysome fractionation experiments showed that nuclear pA+ eRNAs can 
77
 also accumulate in the cytoplasm following Mtr4 KD, associate with monosomes/polysomes, and 
we suggest facilitate the suppression of coding-gene translation. To extend this finding, we 
investigated whether those eRNAs, containing short open reading frames (sORFs), can be 
translated. While ribosome occupancy doesn’t necessarily guarantee translation (Guttman et al., 
2013), lncRNAs, defined as noncoding RNAs longer than 200 nucleotides, represent a source of 
short open reading frames (sORFs), which have the coding potential for micropeptides (Cohen, 
2014; Frith et al., 2006; Pauli et al., 2015). Moreover, another study showed that a large amount 
of monosomes are translating sORFs actively (Heyer and Moore, 2016). It is reasonable to suspect 
that some of pA+ eRNAs, which can be transported to the cytoplasm and bind ribosomes, might 
also be a source to generate micropeptides, or even longer ones. In addition, enhancers lack 
sequence conservation, and undergo rapid evolution across mammalian species (Villar et al., 2015), 
thus are tend to contain de novo sORFs and produce de novo micropepides, if translated. The 
generation of de novo micropepides have been suggested to provide advantages to species during 
evolution (Ruiz-Orera and Alba, 2019). The concept of enhancer-derived translation merits further 
study. 
Our findings are summarized and illustrated in Figure 7B. Both pA- and pA+ eRNAs can 
be generated from the enhancer-promoter loops. All of these naturally undergo exosome 
mediated degradation through the NEXT and PAXT pathways. Consistent with this, a recent 
study found that the RNA helicase activity of Mtr4, a subunit of both PAXT/PPC and NEXT 
complexes, is enhanced when incorporated into the NEXT complex, whose optimal substrates 
actually require a polyadenylated 3’ end (Puno and Lima, 2018). We have also highlighted a 
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 critical and novel mechanism of eRNA polyadenylation, which indicates a substantially greater 
pool of naturally unstable polyadenylated eRNAs than previously thought. This further validates 
the enhancer-promoter interaction model by characterizing their shared regulators as well as 
shared polyadenylation mechanism. Lastly, we have provided evidence that under certain 
conditions eRNAs can be stabilized, transported to the cytoplasm and even translated. The 
significance of these unexpected findings will be the topic of future studies.  
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 Materials & Methods 
Primers and siRNAs 
All siRNAs, primers and enhancer genome locations in this study are listed below. 
Primers for RT-qPCR Sense (5'-3') Antisense (3'-5') 
GAPDH ACGACCACTTTGTCAAGCTC TTCCTCTTGTGCTCTTGCTG 
NEAT1 TTGGTTCTGAGCTGCGTCTA GTGCTGTAAAGGGGAAGAAA 
EN11+ CTTACGAACTGGGGAGTCCA TTAATAGAGACCGGGTCTGGC 
EN11- CCTACATTGTCTGCATTCAGGA AACAGAGCCAGACCCTGTGT 
EN14+ GGGCATCATTATGGATTTGG GGCTCCTTCCAGTACTAAAAAGC 
EN14- CGCTTGAACGAGTGACTGAA GGGCATCATTATGGATTTGG 
EN17+ ACACAATGTCCTGTGGGTGA GAAGAAAGCCCTTCTGCTCA 
EN17- GAGCCATGGATGGGTGATAA GGGTCTTCCAAAGTGCAAAG 
EN323+ AACCGAGATTGCTGTCCCAG AACGGCTACTCCTAAACGGG 
EN323- TCGCTTGTGAGTCGGTAACC TGGGGTGGCTTACTGCTTTT 
EN20600+ AGCACTTTGAGCGGATCACA CCTCCCGGGTTAAAGCGATT 
EN20600- CCGCACCGTTGACCTAGAAT AGAAGACCAAGCAGGCAGAC 
EN23771+ TGCCATACTACACCGTGCTG TGCCCCCTTGCTGTTTTAGT 
EN23771- TGTACACCTGGCTCCTCCTT TTCCCTTTGTGGTAGCCGAG 
EN50286+ TCACTGCAGTATTGGGAGCC CAGGCCGTCCCTAACAATGT 
EN50286- CAGGCCGTCCCTAACAATGT TCACTGCAGTATTGGGAGCC 
 
 
Primers for 3' cleavage RT-qPCR Sense (5'-3') Antisense (3'-5') 
GAPDH-internal probe ACCTGACCTGCCGTCTAGAA ACCTGACCTGCCGTCTAGAA 
GAPDH-uncleaved CCGCACCTTGTCATGTACCA TCTCACCTTGACACAAGCCC 
b-actin-internal probe ACTTCGAGCAAGAGATGGCC AAGGAAGGCTGGAAGAGTGC 
b-actin-uncleaved AAGGCTTTTGGTCTCCCTGG AAGGCTTTTGGTCTCCCTGG 
fos-internal probe GTGCCAACTTCATTCCCACG TCATGGTCTTCACAACGCCA 
fos-uncleaved CTTGAGGTCTTTTGACATGTGG AAGGTTGGTCGCATTCAACT 
fn1-internal probe AAGGTTGGTCGCATTCAACT AGGGACTTTCCTCTCTGCCA 
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 fn1-uncleaved GATTGCCTGCAAGGGAAATA GCCATGCCAAAAGTGTCAG 
EN11+ upstream of cleavage site CTTACGAACTGGGGAGTCCA TTAATAGAGACCGGGTCTGGC 
EN11+ downstream of cleavage site CTTACGAACTGGGGAGTCCA AAAGGGAGGAAAAGGGGACG 
EN11- upstream of cleavage site CCTACATTGTCTGCATTCAGGA AACAGAGCCAGACCCTGTGT 
EN11- downstream of cleavage site CCTACATTGTCTGCATTCAGGA TCCTGAAGGGCCTGCTGTAA 
EN14+ upstream of cleavage site GGGCATCATTATGGATTTGG GGCTCCTTCCAGTACTAAAAAGC 
EN14+ downstream of cleavage site AGGCTCAGCTGGAAAATGGA AGGCTCAGCTGGAAAATGGA 
EN14- upstream of cleavage site CGCTTGAACGAGTGACTGAA GGGCATCATTATGGATTTGG 
EN14- downstream of cleavage site GGCCAAATCCATAATGATGCCC GCCACAGAGTGAGAGCTTGT 
EN17+ upstream of cleavage site ACACAATGTCCTGTGGGTGA GAAGAAAGCCCTTCTGCTCA 
EN17+ downstream of cleavage site ACACAATGTCCTGTGGGTGA CTCTGTTTTCTGTTTCGTCAGC 
EN17- upstream of cleavage site GAGCCATGGATGGGTGATAA AACCCATCTTGTCAGGCAGA 
EN17- downstream of cleavage site ACTCATGAGCTGCCAATCCT CTTGCATGATGCCTGGAAGC 
 
 
Primers for RL-PAT 1st Round PCR 2nd Round PCR 
EN11+ ATCTCTGCACTGGCCTTACGAA AGTCCAAGGGGTTCCAGGA 
EN11- CCTACATTGTCTGCATTCAGGA ACACAGGGTCTGGCTCTGTT 
EN14+ TGTCAGATCAGCACAAAGCA GAGCTGGGATTGAAAAGACC 
EN14- GGATTTCTCAGGCTCCTTCC CCAAATCCATAATGATGCCC 
EN17+ ACACAATGTCCTGTGGGTGA TGAGCAGAAGGGCTTTCTTC 
EN17- GAGCCATGGATGGGTGATAA TCTGCCTGACAAGATGGGTT 
EN323+ ACTGGAGCGTGATTGGTGAG AACCGAGATTGCTGTCCCAG 
EN323- TCGCTTGTGAGTCGGTAACC AACGGCTACTCCTAAACGGG 
EN20600+ AGCACTTTGAGCGGATCACA CGAGACCAACCTGACCAACA 
EN20600- CCGCACCGTTGACCTAGAAT ACTCCGTGGCTACATTGTCG 
EN23771+ TGACCACATTTCCAGGGCTC TGCCATACTACACCGTGCTG 
EN23771- AGGTCTGACATTAGCCAGGC TGTACACCTGGCTCCTCCTT 
EN50286+ TTTGCCTTGGCCAGATAGGA TCACTGCAGTATTGGGAGCC 




 siRNA Sense (5'-3') Antisense (3'-5') 
siMtr4 #1 CAAUUAAGGCUCUGAGUAATT UUACUCAGAGCCUUAAUUGTT 
siMtr4 #2 siRNA ID: s223606 (ThermoFisher) Catalog # 4392420 
siPABPN1 #1 AGUCAACCGUGUUACCAUATT UAUGGUAACACGGUUGACUTT 
siPABPN1 #2 GGCCUUAGAUGAGUCCCUATT UAGGGACUCAUCUAAGGCCTT 
siZCCHC8 #1 GAAAUACAACAGAAUAAAATT UUUUAUUCUGUUGUAUUUCTT 
siZCCHC8 #2 GGAAUGUACCUCAGGAUAATT UUAUCCUGAGGUACAUUCCTT 
siINTS4 #1 UUGCAGUUUUGGUACUUAUTT AUAAGUACCAAAACUGCAATT 
siINTS4 #2 CCUGUAAAAGUUUAUAUAATT UUAUAUAAACUUUUACAGGTT 
siZFC3H1 GAAACAAGCUGAAGAAGAATT UUCUUCUUCAGCUUGUUUCTT 
siPAP-α CAAAUCCAGUGCUAUUGAATT UUCAAUAGCACUGGAUUUGTT 
siPAP-γ  CAACAGAAUUCUACGUAUATT UAUACGUAGAAUUCUGUUGTT 
   
   









Cell culture and siRNA transfections 
HeLa cells were cultured in DMEM supplemented with 10% FBS. The siRNAs were transfected 
using DharmaFECT 1 (GE Dharmacon) at 20nM and maintained for 48 or 72 hrs. To obtain high 
knockdown efficiency after 72hr treatment, the siRNA transfection was repeated 48hrs after the 




Mtr4 (NB100-1574), ZCCHC8 (NB100-94995), ZCCHC7 (NBP1-89175) INTS4 (NB100-60660) 
antibodies were from Novus Biologicals. ZFC3H1(A301-456A), PABPN1 (A303-523A), PAP-
a(A301-010A), PAP/g(A302-427A) antibodies were from Bethyl Laboratories. CPSF-30 (sc-
393316) and CPSF-73 (sc-393001) antibodies were from Santa Cruz Biotechnology. GAPDH 




Total RNA was purified from control and siRNA-treated cells. RNA integrity was analyzed by 
using Agilent Bioanalyzer. Samples with an RNA integrity number (RIN) >9.0 were subjected to 
3′READS+ analysis following the protocol described in Zheng et al., (2016). Briefly, after RNA 
fragmentation, poly(A)+ RNA fragments were captured on magnetic beads coated with a chimeric 
oligonucleotide (oligo CU5T45), which contained 45 thymidines at the 5′ portion and five uridines 
at the 3′ portion, and subjected to RNase H digestion, which removed the bulk of the poly(A) tail 
and eluted RNA from beads. Eluted RNA was ligated to 5′ and 3′ adapters followed by reverse 
transcription, PCR amplification, and deep sequencing on an Illumina platform. 3′READS+ data 
were analyzed as described (Zheng et al., 2016). 
 
Poly (A) + RNA motifs analysis 
Number of eRNA polyadenylation motifs were counted in the corresponding loci of the GRCh37 
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 hg19 reference genome. Distances between pA motifs and cleavage sites were obtained by 
subtracting their genomic positions. Only the motifs upstream of the cleavage sites were 
considered as effective pA motifs.  
 
RT-qPCR 
Total RNA was isolated using TRIzol (Thermo Fischer Scientific) according to the manufacturer's 
instructions, followed by DNase I digestion at 37°C for 30min (Thermo Fischer Scientific). 2µg 
of DNaseI-treated RNA was reverse-transcribed with oligo(dT) primer using Maxima Reverse 
Transcriptase (Thermo Fischer Scientific). Reactions were diluted 15 times in water, and qPCR 
was performed with primers listed in Table. S1 using Power SYBR (Thermo Fischer Scientific). 
All data were normalized to GAPDH. 
 
RNA-ligation coupled PAT assay (RL-PAT) 
DNase I-treated total RNAs were ligated with KO109 P-anchor-NH2 oligonucleotide using T4 
RNA ligase 1 (New England Biolabs) in the presence of 15% PEG8000 at 14°C for 30min, and 
reverse-transcribed with KO108 anchor AS primer using Maxima Reverse Transcriptase (Thermo 
Fischer Scientific). Semi-nested PCR was performed using gene-specific forward primers and 
KO105 reverse primer. PCR products were resolved in 1.5-2.0% agarose gel prestained with EtBr. 
To remove poly(A) tails, 10µg of DNase I-treated RNAs were mixed with 50 pmol of oligo(dT)18 
in RNase H buffer (50mM Tris-HCl (pH 7.4), 100mM NaCl, 10mM MgCl2) and incubated at 85°C 
for 5min, 42 °C for 10min, and then incubated in the presence of 2U Hybridase-Thermostable 
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 RNase H (Epicentre) at 42°C for 30min. RNase H-treated RNAs were isolated using TRIzol. 
 
Subcellular fractionation  
Seventy-two hours after siRNA transfection, HeLa cells grown in a 10-cm dish were washed twice 
with PBS and collected by scrap- ing and centrifugation. Cell pellets were resuspended in 400 µL 
of swelling buffer (10 mM Tris-HCl at pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 5 U of RNasin, 1× 
protease inhibitor cocktail) and incu	bated for 15 min on ice. Cells were homogenized by passing 
a 26- gauge needle attached to a 1-mL syringe until >90% of cells were disrupted (typically 10∼20 
strokes). Half of the lysate was kept in a new tube and used as whole-cell lysate. The rest of the 
200 µL of lysate was mixed with 2 µL of 10% NP-40, gently tapped, and im- mediately centrifuged 
in an Eppendorf centrifuge 5424 at 6,000 rpm for 5 min. The supernatant was kept in a new tube 
and used as cytoplasmic fraction. The pellet was washed once with swelling buffer, resuspended 
in 100 µL of glycerol buffer (20 mM Tris-HCl at pH 8.0, 75 mM NaCl, 0.5 mM EDTA, 50% glyc- 
erol, 0.85 mM DTT, 5 U of RNasin, 1× protease inhibitor cocktail) by pipetting, and then mixed 
with 100 µL of nucleus lysis buffer (20 mM HEPES-NaOH at pH 7.6, 7.5 mM MgCl2, 0.2 mM 
EDTA, 300 mM NaCl, 1 M urea, 1% NP-40, 1 mM DTT, 5 U of RNasin, 1× protease inhibitor 
cocktail). The mixture was pulse-vortexed three times, incubated for 1 min on ice, and then 
centrifuged in an Eppendorf centrifuge 5424 at 14,000 rpm for 2 min. The supernatant was used 
as nuclear-soluble fraction. The pellet was washed once with a 1:1 mixture of glycerol/nucleus 
lysis buffer and then resuspended in 200 µL of water. RNA was extracted using TRIzol, DNase I-
treated, and then reverse-transcribed with oligo(dT) or random primer using Maxima RT.  
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 Polysome fractionation  
HeLa cells were transfected with either siCtrl or siMtr4 and maintained in the same medium for 
the indicated times in five 10-cm dishes. On the day of harvest (∼80% confluency), cells were 
treated with either 50 µM BTdCPU or 100 µg/mL CHX for 3 h and 5 min, respectively, at 37°C. 
Cells were washed once with ice-cold PBS containing either 50 µM BTdCPU (Millipore) or 100 
µg/mL CHX and then resuspended in 400 µL of polysome lysis buffer (20 mM HEPES-NaOH at 
pH 7.6, 150 mM NaCl, 15 mM MgCl2, 0.5% NP-40, 80 U RNasin, 1× protease inhibitor cocktail) 
containing either 50 µM BTdCPU or 100 µg/mL CHX. After 10 min of incubation on ice, the 
lysates were centrifuged at 3000 rpm for 5 min, and the supernatant was centrifuged at 15,000 rpm 
for 5 min in a new tube. The supernatant was loaded onto 15%–45% sucrose gradients (20 mM 
HEPES-NaOH at pH 7.6, 150 mM NaCl, 5 mM MgCl2, 100 µg/mL CHX) followed by 
centrifugation at 39,000 rpm for 90 min using an SW41Ti rotor. Fractions (200 µL each) were 
manually collected, and A254 was determined using a Nanodrop spectrophotometer. RNA was ex- 
tracted by mixing with 1 vol of TRIzol, isopropanol-precipitated in the presence of GeneElute-
LPA (Sigma), and then reverse-transcribed with oligo(dT) primer using Maxima RT. To avoid 
efficiency differences in RT reactions, RNA amounts were equalized by adding purified yeast RNA 
(Thermo Fisher Scientific). No PCR products were generated when yeast RNA RT products alone 
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Figure legends 
Figure 1. Polyadenylated eRNAs were detected under Mtr4 depletion via RL-PAT assay and 
RT-qPCR. (A) Table of pA+ eRNAs detected by reanalyzing the published 3’READS data. Each 
pA+ eRNA characterized here had at least 2 reads in at least 2 experiment samples. (B) RL-PAT 
assay analysis of pA+ eRNAs following control, Mtr4, or PABPN1 siRNA treatment of Hela cells 
for 72 hours. RNase H treatment in the presence of oligo(dT) were applied to remove the poly(A) 
tails of RNA. The gel bands were cut out for sequencing to validate the amplification specificity. 
(C) RT-qPCR analysis of pA+ eRNAs after Mtr4, ZFC3H1, PABPN1 siRNA transfection. cDNAs 
were synthesized using oligo(dT) primers. 
 
Figure 2. Global analysis of polyadenylated transcripts under Mtr4 depletion condition 
identified a large fraction of pA+ eRNAs. (A) Western blot analysis of HeLa cells extracts after 
48hr of transfection of control, ZCCHC8, ZFC3H1, INTS4 siRNAs with two biological replicates. 
(B) Table of the classification of pA+ eRNAs detected in 3’READS+ based on their genomic 
locations. (C) Pie chart of the numbers of each group of pA+ eRNAs identified by 3’READS+ 
analysis under deficient nuclear surveillance condition. (D) Venn diagram of intergenic, intragenic 
and ua/eRNAs, which were upregulated at least 2 fold following indicated siRNA treatment as 
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 compared with control siRNA. (E) RT-qPCR analysis of six bidirectional pA+ eRNAs (EN323+/-, 
EN16441+/-, EN20600+/-, EN23771+/-, EN28928+/-, EN50286+/-) identified in 3’READS+ 
experiment under the treatment of control, ZCCHC8, ZFC3H1 and INTS4 siRNAs. cDNAs were 
synthesized using oligo(dT) primer.  
 
Figure 3. Alternative polyadenylation rarely exists in pA+ eRNAs, and is not affected by 
ZFC3H1, INTS4 or ZCCHC8 KD.  (A) Regulation of alternative polyadenylation of protein-
coding genes and pA+ eRNAs following KD indicated factors. mRNAs (upper panel) and pA+ 
eRNAs (lower panel) with significantly upregulated distal (red) and proximal (blue) pA isoforms 
are indicated in each graph, along with total numbers and ratios of upregulated versus 
downregulated. Dots and numbers in grey color indicate mRNAs and pA+ eRNAs with no 
significant change of APA after KD of indicated factor. Significantly regulated isoforms are those 
with P < 0.05 (Fisher’s exact test) and abundance change >5%. (B) Changes in relative abundance 
of the indicated transcript types following knockdown of ZCCHC8, ZFC3H1 or INTS4. The 
number of genes showing increases (UP) or decreases (DOWN) of each type of transcript are 
indicated. False discovery rate < 0.05. Schematic of various transcript types analyzed is shown on 
the right side: transcripts using the first (F), middle (M), or last (L) potential PAS in the 3′ 
untranslated region (UTR); the intronic PAS(I); the upstream (not 3′-most) exonic PAS (E); and 
the upstream antisense transcripts (UA). 
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 Figure 4. Poly(A) signals are highly enriched in enhancers and actively utilized in pA+ 
eRNAs. (A) The ratio of intergenic, intragenic, and ua pA+ eRNAs with canonical PAS detected 
in 3’READS+ analysis. (B) The ratio of ZCCHC8 KD, ZFC3H1 KD, INTS4 KD sensitive pA+ 
eRNAs with canonical PAS. (C) Histogram of PAS locations in pA+ eRNAs under indicated factor 
knockdown conditions. Data are presented as the frequencies of PAS positions within 6 kb of the 
transcription start site in a strand specific way (each column is 20 nt).  
 
Figure 5. Canonical poly(A) polymerase PAP-a/g assure proper 3’ processing of pA+ eRNAs. 
(A) Western blot analysis of HeLa cell extracts after 48h of transfection with control, Mtr4, PAP-
a, and PAP-g siRNAs. (B) Agarose gel of RL-PAT assay of bidirectional pA+ eRNA EN11 
following PAP and Mtr4 KD as indicated. Gel bands were excised and sequenced, then mapped 
back to the enhancer regions. Gel bands and termination sites are boxed with different color to 
indicate different knockdown conditions (yellow box on gel and yellow triangle on genome 
sequence for control siRNA KD, red for Mtr4 KD, light green for double KD of PAP-a or PAP-g 
with Mtr4, dark green for triple KD of PAP-a, PAP-g and Mtr4). (C) The plus strand transcripts 
derived from EN11 detected in RL-PAT assay. Both pA+ and pA- status for EN11+ were detected 
simultaneously after sequencing the excised gel bands. Additionally, different poly(A) lengths and 
termination sites of EN11+ were observed in two independent experiments. 
 
Figure 6. pA+ eRNAs are transported into the cytoplasm and associate with polysomes under 
deficient nuclear surveillance. (A) Subcellular fractionation of pA+ eRNAs, EN11, EN14 and 
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 EN17. Subcellular fractionation was performed after 72 hr of siCtrl or siMtr4 treatment, and total 
RNAs were isolated from each fraction. cDNAs were synthesized using oligo(dT) primer, and the 
pA+ eRNA, EN11, EN14 and EN17 were analyzed by PCR. Gels were prestained with EtBr. (B) 
Polysome fractionation profile of bidirectional pA+ eRNA EN11+/- and EN14+/-. RNA extracted 
from polysome fractionation were used for oligo(dT)-primed cDNA synthesis, followed with RT-
PCR. pA+ eRNA level was shown in the EtBr-prestained gel. Ribosome/polysome-associated 
fractions of pA+ eRNAs and GAPDH mRNAs are highlighted with red and green boxes, 
respectively. Quantification by ImageJ is in Figure S9B.  
 
Figure 7. Model for the biogenesis and regulation mechanisms of enhancer derived 
transcripts. (A) Model for Integrator-mediated biogenesis of RNAs. In the scenario of 
transcription elongation of protein-coding genes, depletion of the Integrator complex causes early 
termination of transcription, and thus lead to accumulation of ptRNAs. During transcription 
activation, depletion of the Integrator complex causes the switch of transcription machinery from 
promoters to enhancer regions, and consequently generated a large amount of pA+ eRNAs. (B) 
Model for pA+ eRNA biogenesis and degradation mechanisms. Both pA- and pA+ eRNAs are 
generated by RNAPII with the aid of the Integrator complex, and their 3’ end cleavage and 
polyadenylation requires PAP-a/g. The pA+ eRNAs will be degraded by the exosome via both 





 Supplementary Figure Legends 
Figure S1. The identification of pA+ eRNA under Mtr4 deficient condition via 3’READS 
analysis. (A) Schematic illustration of enhancer classification based on the genomic location: 
intergenic (inter), intragenic (intra), upstream antisense (ua) groups, regardless the overlap of 
certain enhancers with other DNA elements. (B) Pie chart of the number of each group of pA+ 
eRNAs identified by 3’READS analysis under depletion of Mtr4. (C) Table of the classification 
of putative pA+ eRNAs based on the genomic location. (D) The snapshots of 3’READS and RNA-
sequence reads of four pA+ eRNAs (EN515, EN29068, EN27780, EN70250) under deficient 
nuclear surveillance conditions. The polyA peaks are indicated with blue arrows. 
 
Figure S2. Schematic illustration of the RL-PAT assay. RNAs were ligated with the anchor 
oligonucleotide and reverse-transcribed using the primer complementary to the anchor sequence. 
The resulting cDNA was subjected to semi-nested PCR (1st round PCR using primers indicated by 
red and blue arrows; 2nd round PCR using primers indicated by orange and blue arrows), and PCR 
products were resolved in 2.0% agarose gels prestained with EtBr. In the end, the gel bands were 
cut for sequencing.  
 
Figure S3. A very small number of pA+ eRNAs were downregulated under deficient nuclear 
surveillance. Venn diagram of intergenic, intragenic and ua/eRNAs, which were downregulated 
at least 2 folds under each siRNA treatment.  
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 Figure S4. Validation pA+ eRNAs detected in 3’READS analysis with RL-PAT assay. Four 
pA+ eRNAs (EN323, EN20600, EN23771, EN50286) were validated by RL-PAT assay analysis 
following gel sequencing. The snapshots of 3’READS+ reads are displayed below the gel images. 
 
Figure S5. Noncanonical Poly(A) signal AUUAAA is actively utilized in pA+ eRNAs. 
Histogram of noncanonical PAS locations in pA+ eRNAs under indicated factor knockdown 
conditions. Data are presented as the frequencies of PAS positions relative to the transcription start 
site in a strand specific way (each column is 20 nt). Position 0 corresponds to the 3' base of the 
poly(A) signal. 
 
Figure S6. G/U rich regions are enriched at the 20nt downstream of the cleavage sites of both 
pA+ eRNAs and mRNAs. Histogram of the distance between G/U rich regions and the 
termination sites of pA+ eRNAs and mRNAs. Data are presented as the density of positions 
relative to the transcription termination site in a strand specific way for pA+ eRNAs (each column 
is 20 nt). Position 0 corresponds to the 3' base of the poly(A) signal. 
 
Figure S7. CPSF-30/-73 didn’t regulate the 3’ cleavage of pA+ eRNAs. (A) Western blot 
analysis of HeLa cells extracts after 72 hr of transfection with control, Mtr4, CPSF-30, CPSF-73 
siRNAs. (B) RT-qPCR analysis of the uncleaved transcripts of four genes (gapdh, β-actin, fos, fn1). 
The relative amount of the indicated uncleaved transcripts was calculated by using primers 
spanning the last poly(A) site of each gene and normalized to siCtrl and the internal probe of the 
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 gene. (C) RT-qPCR analysis of the uncleaved transcripts of three pA+ eRNAs in both transcription 
directions (EN11+/-, EN14+/-, EN17+/-). The amount of the uncleaved transcripts of pA+ eRNAs 
was calculated by using primers either spanning or locating downstream last poly(A) site and 
normalized to siCtrl and the primer upstream of the poly(A) site. 
 
Figure S8. RL-PAT assay analysis of bidirectional pA+ eRNA EN14 and EN17 following 
knockdown of PAP-a/g together with Mtr4. Agarose gel of RL-PAT assay of bidirectional pA+ 
eRNA EN14 and EN17 following PAP-a/g and Mtr4 KD conditions. The gel bands were cut and 
sequenced, then mapped back to the enhancer regions. Gel bands and termination sites are boxed 
with different color to indicate different knockdown conditions (yellow box on gel and yellow 
triangle on genome sequence for Ctrl siRNA KD, red for Mtr4 KD, light green for double KD of 
PAP-a or PAP-g with Mtr4, dark green for triple KD of PAP-a, PAP-g and Mtr4). 
 
Figure S9. Quantification of polysome fractionation of pA+ eRNA EN11 and EN14. (A) The 
longest putative ORFs detected in EN11 and EN14. (B) Band strength in each fraction in Figure 
6B was quantitated using ImageJ. Absolute signal values after background subtraction are plotted. 



























Chapter 4. Dynamic Subcellular Localization of RBBP6 Isoform3 Is Regulated by 
Monoubiquitylation and Importin 7 
  
119
 Dynamic Subcellular Localization of RBBP6 Isoform3 Is Regulated by 
Monoubiquitylation and Importin 7 
 
Yaqiong Chen1, Dafne Campigli Di Giammartino1,2, James J. Moresco3, John R. Yates III3, Carol 
Prives1 and James L. Manley1*  
 
1. Department of Biological Sciences, Columbia University, New York, New York 10027, USA. 
2. Joan & Sanford I. Weill Department of Medicine, Sandra and Edward Meyer Cancer Center, 
Weill Cornell Medicine, New York, NY 10021, USA. 
3. Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92037, 
USA 
 
* Corresponding author 
E-mail: jlm2@columbia.edu 
120
 Abstract  
Retinoblastoma-binding protein 6 (RBBP6) was initially identified as a large multidomain 
protein, interacting with p53 and Rb. Later, its diverse roles were uncovered in cell cycle 
progression, apoptosis, nucleic acid metabolism, differentiation, and mRNA processing. RBBP6 
protein has four isoforms, among which the shortest isoform, iso3, has only one domain: the 
DWNN (domain with no name) domain. The DWNN domain displays high similarities with 
ubiquitin, implying its function as a novel ubiquitin-like modifier. However, we show that the 
DWNN domain is actually not a ubiquitin-like modifier, but is itself ubiquitinated. Moreover, the 
monoubiquitylation of iso3 can facilitate its localization at chromatin. Additionally, we found that 
the C-terminal tail of iso3 also plays a role in iso3 chromatin localization, presumably by 
interacting with other factors of the polyadenylation machinery. Pulldown experiments of iso3 
followed by mass spectrometry identified Importin 7 as an iso3-interacting factor that assists its 
cytoplasmic localization. Our results identified novel mechanisms for the dynamic localization of 




The retinoblastoma-binding protein 6 (RBBP6) was initially discovered as a large 
multidomain protein (~ 250 KDa), interacting with both p53 and Rb (Saijo et al., 1995; Sakai et 
al., 1995; Simons et al., 1997). While the human RBBP6 gene codes for four protein isoforms, a 
majority of the early studies focused on the long-form RBBP6 protein, and revealed its crucial 
roles in various biological processes, including cell-cycle progression, apoptosis, nucleic acid 
metabolism, differentiation and mRNA processing (Di Giammartino et al., 2014; Gao and Scott, 
2003; Li et al., 2007; Miotto et al., 2014). RBBP6 was also found to be involved in various 
diseases: for example, the protein is overexpressed in many types of cancer (Chen et al., 2013; 
Moela and Motadi, 2016; Motadi et al., 2011; Motadi et al., 2018; Yoshitake et al., 2004). This is 
consistent with the finding that the long isoform of RBBP6 is a negative regulator of p53, by 
functioning as a scaffold protein to promote MDM2-mediated ubiquitination and degradation of 
p53/TP53 (Li et al., 2007). Another example is that RBBP6 mutation in its p53-binding domain 
leads to predisposition to myeloproliferative neoplasms, which suggests a p53-dependent pathway 
of RBBP6 in pathogenesis (Harutyunyan et al., 2016). Additionally, a more recent study identified 
RBBP6 as a negative regulator of Ebola virus replication, and thus has the potential to be a 
therapeutic target (Batra et al., 2018).  
Despite the diverse roles of RBBP6 revealed in previous studies, mRNA 3’ processing has 
been one of the most conserved function of RBBP6, from human (Di Giammartino et al., 2014) to 
yeast (Lee and Moore, 2014; Vo et al., 2001). Interestingly, RBBP6 is expressed in all eukaryotic 
organisms but its p53- and Rb-binding domains are only present in vertebrates (Figure 1A), 
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 indicating that the ability to modulate mRNA processing might be a more conserved functions of 
RBBP6 in all organisms, while the p53 and Rb binding domains in vertebrates allows for more 
specific regulatory mechanisms. 
RBBP6 homologs across species share three well-conserved domains at their N-terminus: 
the “Domain With No Name”, i.e. DWNN, the Zinc knuckle, and the RING finger domains (Figure 
1A). It has been found that the DWNN domain itself is expressed in vertebrates with a short C-
terminal tail, which is identified as RBBP6 isoform3 (iso3). A previous study in our lab has 
revealed the inhibitory function of RBBP6 iso3 by competing with long-form RBBP6 for the 
polyadenylation machinery binding (Di Giammartino et al., 2014). Remarkably, the structure of 
the DWNN domain displays high similarities with ubiquitin, which raised the intriguing possibility 
that RBBP6 iso3 itself may function as a novel ubiquitin-like modifier of other protein substrates 
(Pugh et al., 2006). Furthermore, the RING domain of the long-form RBBP6 is a signature domain 
for E3 ubiquitin ligases, and RBBP6 has been found to be an E3 ligase for several proteins 
including YB-1, ZBTB38, and TP53 (Chibi et al., 2008; Li et al., 2007; Miotto et al., 2014). We 
consequently speculated that the long-form RBBP6 might serve as the E3 ligase for iso3 
modification, if such modification exists. 
Here we describe experiments that explore whether iso3 is a ubiquitin-like modifier, and 
whether long-form RBBP6 functions as an E3 ligase for such a modification mediated by iso3. 
Surprisingly, we found that the DWNN domain is not a ubiquitin-like modifier, but instead is itself 
ubiquitinated. We investigated further the ubiquitylation process of iso3, and found that different 
ubiquitylation status, especially monoubiquitylation of iso3, can modulate its subcellular 
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 localization. We also found that the C-terminal tail of iso3 facilitates its nuclear localization. We 
also showed that the long form of RBBP6 is not the E3 ligase of iso3 ubiquitination. Furthermore, 
we identified by his-tag pulldown and mass spectrometry analysis an import factor, Importin 7 
(Imp7), that physically interacts with iso3, and revealed its crucial function in facilitating iso3 
cytoplasmic retention. Finally, we discuss the functional significance of such dynamic subcellular 
localization of RBBP6 iso3 protein, using cancer development as an example.   
 
Results 
Lysine-dependent protein modification is observed in RBBP6 iso3 protein 
The DWNN domain at the N-terminus of all four isoforms of the RBBP6 protein has been 
found to have a ubiquitin-like structure, and lysine residues that are likely to be equivalent to 
ubiquitin lysines (Pugh et al., 2006). Consequently, the initial aim of our experiments was to 
investigate whether the DWNN domain is a ubiquitin-like modifier as previously suggested. As 
shown in Figure 1A, the DWNN is expressed as a small single-domain protein, RBBP6 isoform3 
(iso3), in human. We constructed an N-terminally HA- and his-tagged iso3 (HA-his-iso3) vector, 
and overexpressed iso3 protein in HeLa cells. Exogenous iso3 protein accumulated in a time-
dependent manner, and, intriguingly, multiple bands appeared after 36hr transfection (Figure 1B). 
The molecular weight of HA-his-iso3 protein is approximately 17KDa, thus bands with molecular 
weights above 17KDa suggested that either RBBP6 iso3 protein can act as a modifier that can be 
attached to other proteins, or is itself modified. We further validated the existence of such protein 
modification by Western blot analysis with 3 different RBBP6 antibodies, which recognize distinct 
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 epitopes of the DWNN domain (Figure S1). Consistent with this, we obtained similar results for 
RBBP6 iso3 specific antibodies, showing that iso3 is indeed itself modified. 
We next wanted to investigate whether this iso3-involved protein modification is also 
lysine-dependent, just as ubiquitylation. We did a side-by-side comparison of the protein sequences 
of ubiquitin and the DWNN domain (Figure 2A). Lysine residues are highlighted in blue and 
labeled with amino acid numbers while the di-Glycine (di-Gly) residues are highlighted in pink. 
Mutation of lysine/di-Gly residues in ubiquitin has been widely used to abolish ubiquitination. The 
first ubiquitin molecule is covalently bound through its C-terminal di-Gly motif to lysine residues 
(sometimes cysteine, serine, threonine etc.) on protein substrates, which can be eliminated by 
mutating di-Gly residues. The second ubiquitin molecule in polyubiquitin chains are always bound 
to one of the seven lysine residues or the N-terminal methionine of the previous ubiquitin molecule. 
Therefore, mutating lysine residues on ubiquitin abolishes the formation of polyubiquitin chains 
(Hershko and Ciechanover, 1998; Varshavsky, 2012). For this reason, we mutated the lysine/di-
Gly residues of the DWNN domain into arginine and alanine, respectively, to check the effect on 
protein modification. Surprisingly, even after mutating all the lysine residues and di-Gly residues 
in the DWNN domain (the last two lanes: K8-66 and diGly in Figure 2B), we still observed protein 
modification by Western blot.  
RBBP6 iso3 actually has four additional lysine residues outside of the DWNN domain 
(Figure 2C). RBBP6 iso3 consists of the DWNN domain (76 amino acids), and a short C-terminal 
tail (32 amino acids). To examine the effect of the lysine residues in the C-terminal tail on protein 
modification, we next mutated these residues to arginine. Strikingly, only mutation of every single 
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 lysine residue in iso3 can fully eliminate the high molecular weight protein modifications (last lane 
“D+C1+C2” in Figure D2). This result provided evidence that the protein modification observed 
in RBBP6 iso3 is lysine-dependent. Especially, this modification doesn’t appear to rely on any 
specific lysine of iso3, since one lysine mutation can always be compensated by other remaining 
lysine residues without affecting the pattern of the protein modification. 
 
DWNN is not a ubiquitin-like modifier, but is itself ubiquitinated 
We next considered two possibilities that can explain what we have observed so far: The 
observed protein modification is due to ubiquitylation of RBBP6 iso3, or to a novel modification 
mediated by the DWNN domain. Given the fact that the modification is lysine-dependent, it is 
more likely to be ubiquitylation of RBBP6 iso3 protein. To test this, we transfected HeLa cells 
with HA-his-tagged iso3/DWNN vector and FLAG-ubiquitin vector together and performed his-
tag purification under denaturing conditions, in which only covalent protein-protein interaction 
could be detected. FLAG-Ub bound to both iso3 (Figure 3A) and the DWNN (Figure 3B) 
covalently. Consistently, overexpression of FLAG-Ub enhanced iso3 ubiquitylation significantly. 
It is noteworthy that the molecular weights of the bands detected by the FLAG antibody (i.e. 
ubiquitylated protein) were also consistent with those detected by HA antibody (i.e. modified iso3). 
Together, these results indicate that the DWNN domain is not a ubiquitin-like modifier, but is 
instead itself ubiquitylated.   
Finally, to validate iso3 ubiquitylation, we determined whether ubiquitylated iso3 is 
regulated by proteasome-mediated degradation. Iso3 transfected HeLa cells were cultured in the 
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 presence or absence of the proteasome inhibitors MG132, MG115 or lactacystin in a time-course 
manner (0hr, 6hr, 12hr, 24hr treatment, respectively). MG132 and MG115 can block the ubiquitin-
dependent 26S proteasome reversibly (Lee and Goldberg, 1998), whereas lactacystin inhibits the 
proteolytic activity of 20S proteasome, which is ubiquitin-and ATP-independent (Fenteany and 
Schreiber, 1998). Interestingly, we found iso3 protein modification only responded to MG132 and 
MG115 treatment, but not lactacystin (Figure 3C), confirming that this lysine-dependent and 
MG132/MG115-inducible protein modification of RBBP6 iso3 is indeed ubiquitylation. 
Given the fact that the long forms of RBBP6 are known to be a E3 ubiquitin-protein ligases, 
an intriguing possibility was that ae long-form RBBP6 might function as the E3 ligase for iso3 
ubiquitylation. As in Figure 1A, all RBBP6 homologs share three well-conserved domains at their 
N-terminus: the DWNN, the RING, and the Zinc knuckle domains. The RING domain is known 
to be a key domain to carry E3 ligase activity by binding to E2-ubiquitin thioester and activating 
discharge of ubiquitin cargo (Deshaies and Joazeiro, 2009). To test the possibility that RBBP6 
functions as the iso3 E3 ligase, we constructed a 3xFLAG-tagged RBBP6 N-terminal derivative 
(RBBP6N), containing the key RING domain, Zinc knuckle, the DWNN domain, as well as a 
RBBP6N derivative that only contained the RING domain and the Zinc knuckle (DDWNN). We 
additionally made two mutant RBBP6N vectors (“RING mut” and “Zinc mut” vectors), in which 
the conserved cysteine residues of either the RING or the Zinc knuckle domains are mutated into 
alanine. The mutated cysteines are highlighted in red in Figure 4A. The FLAG-tagged RBBP6N 
plasmid and its mutant derivatives were co-transfected with HA-his-iso3 into HeLa cells for 48hrs. 
Overexpression of neither RBBP6N nor its mutants affected iso3 ubiquitination, even when 
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 transfecting increasing amounts of the vectors into cells. Taken together, we concluded that 
RBBP6N is not the E3 ligase for iso3 ubiquitylation (Figure 4B). 
 
Chromatin localization of RBBP6 iso3 is facilitated by monoubiquitylation and the C-
terminal tail of iso3 
We next wished to look into what role ubiquitylation plays in RBBP6 iso3 regulation. 
Ubiquitin is a small protein of about 8.6 kDa that can be linked to proteins as a monomer on single 
(monoubiquitylation) or multiple substrate lysine residues (multi-monoubiquitylation) or as a 
polymer (polyubiquitylation) by the sequential addition of ubiquitin to each other through 
ubiquitin lysines (reviewed by Sadowski et al., 2012) (Figure 3D). Iso3 appeared to be both 
monoubiquitylated (MW ~25 kDa) and multi-monoubiquitylated or poly-ubiquitylated (Figure 
3C).   
Our next question was whether and how the various ubiquitylation states help modulate 
the function of iso3 protein. Studies have found that monoubiquitylation regulates DNA repair, 
histone function, gene expression and intracellular localization (Bergink and Jentsch, 2009; 
Haglund et al., 2003b; Hicke, 2001; Passmore and Barford, 2004; Trotman et al., 2007). Multi-
monoubiquitylation plays crucial roles in receptor endocytosis (Haglund et al., 2003b). 
Polyubiquitylation is widely-known to target protein substrates mainly for proteasomal 
degradation (Thrower et al., 2000).  
Since monoubiquitylation of iso3 was consistently observed in our experiments, and 
because it can be difficult to distinguish multi-monoubiquitylation from polyubiquitylation, we 
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 decided to focus on investigating whether monoubiquitylation affects the nuclear localization of 
the RBBP6 iso3 protein. As described above, ubiquitylation of iso3 can only be abolished by 
mutating every single lysine in the protein, and this mutant iso3 protein “D+C1+C2” was denoted 
as “iso3-All-K”. We first overexpressed iso3 and iso3-All-K proteins by transfecting HeLa cells 
with specific vectors, then separated cell compartments into cytoplasmic, nuclear-soluble, and 
chromatin fractions, analyzed different fractions by Western blotting, and quantified images using 
ImageJ. The effectiveness of the fractionation protocol was also verified by Western blotting: 
GAPDH, U2AF65, and histone H3 were detected predominantly in the cytoplasmic, nuclear-
soluble, and chromatin fractions, respectively (Figure 5A). As shown in Figure 5A, both iso3 and 
iso3-All-K were predominantly enriched in the chromatin fractions. Yet, more iso3-All-K, as 
compared with wild-type iso3 protein, was observed in the cytoplasmic and nuclear-soluble 
fractions, indicating that chromatin localization of iso3 is facilitated by monoubiquitylation. 
Furthermore, multiple bands above 25 KDa (molecular weight of monoubiquitinated iso3) were 
also detected in the chromatin fractions. We suspected that those species were more likely to be 
multi-monoubiquitinated rather than polyubiquitinated, given their enrichment in the chromatin 
fraction and absence in the cytoplasmic fraction. In other words, polyubiquitinated substrates 
should be degraded in the cytoplasm, instead of being transported into the nucleus. We note that, 
although there are numerous studies showing that polyubiquitination can also serve for non-
degradation purposes, all the non-proteolytic functions of polyubiquitin described appear to be 
carried out in the cytoplasm (Husnjak and Dikic, 2012; Li and Ye, 2008; Swatek and Komander, 
2016). Therefore, it's possible that multi-monoubiquitylation of iso3 also facilitates its chromatin 
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 localization.  
Next, we determined the subcellular localization of the DWNN domain itself by mutating 
every lysine to arginine, i.e. “DWNN-All-K”. In contrast to the localization of iso3 and its All-K 
mutant, both the DWNN and the DWNN-All-K mutant were almost evenly distributed in the 
cytoplasmic and chromatin fractions (compare lane “cyto” with lane “chromatin” in Figure 5A and 
B). Since the only difference between iso3 and the DWNN is a short C-terminal tail, our data 
suggested that the C-terminal tail facilitates chromatin localization of iso3. Indeed, given that the 
RBBP6 iso3 is a small protein lacking a nuclear localization signal, and that iso3 competes with 
the long forms of RBBP6 for binding to the core 3’ processing machinery, it is very possible that 
the C-terminal tail helps iso3 to localize to chromatin by interacting with other nuclear proteins. 
To characterize the role of the C-terminal tail in iso3 nuclear localization, we performed 
immunofluorescence (IF) in HeLa cells transfected with HA-his-tagged iso3/DWNN using a HA 
antibody as well as RBBP6 Ab1, which recognizes an epitope of the DWNN domain (RBBP6 Ab1 
shown in Figure S1) (Figure 5C). Consistent with our subcellular fractionation data, the iso3 
protein was almost entirely enriched in the nucleus, whereas the DWNN protein was located in 
both cytoplasm and nucleus. Altogether these data suggest that the chromatin localization of iso3 
is facilitated by monoubiquitylation (and possibly multi-monoubiquitylation) as well as the C-
terminal tail of iso3. 
 
Importin7 interacts with RBBP6 iso3 and facilitates its cytoplasmic retention 
We next wanted to characterize proteins interacting with ubiquitylated iso3, such as its E3 
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 ubiquitin ligase. To investigate this, we prepared extracts from HEK293 cells overexpressing HA-
his-tagged iso3, performed his-tag pull down under stringent conditions (Figure 6A and B) 
followed by Mass Spectrometry (MS) analysis of mock and iso3 transfected cells (Figure 6C). 
Two independent purifications (i.e. Group1 and Group2, indicated in Figure 6A and B) identified 
12 overlapping proteins interacting with iso3. As expected, the top 4 most enriched proteins 
identified in MS were all ubiquitin. The other 8 proteins were classified by their spectral count 
numbers into two groups. In the high spectral counts group, which reflects higher protein 
abundance in the purified samples, two proteins were notable. The first was E3 ubiquitin-protein 
ligase CBL, which might function as the E3 ligase for iso3. However, there is a natural 6xHis 
sequence in the protein sequence of CBL, which might be why it was present in the his-tag 
pulldown samples. The second protein, Importin 7 (Imp7), is an import factor that shuttles between 
nucleus and cytoplasm to transport several nucleic acids-binding proteins, such as ribosomal 
proteins (Jakel and Gorlich, 1998) and the HIV-1 integrase protein (Ao et al., 2007; Fassati et al., 
2003).  
We next performed Metascape analysis (http://metascape.org/) of all the proteins detected 
in the MS analysis to obtain a better idea of the enrichment networks of iso3 interacting proteins. 
As shown in Figure S2, the 78 proteins detected in Group1, and the 165 proteins in Group2, were 
bundled into biological process nodes, which implied the potential participation of iso3 protein in 
those pathways. It is noteworthy that the Western blot analysis of Group1 and Group2 pulldown 
samples displayed distinctive ubiquitylation statuses (Figure 6A). Indeed, Group2 showed much 
less monoubiquitylated and more multi-/poly-ubiquitylated iso3 compared to Group1 samples, 
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 corresponding with more cell death in Group2 than Group1, as observed during sample collection 
and preparation. The differences of the enrichment networks between the two groups might imply 
the different functions of iso3 under mono-/multi-mono-/poly-ubiquitylation. 
We next investigated whether Imp7 plays a role in the nuclear trafficking of iso3. We first 
verified the physical interaction between Imp7 and iso3 in the his-tag pulldown experiment. As 
indicated in Figure 7A, Imp7 indeed physically interacts with the iso3. We next determined 
whether depletion of Imp7 affects the localization of iso3. We depleted Imp7 by siRNA 
transfection, simultaneously overexpressed iso3 into HeLa cells, and performed subcellular 
fractionation as described earlier (Figure 7B). Imp7 is predominantly located in the cytoplasmic 
fraction, which is consistent with a previous report (Gorlich et al., 1997). Strikingly, we found that 
depletion of Imp7 led to decreased level of the iso3 protein in the cytoplasmic fraction. 
Quantification of three independent replicates is indicated in Figure7C. This data strongly indicates 
that Imp7 might facilitate the cytoplasmic transport of iso3 protein. 
To extend our findings, we wished to investigate the possible physiological significance of 
the RBBP6-IMP7 interaction. To this end, we examined the cross-cancer alteration of RBBP6 and 
IPO7 genes using cBioPortal for Cancer Genomics (http://www.cbioportal.org/). Remarkably, 
RBBP6 and IPO7 alterations are found in the same top five most altered cancer types: prostate 
cancer, endometrial cancer, cutaneous melanoma, colorectal adenocarcinoma and bladder cancer 
(highlighted in red boxes) (Figure S3A). Significant co-occurrence of amplifications is associated 
with neuroendocrine prostate cancer, which has the highest frequency of alteration for RBBP6 and 
IPO7 (Trento/Cornell/Broad 2016) (Figure S3B). mRNA expression level of RBBP6 and IPO7 
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 was also found to be significantly positively correlated (Pearson correlation = 0.62 and Spearman 
correlation = 0.75) (Figure S3C). A number of studies have observed a decreased level of iso3 and 
an increased level of long-form RBBP6 in cancer (Chen et al., 2013; Moela and Motadi, 2016; 
Motadi et al., 2011; Motadi et al., 2018; Yoshitake et al., 2004). Consistent with this, our results 
suggest that upregulation of Imp7 in cancer would retain more iso3 in the cytoplasm, so that less 
iso3 would compete with long-form RBBP6 in the nucleus. 
 
Discussion 
In this study, we investigated whether the RBBP6 iso3 protein is a ubiquitin-like modifier, 
and how its subcellular localization is regulated in the cell. Our results showed that the DWNN, 
previously known as a ubiquitin-like domain (Pugh et al., 2006), doesn’t exert ubiquitin-like 
modification function. We however showed that RBBP6 iso3 is itself ubiquitinated. Next, we 
demonstrated that the nuclear localization of iso3 is facilitated by its monoubiquitylation as well 
as the C-terminal tail. In addition, our MS analysis confirmed the ubiquitylation of iso3, and further 
identified a novel interaction between Imp7 and iso3. Finally, we showed that Imp7 can facilitate 
the cytoplasmic retention of iso3. Below we discuss how the dynamic regulation of iso3 subcellular 
localization contributes to the functions of RBBP6 in a variety of biological processes, with an 
emphasis in mRNA processing and cancer.  
 Previous studies have found that the DWNN domain adopts a ubiquitin-like structure, 
with characteristic ubiquitin di-Glycine and lysine residues (Pugh et al., 2006). Ubiquitin is a 76-
residues protein with seven lysine residues and di-Glycine residues at the C-terminus. The DWNN 
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 domain contains 81 residues with eight lysine residues and C-terminal di-Glycine motif. It is 
expressed as a single domain protein with an additional C-terminal tail in human, also known as 
RBBP6 isoform3. The similarities between ubiquitin and DWNN raised the intriguing possibility 
that the RBBP6 iso3 protein might be able to modify protein substrates, as a novel ubiquitin-like 
modifier. Indeed, we observed multiple high molecular weight bands above the RBBP6 iso3 
protein in Western blot analysis of cell lysate overexpressing tagged iso3, and such modification 
disappeared when all lysine residues were mutated. Yet, we showed evidence indicating that the 
observed lysine-dependent modification in RBBP6 iso3 is most likely ubiquitylation 
Although we have shown that iso3 is extensively ubiquitinated, we cannot exclude the 
possibility that iso3 can modify ubiquitin and even form “iso3 chain” on ubiquitin. Indeed 
ubiquitin-like molecules such as SUMO and NEDD8 are able to modify ubiquitin to generate 
NEDDylated ubiquitin and SUMOylated ubiquitin, respectively (Galisson et al., 2011; Hendriks 
et al., 2014; Lamoliatte et al., 2013; Singh et al., 2012). Nevertheless, this is made unlikely by 
comparing the molecular weight of the iso3 modification bands in Western blot images: the iso3 
protein is around 18 KDa, whereas its modification bands are approximately 25 KDa, 37 KDa, 50 
KDa, and above 75 KDa. The molecular weight difference between modification bands is around 
8 KDa, which matches the molecular weight of ubiquitin, 8.6KDa. If iso3 could modify ubiquitin 
and form “iso3 chain” on ubiquitin, bands with much higher molecular weight should be observed 
in Western blot analysis. Also, the di-glycine motif, which is essential for attaching ubiquitin-like 
proteins to substrates, can be substituted with alanine residues without affecting the modification 
of iso3. Taken together, we conclude that iso3 is not a ubiquitin-like modifier but is itself 
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 ubiquitylated. Additionally, although long-form RBBP6 is known to be an E3 ligase for various 
proteins, we found that overexpression of recombinant RBBP6 N-terminal derivative containing 
the DWNN, Zinc knuckle, and RING domains, had no impact on iso3 ubiquitination. We cannot 
exclude the possible that full-length RBBP6 might facilitate iso3 ubiquitination. Nevertheless, we 
were unfortunately unable to construct a full-length RBBP6 plasmid to test whether the protein is 
the E3 ligase for iso3 ubiquitination. To date, the E3 ubiquitin ligase responsible for iso3 
ubiquitination remains unknown.  
Predominant chromatin localization of iso3 is consistent with our previous finding that iso3 
can bind to the 3’ pre-mRNA processing core machinery (Di Giammartino et al., 2014). 
Intriguingly, we also observed enrichment of monoubiquitylated iso3 at chromatin, and a higher 
level of all-lysine mutated iso3 in the cytoplasm, as compared with wild-type iso3. Those results 
indicate that monoubiquitylation might facilitate the chromatin localization of iso3 protein. 
Monoubiquitylation has been widely implicated as a signal for intracellular trafficking (reviewed 
by Komander and Rape, 2012; Sadowski et al., 2012; Sigismund et al., 2004). For example, several 
receptors such as epidermal growth factor receptor and receptor tyrosine kinase that undergo 
endocytosis require monoubiquitylation (reviewed by Haglund et al., 2003a; Hicke, 2001). Since 
iso3 is not a receptor, monoubiquitylation might affect iso3 localization in an indirect way, possibly 
by affecting the accessibility of iso3 protein to its binding partners, rather than being an export 
signal itself. For example, monoubiquitylation of the transcription factor p53 will lead to its 
cytoplasmic accumulation, possibly by altering the accessibility of p53’s nuclear export sequence 
to the export machinery (Carter et al., 2007; Li et al., 2003). In our analysis of iso3 subcellular 
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 fractionation, we also noticed two modified iso3 species (approximately 37 KDa and 50 KDa, 
respectively) larger than the monoubiquitinated iso3 species (~ 25 KDa), which can be either 
polyubiquitylated or multi-monoubiquitylated iso3. Given their enrichment in the chromatin 
fraction, we suspect these two isoforms correspond to multi-monoubiquitylated iso3 proteins and 
facilitate iso3 chromatin localization. However, further experiments are needed to prove the 
existence of such modifications in iso3.  
We also discovered a novel interaction between Importin 7 (Imp7) and iso3, which further 
extended our understanding about the dynamic subcellular localization of iso3. Imp7, encoded by 
the gene IPO7, is a nucleocytoplasmic transport protein related to the importin-β family, which 
can cross the nuclear envelope rapidly in both directions (Gorlich et al., 1997). Studies have shown 
that imp7 acts as an import factor for various nucleic acid-binding proteins, such as ribosomal 
proteins (Jakel and Gorlich, 1998), the glucocorticoid receptor, the HIV-1 integrase protein (Ao et 
al., 2007; Fassati et al., 2003), as well as histone H1, by forming a heterodimer with importin-β 
(Jakel et al., 1999). Additionally, Imp7 can also mediate the nuclear trafficking of both endogenous 
and exogenous DNA in mammalian cells, such as mitochondrial DNA and adenovirus DNA 
(Dhanoya et al., 2013; Trotman et al., 2001). Besides acting as an import factor, Imp7 can also 
facilitate cytoplasmic retention. For example, Imp7 can bind to the androgen receptor and block 
its nuclear localization signal, thus causing its cytoplasmic retention (Ni et al., 2013). It is very 
likely that Imp7 facilitates the cytoplasmic retention of iso3 by blocking the region responsible for 
its nuclear localization.  
Previous studies of RBBP6 suggested that its function in various cellular processes is 
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 modulated by the ratio between the long and short isoforms of RBBP6 (i.e. long-form RBBP6 and 
iso3). For example, long-form RBBP6 has been discovered to be overexpressed in a number of 
tumors (Chen et al., 2013; Moela and Motadi, 2016; Motadi et al., 2011; Motadi et al., 2018; 
Yoshitake et al., 2004) while iso3 has been found to be down-regulated in cancers (Mbita et al., 
2012). Besides cell proliferation, the ratio change between RBBP6 isoforms also affects 3’ pre-
mRNA processing efficiency. We showed previously that iso3 can compete with RBBP6 long-
form for the binding to the core factors of the 3’ pre-mRNA processing machinery, and therefore 
play an inhibitory role in 3’ processing. In other words, pre-mRNA 3’ processing efficiency of 
RBBP6-sensitive transcripts can be regulated by changing the ratio between active long-form 
RBBP6 and inhibitory iso3 (Di Giammartino et al., 2014). Here, we propose a model that explains 
the dynamic subcellular localization of RBBP6 iso3 protein (Figure 7D). Monoubiquitylation and 
the C-terminal tail of iso3 facilitate the nuclear localization of iso3, whereas Imp7 participates in 
the cytoplasmic retention of iso3, possibly by blocking its interaction with other nuclear proteins. 
By shuttling between cytoplasm and nucleus, iso3 can either participate in cell proliferation, 
mRNA processing, differentiation, or be degraded. Additionally, we observed a striking correlation 
between RBBP6 and IPO7 in cancer types as well as in their mRNA expression levels, by analyzing 
cancer genomic data. This is consistent with previous findings as well as our model: On the one 
hand, long-form RBBP6 is overexpressed in cancer, whereas the level of iso3 is decreased. On the 
other hand, upregulation of Imp7 would retain more iso3 in the cytoplasm so that less iso3 would 
compete with long-form RBBP6 in the nucleus.  
In conclusion, we have shown that RBBP6 iso3 is not a ubiquitin-like modifier but is a 
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 ubiquitylated protein. The monoubiquitylation of iso3 and its C-terminal tail facilitate its 
chromatin localization, whereas the import factor Imp7 participates in its cytoplasmic retention. 
Our study highlighted a novel mechanism by which iso3 subcellular localization can modulate the 
ratio between long-form RBBP6 and iso3, and possibly regulate mRNA 3’end processing. 
	
Material & Methods  
Cell culture and siRNA transfections 
HeLa and HEK293 cells were cultured in DMEM supplemented with 10% FBS. The 
siRNAs against IPO7 were transfected using DharmaFECT1 (GE Dharmacon) (#1, 
GAUGGAGCCCUGCAUAUGA; #2, UGAUGACCUUACCAAUGUA) at 20nM and maintained 
for 72 hrs. To obtain high knockdown efficiency after 72hr treatment, the siRNA transfection was 
repeated 48hrs after the first transfection with half the amount of siRNA and cells were harvested 
24hrs after the second transfection. 
 
Antibodies 
RBBP6 Ab1, RBBP6 Ab2, RBBP6 Ab3 antibodies were made by courtesy of Bethyl 
Labortories. RBBP6 C-terminus were from Santa Cruz (sc-6359). GAPDH (G8795; Sigma), 
U2AF65 (U4758; Sigma), histone H3 (ab1791; abcam), HA (901501; Biolegend), FLAG (F1804; 
Sigma) were also used in this study. 
 
Subcellular fractionation  
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 Seventy-two hours after siRNA/plasmid transfection, HeLa cells grown in a 10-cm dish 
were washed twice with PBS and collected by scrapping and centrifugation. Cell pellets were 
resuspended in 400 µL of swelling buffer (10 mM Tris-HCl at pH 8.0, 1.5 mM MgCl2, 10 mM 
KCl, 5 U of RNasin, 1×protease inhibitor cocktail) and incubated for 15 min on ice. Cells were 
homogenized by passing a 26-gauge needle attached to a 1 mL syringe until >90% of cells were 
disrupted (typically 10∼20 strokes). Half of the lysate was kept in a new tube and used as whole-
cell lysate. The rest of the 200 µL of lysate was mixed with 2 µL of 10% NP-40, gently tapped, 
and immediately centrifuged in an Eppendorf centrifuge 5424 at 6,000 rpm for 5 min. The 
supernatant was kept in a new tube and used as cytoplasmic fraction. The pellet was washed once 
with swelling buffer, resuspended in 100 µL of glycerol buffer (20 mM Tris-HCl at pH 8.0, 75 mM 
NaCl, 0.5 mM EDTA, 50% glycerol, 0.85 mM DTT, 5 U of RNasin, 1× protease inhibitor cocktail) 
by pipetting, and then mixed with 100 µL of nucleus lysis buffer (20 mM HEPES-NaOH at pH 
7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl, 1 M urea, 1% NP-40, 1 mM DTT, 5 U of 
RNasin, 1× protease inhibitor cocktail). The mixture was pulse-vortexed three times, incubated for 
1 min on ice, and then centrifuged in an Eppendorf centrifuge 5424 at 14,000 rpm for 2 min. The 
supernatant was used as nuclear-soluble fraction. The pellet was washed once with a 1:1 mixture 
of glycerol/nucleus lysis buffer and then resuspended in 200 µL of water.  
 
His-Tag Pulldown  
HeLa or HEK293 cells grown in 10-cm dishes were washed twice with PBS and lysed in 
lysis buffer (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM Tris-HCl (pH 8), 0.005 
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 M imidazole, 5mM dithiothreitol, 1× protease inhibitor cocktail) for 5 min on ice. The lysates were 
sonicated and then centrifuged in an Eppendorf centrifuge 5424 at 6000 rpm for 15 min at 4°C, 
and supernatants were rotated with NTA agarose beads (Sigma) for 1hr. The beads were then 
washed three times with washing buffer (8 M urea, 0.1 M Na2HPO4/NaH2PO4, 10 mM Tris-HCl 
(pH 6.8), 0.005 M imidazole, 5mM dithiothreitol), and eluted by the elution buffer (0.5 M 
imidazole, 0.15 M Tris-HCl (pH 6.8), 30% glycerol, 5mM dithiothreitol, 5% SDS) for Western 
blot analysis or Mass spectrometry analysis. 
 
Mass Spectrometry Analysis 
Protein samples were digested for 18 h at 37°C in 2 M urea, 100 mM Tris (pH 8.5), and 1 
mM CaCl2 with 2µg of trypsin (Promega). Multidimensional protein identification technology 
(MudPIT) analysis was performed using an Eksigent nanoLC pump and a Thermo LTQ-Orbitrap 
using an in-house built electrospray stage (Wolters et al. 2001). Protein and peptide identification 
and protein quantitation were done with Integrated Proteomics Pipeline (IP2; Integrated 
Proteomics Applications, Inc., http://www.integratedproteomics. com). Tandem mass spectra were 
extracted from raw files using RawConverter (He et al. 2015) and were searched against a UniProt 
human database with reversed sequences using ProLuCID (Peng et al. 2003; Xu et al. 2015). The 
search space included all fully tryptic and half-tryptic peptide candidates. Peptide candidates were 
filtered using DTASelect with the following parameters: -p 2 -y 1 --trypstat --extra --pI -DM 10 -
-DB --dm -in --brief --quiet (Tabb et al. 2002). 
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 Immunofluorescence Staining 
Cells were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. 
Following fixation, cells were permeabilized with 1% Triton X-100 in PBS for 10 min, followed 
by 30 min incubation with 3% BSA in PBS. Cells were next incubated with rabbit anti-RBBP6 
Ab1 (Bethyl Lab) and mouse anti-HA (901501; Biolegend) overnight at 4°C. Both antibodies were 
used at a dilution of 1:500. After three washes with PBS, cells were incubated with an appropriate 
secondary antibody (goat anti-rabbit Alexa Fluor 488 or rabbit anti- mouse Alexa Fluor 564) for 
2hrs at room temperature. Nuclei were counterstained with DAPI. Images were taken with a Zeiss 
LSM700 confocal microscope.   
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 Figure legends 
Figure 1. RBBP6 iso3 is extensively modified. (A) Schematic of RBBP6 isoforms identified in 
different species. RBBP6 isoform3 was only identified in human, while the longer isoforms were 
characterized in various species, containing not only the DWNN domain, but also the Zinc knuckle 
and RING domains. (B) Western blot analysis of RBBP6 iso3 protein modification. HA-his-iso3 
in pCMV plasmid was overexpressed in HeLa cells in a time course of transfection from 0hr to 
48hr. (C) Validation of RBBP6 iso3 protein modification with RBBP6 specific antibodies. The 
epitopes of each antibody were shown in Fig. S1.  
 
Figure 2. RBBP6 isoform3 protein is modified in a lysine-dependent manner. (A) Comparison 
of the amino acid sequences between ubiquitin and DWNN domain. Lysine residues were 
highlighted in blue and labeled with amino acid numbers, while the di-Glycine residues in pink. 
(B) Western blot analysis of RBBP6 iso3 mutants. Lysine8 and 11 were mutated to arginine in 
“K8/K11” mutant. Lysine 30, 31, 38, 40 were mutated to arginine in “K30-40” mutant. Every 
Lysine (from K8 to K66) in the DWNN domain of RBBP6 iso3 was mutated to arginine in “K8-
66” mutant. Di-Glycine of iso3 were mutated to Alanine in “diGly” mutant. The upper panel for 
long exposure, lower panel for short exposure. (C) Schematic of the DWNN domain and the C-
terminal tail in RBBP6 iso3 protein. The first 76 amino acids of the iso3 protein are the DWNN 
domain, whereas the last 43 amino acids are the C-terminal tail of iso3. The abbreviations of 
various mutations in iso3 plasmid are listed on the right side: we abbreviated the first two lysine 
mutations in the C-terminal tail as “C1”, while the last two lysine mutations as “C2”. Also, 
148
 mutation of all lysine residues (K8-66) in the DWNN domain was indicated as “D”. (D) 
Abolishment of protein modification by mutating every single lysine of RBBP6 iso3. HA-iso3 
vector with four lysine residues mutated in the C-terminal tail, was indicated as “C1+C2”, whereas 
HA-iso3 with every single lysine mutated was denoted as “D+C1+C2”. HA-iso3 vectors carrying 
various combinations of lysine mutations in the C-terminal tail were transfected into HeLa cells, 
and protein extracts were analyzed by Western blot after 48hr of transfection. 
 
Figure 3. The protein modification of RBBP6 isoform3 is ubiquitylation. (A) His-tag pulldown 
of HA-his-iso3 under denaturing conditions. Cell extracts prepared from HeLa cells expressing 
HA-his-iso3 or/and FLAG-Ubiquitin were used for the denaturing his-tag pulldown experiments. 
(B) His-tag pulldown of HA-his-DWNN under denaturing conditions. Cell extracts prepared from 
HeLa cells expressing HA-his-DWNN or/and FLAG-Ubiquitin were used for denaturing his-tag 
pulldown experiment. (C) MG132, MG115 and lactacystin treatment of iso3 overexpressed HeLa 
cells. HeLa cells were first transfected with HA-his-iso3 vectors for 24hrs, and then treated with 
DMSO, 10uM MG132. 10uM MG115, and 10uM lactacystin, respectively. Four time points of 
drug treatment were taken in the experiment: 0hr, 6hr, 12hr, and 24hr. The overall plasmid 
transfection time across all the samples is 48hrs. Cell lysates were analyzed by Western blotting. 
The signal intensity of protein modification was quantified by ImageJ, and normalized to GAPDH. 
(E) Illustration of poly-/multi-mono-/mono-ubiquitylation on protein substrates. 
 
Figure 4. Overexpression of the E3 ligase RBBP6N does not affect iso3 ubiquitylation. (A) 
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 Western blot analysis of His-tag pulldown of HeLa cells co-expressing HA-his-iso3 and RBBP6N-
FLAG/DDWNN-FLAG under denaturing conditions. (B) Western blot analysis of HeLa cell 
extracts co-expressing of RBBP6N-FLAG and its mutants (RING mut and Zinc mut) together with 
HA-his-iso3. Four Cystines in the RING domain of RBBP6N were mutated to alanine in the 
“RING mut”. 2 Cystines in the ZINC domain of RBBP6N were mutated to alanine in the “Zinc 
mut”. 
 
Figure 5. Chromatin localization of RBBP6 iso3 is facilitated by monoubiquitylation and the 
C-terminal tail of iso3. (A) Subcellular fractionation of wild-type iso3 and its all Lysine mutant 
D+C1+C2 (i.e. “iso3-All-K”). Western blot analysis of iso3 subcellular localization was shown in 
the left panel. The quantification by ImageJ was shown in the right panel. (B) Subcellular 
fractionation of wild-type DWNN and its all Lysine mutant (i.e. “DWNN-All-K”). (C) 
Immunofluorescence of HeLa cells expressing HA-his-iso3/-DWNN. HeLa cells were transfected 
with iso3/DWNN plasmids for 48hrs, then fixed and immunostained with antibodies against HA 
(green) and RBBP6 Ab1 (red). Nuclei were counterstained with DAPI (blue). The fluorescence 
intensity in the nucleus and cytoplasm was quantified by ImageJ, and compared using an unpaired 
Student’s t-test (p<0.05). 
 
Figure 6. Mass Spectrometry analysis of his-tag pull down of HA-his-iso3 under denaturing 
conditions. (A) Western blot analysis of denaturing his-tag samples of HA-his-iso3 overexpressed 
HeLa cells. Two biological replicates were shown as Group1 and Group2, respectively. (B) Silver 
150
 staining of Group1 and Group2 input and pulldown samples. (C) Venn diagram of proteins detected 
in Group1 and Group2 via Mass Spectrometry analysis. (D) List of accession numbers and spectral 
counts of the 12 proteins detected in both groups. The top 4 proteins were all ubiquitin protein 
fragments. The next 4 proteins were classified as “high spectral counts”, while the last 4 proteins 
“low spectral counts” were based on the number of their spectral counts. 
 
Figure 7. Importin 7 physically interacts with RBBP6 iso3 and facilitates its cytoplasmic 
retention. (A) Western blot analysis of the his-tag pulldown of HeLa cells overexpressing HA-
his-iso3 using HA antibody and Imp7 antibody. (B) Subcellular fractionation of iso3 under control 
siRNA and siImp7 KD conditions. (C) ImageJ quantification of the subcellular fractionation 
western blotting results. Values were normalized to the Whole cell signals and set as percentage. 
Bar represent mean  SD. n=3. Asterisk denotes significant difference of the cytoplasmic signals 
between siCtrl and siImp7 using a paired Student’s t-test. (D) Schematic illustration of dynamic 
nuclear localization of RBBP6 iso3. Imp7 facilitates the cytoplasmic retention of iso3, while 
monoubiquitylation and iso3 C-terminal tail enhance its nuclear localization. 
 
Supplementary Figure legends 
Figure S1. The epitopes of RBBP6 antibodies in iso3 and RBBP6N proteins. The protein 
sequences of RBBP6 iso3 (upper) and RBBP6N (lower) were listed. The epitope of RBBP6 Ab1, 
Ab2, Ab3 antibodies are highlighted in orange, green, and and red, respectively. *Only partial 
amino acid sequence on the N-terminus is shown here. 
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 Figure S2. Metascape analysis of proteins detected in mass spectrometry of denaturing HA-
his-iso3 pulldown samples. 78 proteins detected in group1, and 165 proteins detected in group2 
were annotated using Metascape Analysis (http://metascape.org/), respectively.  
 
Figure S3. Significant co-occurrence of RBBP6 and IPO7 was observed in cancer. (A) Cross-
cancer alteration summary for RBBP6 and IPO7 by cBioPortal for Cancer Genomics. RBBP6 and 
IPO7 share the top 5 most altered cancer types: prostate cancer, endometrial cancer, cutaneous 
melanoma, colorectal adenocarcinoma, and bladder cancer. (B) Significant co-occurrence of 
RBBP6 and IPO7 amplification was observed in neuroendocrine prostate cancer 
(Trento/Cornell/Broad 2016) by cBioPortal for Cancer Genomics (p-value<0.001). (C) Positive 
correlation was detected in RBBP6 and IPO7 mRNA expression levels (Pearson correlation = 0.62 


























In the first part of the thesis, I explored the biogenesis and degradation mechanisms of 
eRNAs. Our genome-wide analyses characterized a large pool of human polyadenylated enhancer 
RNAs under nuclear surveillance deficient conditions. This result expanded our knowledge about 
eRNAs, which are typically considered to be nonpolyadenylated. I further investigated the roles 
of the three complexes, PAXT/PPC, NEXT, and the Integrator, in regulating pA+ eRNA 
metabolism, and proposed a model of the Integrator-mediated RNAP II switch between enhancers 
and promoters. Additionally, I found an enrichment of PAS and GU-rich sequences near the 3’ 
cleavage sites of those pA+ eRNAs, and provided evidence of the involvement of canonical poly(A) 
polymerase in their 3’ processing. Lastly, I showed that stabilized nuclear pA+ eRNAs were 
transported into the cytoplasm and associated with polysomes, implying translational potential.  
Nevertheless, several questions remain to be answered. For example, do all enhancers 
produce pA+ and pA- eRNA simultaneously? If yes, then what is the ratio of pA+ and pA- eRNA 
levels for any given enhancer under deficient nuclear surveillance conditions? My RL-PAT assay 
indeed detected the coexistence of pA+ and pA- eRNAs derived from individual enhancers. 
Nevertheless, a genome-wide analyses would provide a more comprehensive picture. Since the 
3’READS+ technique only analyzes polyadenylated RNA species, it would be nice to conduct 
both RNA-seq and 3’READS+ side by side, and analyze eRNAs with different polyadenylation 
statuses under the same experiment conditions.  
Another question is whether the canonical poly(A) polymerases PAP-α/γ regulate the 3’ 
processing of all pA+ eRNAs? My analyses of individual eRNAs showed that depletion of PAP-
α/γ led to transcript readthrough and polyadenylation at much more downstream sites. To find out 
whether the involvement of PAP-α/γ in pA+ eRNA 3’ processing applies globally, a genome-wide 
analysis is necessary.  
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The polysome fractionation experiments in Chapter 3 indicated that stabilized pA+ eRNAs 
accumulated in the cytoplasm and associated with polysomes, implying the possibility of 
producing de novo micropeptides. The genome editing technique CRISPR/Cas9 would be an ideal 
tool to help identify those micropeptides, if there are any, by adding specific tags such as GFP on 
them (Lackner et al., 2015). One big technical challenge would be detecting micropeptides, 
especially those with very low abundance (Makarewich and Olson, 2017). Nevertheless, this topic 
might be key evidence for the evolutional significance of enhancers, and merits further study.  
Lastly, I’d like to discuss some preliminary data about the role of Mtr4 in stem cell 
differentiation. Chapter 2 has reviewed the importance of the nuclear surveillance system in stem 
cell self-renewal and differentiation, which requires precise regulation and fidelity maintenance of 
gene expression. Aberrant accumulation of RNAs under deficient nuclear surveillance conditions 
would lead to the imbalance between proliferation and differentiation (Ogami et al., 2018). It has 
been reported that Mtr4 depletion in murine cancer cell lines Neuro2A and P19 cells resulted in 
decreased cellular proliferation and increased expression of genes indicative of cell differentiation 
(Onderak and Anderson, 2017). Consistent with this, I also found the involvement of Mtr4 in 
human embryonic stem cell (ESC) differentiation, by collaborating with Dr. Takashi Yamazaki, 
who performed the embryonic body differentiation assay presented below (Figure 5-1).  
A human H9 ESC line (WA09) was differentiated using a 20-day embryoid body (EB) 
differentiation assay (protocol from Yamazaki et al., 2018), and then harvested at various time 
points (0, 5, 10, 20 days of differentiation, respectively) for qRT-PCR and Western blotting 
analyses. Downregulation of the pluripotency markers OCT4 and NANOG, accompanied with 
upregulation of differentiation markers IGBP7, RUNX1, FOXA, and MSX1 validated the 
effectiveness of the EB differentiation assay (Figure 5-1A). Remarkably, the protein levels of Mtr4 
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and ZCCHC8, both of which are subunits of the NEXT complex, were drastically decreased after 
10 days of differentiation. In contrast, the protein level of PABPN1, a subunit of PAXT complex, 
remained unchanged (Figure 5-1B). This result indicates that different nuclear exosome adaptor 
complexes might play distinct roles in ESC differentiation. I further examined the expression level 
of two eRNAs (eRNA11+ and eRNA17+) and two well-known lncRNAs (MALAT1 and NEAT1). 
One eRNA and both lncRNAs (eRNA17+, MALAT1, NEAT1) showed tens of folds increase after 
hESC differentiation. Additionally, I transfected hESCs with control or Mtr4 siRNAs, and noticed 
that KD of Mtr4 induced a flattened epithelial-like appearance (Figure 5-1D), which is typically 
observed in differentiating ESCs (Ji et al., 2012; Tay et al., 2008). Nevertheless, it is noteworthy 
that transfecting ESCs with siRNAs is rather difficult. Based on the experiences in our lab, the 
maximum siRNA transfection efficiency in ESC is 10%. Thus, we wondered whether 
downregulation of Mtr4 in a small number of cells is sufficient to induce differentiation. Viral 
transfection and differentiation marker staining would be necessary to test this hypothesis. 
Nevertheless, these preliminary observations strongly suggested the involvement of Mtr4 in ESC 





Figure 5-1. Mtr4 decreased drastically after ESC differentiation.  
A. RT-qPCR analysis of ESC pluripotency and differentiation markers in a 20 day embryoid body differentiation 
assay: OCT4 and NANOG (pluripotency markers, IGBP7 (differentiation marker), RUNX1 (mesoderm marker), 
FOXA (endoderm marker), MSX1 (ectoderm marker). B. Western blot analysis of embryoid body after 20 days of 
differentiation with antibodies listed on the right. C. RT-qPCR result of eRNA17+, eRNA11+, MALAT1, and NEAT1. 







































































































































































































































In the second part of the thesis, I studied RBBP6, a polyadenylation factor. The RBBP6 
isoform3 protein displays high similarities with ubiquitin, indicating its potential role as a 
ubiquitin-like modifier. Nevertheless, I found that RBBP6 iso3 is not a ubiquitin-like modifier, 
instead is itself ubiquitylated by both monoubiquitin and polyubiquitin chains. I also showed that 
the nuclear localization of iso3 is facilitated by monoubiquitylation and its C-terminal tail. Finally, 
I identified a novel interaction between iso3 and Importin7, which assists the cytoplasmic retention 
of iso3. My work revealed the dynamic subcellular localization mechanism of RBBP6 iso3, which 
can further modulate the ratio between long-form RBBP6 and iso3 in a variety of biological 
processes. 
I also examined the cross-cancer alteration of RBBP6 and Importin7 genes in the Cancer 
Genomics database, and observed a significant co-occurrence of amplification of the two genes. 
All the findings combined together show that Importin7 and RBBP6 iso1 are often upregulated in 
cancer, while RBBP6 iso3 is downregulated. Therefore, I proposed a model: upregulation of 
Importin7 would retain more iso3 protein in the cytoplasm, so that less iso3 competes with RBBP6 
iso1 in the nucleus. However, this cause-effect relationship between Importin7 and RBBP6 iso3 
in cancer still needs more evidence to back it up, which can be a direction for future study.  
Another open question is about the unexpected peptide cleavage of the RBBP6N protein. 
As shown in Figure 4 of Chapter 4, two RBBP6 N-terminal derivative plasmids were constructed: 
a 3xFLAG-tagged RBBP6N containing the key RING domain, Zinc knuckle, the DWNN domain, 
as well as a 3xFLAG-tagged DDWNN only containing the RING domain and Zinc knuckle. Both 
RBBP6N and  DDWNN were tagged on the C-terminus. Surprisingly, I noticed that the western 
blot analyses of RBBP6N-FLAG always detected two bands, with molecular weights of 75 KDa 
and 50 KDa, respectively, whereas DDWNN-FLAG showed one band (approximately 50KD) 
168
  
(Figure 5-2A). Given that the molecular weight of RBBP6N-FLAG is 75 KDa, it’s very possible 
that the 50 KDa band is generated by peptide cleavage of RBBP6N protein, by cleaving off the 
DWNN domain (approximately 15 KDa). To test this possibility, I constructed another RBBP6N 
plasmid, with 3xFLAG tag on the C-terminus (FLAG-RBBP6N), and transfected it side by side 
with RBBP6N-FLAG into HeLa cells, with MG132 treatment to block potential protein 
degradation. As shown in Figure 5-2B, FLAG-RBBP6N only displayed one band at 75 KDa, while 
RBBP6N-FLAG displayed two bands. It is very likely that the N-terminus of RBBP6N is cleaved 
off, so that the cleaved RBBP6N derivative of FLAG-RBBP6N didn’t contain the FLAG tag 
anymore, and therefore couldn’t be detected via Western blot analysis.  
In order to determine the peptide cleavage site, I performed immunoprecipitation of HeLa 
cells overexpressing RBBP6N-FLAG proteins with an anti-FLAG antibody. As shown in Figure 
5-2C, both RBBP6N and cleaved RBBP6N were pulled down. The gel band of the cleaved 
RBBP6N protein was analyzed by mass spectrometry, and the peptide closest to the N-terminus 
of RBBP6N was shown in Figure 5-2D. Thus, the peptide cleavage site of RBBP6N should be at 
least before this peptide sequence detected by mass spectrometry. 
Next, I used three RBBP6 antibodies recognizing different N-terminal epitopes of RBBP6 
protein, to further pinpoint the peptide cleavage site (Figure 5-2E). I found that all three RBBP6 
antibodies could only detect the uncleaved RBBP6N, which implied that the cleavage occurs after 
their epitopes. Taken together, as shown in Figure 5-2F, we concluded that the peptide cleavage 
site of RBBP6N is after the DWNN domain, and is very likely within the epitope recognized by 





Figure 5-2. RBBP6N underwent peptide cleavage after the N-terminal DWNN domain. 
(A) Western blot analysis of the overexpression of RBBP6N-FLAG and DDWNN-FLAG in HeLa cells from 12hrs to 
48hrs after plasmid transfection. (B) Western blot analysis of C-terminal FLAG tagged RBBP6N (RBBP6N-FLAG) 
and N-terminal FLAG tagged RBBP6N (FLAG-RBBP6N) under 20uM MG132 treatment. (C) Coomassie blue 
staining of FLAG-IP samples of RBBP6N-FLAG transfected HeLa cells. The upper band is the RBBP6N protein, 
while the lower band is cleaved C-terminal RBBP6N. (D) Mass spectrometry analysis of the cleaved RBBP6N gel 
band. The peptide detected closest to the N-terminus of RBBP6N was boxed in blue. (E) Western blot analysis of 
RBBP6N peptide cleavage with the FLAG antibody and RBBP6 specific antibodies. The epitopes of RBBP6 specific 
antibodies were highlighted in orange (Ab1), green (Ab2), and red (Ab3), respectively. The peptide fragment detected 
by mass spectrometry was highlighted in blue. (F) Schematic illustration of RBBP6N peptide cleavage. The peptide 
cleavage of RBBP6N occurred right after the DWNN domain.  
 
It is known that the DWNN domain itself has opposite functions from the full-length 
RBBP6 in various biological process, such as mRNA 3’ processing and cell proliferation. 
Consequently, different ratios between isoforms could help regulate those processes (Di 
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Giammartino et al., 2014; Mbita et al., 2012). Therefore, the peptide cleavage of the N-terminus 
DWNN domain from the RBBP6N protein might facilitate the ratio change between the isoforms. 
For example, enhanced peptide cleavage of RBBP6N would generate more DWNN proteins and 
less functional RBBP6N, and vice versa. However, we didn’t observe such peptide cleavage in 
full-length RBBP6 (Figure 5-3A). We treated HeLa cells with control siRNAs, siRNAs against 
only isoform1 and 2, as well as all three isoforms of RBBP6, and performed Western blot analysis 
using two different antibodies recognizing the C-terminus of the RBBP6 protein. If such peptide 
cleavage exists, we should have been able to see the cleaved product (approximately 230 KDa) 
just below full-length RBBP6 (250 KDa).  
 
 
Figure 5-3. The peptide cleavage of RBBP6N was not found in full-length RBBP6 or its yeast homolog Mpe1. 
(A) Western blot analysis of full-length RBBP6 under siRNA knockdown. (B) Western blot analysis of RBBP6 yeast 
homolog Mpe1-FLAG under DMSO and DNA damage treatment conditions. Yeasts expressing Mpe1-FLAG were 





Given that full-length human RBBP6 contains a very long C-terminus compared with 
RBBP6N, we decided to look into the yeast homolog of RBBP6, Mpe1, which only contains the 
DWNN domain, Zinc Knuckle, and RING domain, similar to RBBP6N. We collaborated with Dr. 
Julyun Oh from Dr. Lorraine S. Symington lab, and tagged the endogenous Mpe1 with 3xFLAG 
on the C-terminus in yeast. Still, no peptide cleavage of Mpe1 was detected, with or without DNA 
damage treatment, as indicated in Figure 5-3B.  
Despite the fact that N-terminal peptide cleavage only exists in RBBP6N but not 
endogenous full-length RBBP6, this finding provides crucial information about the features of 
RBBP6N. If this plasmid construct will be used for other studies, researchers should be aware that 
the N-terminus of RBBP6N undergoes peptide cleavage.  
It is still an open question, how and why the DWNN domain is cleaved off in RBBP6N 
proteins. If we can find out the underlying mechanism and reproduce the cleavage in full-length 
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Appendix I. Protein sequence of RBBP6N-FLAG and DDWNN-FLAG 
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An Mtr4/ZFC3H1 complex facilitates
turnover of unstable nuclear RNAs
to prevent their cytoplasmic transport
and global translational repression
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Many long noncoding RNAs (lncRNAs) are unstable and rapidly degraded in the nucleus by the nuclear exosome. An
exosome adaptor complex called NEXT (nuclear exosome targeting) functions to facilitate turnover of some of these
lncRNAs.Herewe show that knockdown of oneNEXT subunit,Mtr4, but neither of the other two subunits, resulted
in accumulation of two types of lncRNAs: prematurely terminated RNAs (ptRNAs) and upstream antisense RNAs
(uaRNAs). This suggested a NEXT-independent Mtr4 function, and, consistent with this, we isolated a distinct
complex containing Mtr4 and the zinc finger protein ZFC3H1. Strikingly, knockdown of either protein not only
increased pt/uaRNA levels but also led to their accumulation in the cytoplasm. Furthermore, all pt/uaRNAs ex-
amined associated with active ribosomes, but, paradoxically, this correlated with a global reduction in heavy
polysomes and overall repression of translation. Our findings highlight a critical role for Mtr4/ZFC3H1 in nuclear
surveillance of naturally unstable lncRNAs to prevent their accumulation, transport to the cytoplasm, and resultant
disruption of protein synthesis.
[Keywords: Mtr4; ZFC3H1; exosome; lncRNA; polyadenylation]
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RNA polymerase II is responsible for production of a
large repertoire of RNAs. In addition to mRNAs, these in-
clude a variety of functional, relatively stable RNAs,
such as small nuclear RNAs (snRNAs) and microRNAs
(miRNAs), and a diverse set of long noncoding RNAs
(lncRNAs). Many of these lncRNAs have well-document-
ed functions in either the cytoplasm or nucleus and are
also often quite stable (Chen 2016). However, a large num-
ber of lncRNAs have no known functions and can be very
unstable and rapidly degraded in the nucleus. These in-
clude, for example, RNAs that are transcribed upstream
of protein-coding gene promoters (Preker et al. 2008;
Flynn et al. 2011) as well as RNAs transcribed, frequently
bidirectionally, from transcriptional enhancers (Djebali
et al. 2012; Andersson et al. 2014a). Synthesis of these
RNAs often involves multiple RNA processing reactions,
which are typically closely linked to their transcription.
Such processing invariably involves 5′ capping, frequently
splicing aswell as 3′ end formation, and often cleavage and
polyadenylation. It is noteworthy that polyadenylation
can have either a stabilizing effect, as typically observed
with mRNAs, or a destabilizing effect, as found with
many nuclear lncRNAs subject to rapid decay (Beaulieu
et al. 2012; Ntini et al. 2013; Bresson et al. 2015).
Two interesting classes of lncRNAs are the promoter
upstream transcripts (PROMPTs) and prematurely termi-
nated RNAs (ptRNAs). PROMPTs are transcribed in both
sense and antisense directions relative to transcription
start sites of protein-coding genes and are polyadenylated
(Preker et al. 2008). Notably, PROMPTs that are tran-
scribed in the antisense direction, which we specifically
refer to as upstream antisense RNAs (uaRNAs) (Flynn
et al. 2011), appear to be processed by mechanisms of
pre-mRNA 3′ end formation that are the same as or
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similar to those of mRNAs (Almada et al. 2013; Ntini
et al. 2013; for review, see Richard andManley 2013). Mo-
tifs similar to those that constitute poly(A) sites (PASs) in
pre-mRNAs are found at the 3′ ends of uaRNAs, andmuch
of the same complex protein machinery that is responsi-
ble for mRNA polyadenylation (Tian and Manley 2017)
functions in uaRNA 3′ end formation (Ntini et al. 2013).
Notably, PASs are more enriched in the upstream anti-
sense region compared with the downstream region,
whereas U1 snRNA-binding sites (which, when bound
by U1 snRNP, prevent polyadenylation at nearby PASs)
(Almada et al. 2013; Ntini et al. 2013) are more frequent
in the sense-coding direction. Failure of the suppression
of proximal PASs results in premature cleavage and poly-
adenylation, giving rise to ptRNAs (Kaida et al. 2010; Berg
et al. 2012). PAS-driven early termination of pt/uaRNAs is
linked to rapid degradation of these RNAs by the nuclear
exosome despite the fact that the RNA signals and protein
factors are very similar to those used for relatively stable
mRNAs (Ntini et al. 2013).
What targets unstable nuclear RNAs for rapid turnover?
An interesting candidate that might link PAS-mediated 3′
processing of lncRNAs to degradation is the exosome
adaptor complex NEXT (nuclear exosome targeting),
which consists of the RNA helicase Mtr4, the RNA-bind-
ing protein RBM7, and the zinc knuckle protein ZCCHC8
(Lubas et al. 2011). NEXT physically associates with the
nuclear exosome to facilitate turnover of various types of
RNA substrates, including PROMPTs, enhancer RNAs
(eRNAs), 3′ extended snRNAs/small nucleolar RNAs
(snoRNAs), and replication-dependent histone-encoding
transcripts (Lubas et al. 2011; Andersen et al. 2013).
Mtr4, which shows a higher affinity for poly(A) relative
to non-poly(A) RNA (Bernstein et al. 2008), plays an es-
sential role in exosome activation, presumably by RNA
unwinding and/or feeding RNA substrates into the exo-
some (Wang et al. 2008; Houseley and Tollervey 2009).
The substrate recognition activity of NEXT is conferred
by RBM7, which shows some preference for U-rich se-
quences (Andersen et al. 2013). Intriguingly, all three
NEXT subunits were identified in a proteomics analysis
of the purified human pre-mRNA polyadenylation com-
plex (Shi et al. 2009), suggesting a possible role for NEXT
coupled to 3′ processing.Humancells possess another exo-
some adaptor complex, TRAMP (Trf4–Air–Mtr4 polyade-
nylation complex), comprising Mtr4, the noncanonical
poly(A) polymerase PAPD5, and the zinc knuckle protein
ZCCHC7. TRAMP substrates, however, are thought to
be restricted to nucleolar RNA targets such as ribosomal
RNA (rRNA) precursors (Lubas et al. 2011).
In this study, we analyzed the polyadenylated transcrip-
tomes of cells depleted of the individual NEXT subunits
to investigate whether NEXT might affect polyadenyla-
tion generally. Unexpectedly, we found that siRNA-medi-
ated knockdown of Mtr4, but neither of the other two
NEXT subunits or a TRAMP subunit, resulted in strong
and specific accumulation of ptRNAs and uaRNAs. We
then examined Mtr4 complexes and interacting proteins
by gel filtration followed by mass spectrometry (MS) and
identified the zinc finger protein ZFC3H1 as anMtr4 part-
ner (see also Meola et al. 2016) also necessary for degrada-
tion of ptRNAs and uaRNAs. Unexpectedly, knockdown
of Mtr4 or ZFC3H1 resulted in accumulation of polyade-
nylated Mtr4 targets in the cytoplasm, and the exported
RNAs were bound by ribosomes. Mtr4/ZFC3H1-deficient
cells also showed a surprising global reduction in heavier
polysomes, suggesting that ribosomes naturally bound to
mRNAs were occupied by the short ORF-containing pt/
uaRNAs. Consistent with this, theMtr4/ZFC3H1-deplet-
ed cells showed a significant specific inhibition of transla-
tion. Our findings illustrate the importance of nuclear
surveillance of polyadenylated lncRNAs by Mtr4/
ZFC3H1 to prevent the unwanted and deleterious trans-
port to and accumulation of these RNAs in the cytoplasm.
Results
Mtr4 prevents accumulation of ptRNAs and uaRNAs
The initial aim of our experiments was to investigate the
significance of the previously observed association of
NEXT with the pre-mRNA polyadenylation machinery.
To this end, we depleted each of the three NEXT subunits
from HeLa cells with siRNAs (Fig. 1A,B) and performed 3′
region extraction and deep sequencing (3′READS) (Hoque
et al. 2013) to analyze the global effects on accumulation
of polyadenylated RNAs. Unexpectedly, depletion of
Mtr4, but neither of the other two NEXT subunits
(RBM7 or ZCCHC8), resulted in preferential accumula-
tion of two types of transcripts: uaRNAs and ptRNAs
(Fig. 1C,D). Consistent with this, metagene plots revealed
that the Mtr4-depleted cells showed a sharp increase of
promoter-proximal PAS usage in both sense and antisense
directions, whereas depletion of RBM7 and ZCCHC8 had
only minimal effects (Fig. 1E). An increase of reads corre-
sponding to intronic PASs was observed in Mtr4 knock-
down cells, while those corresponding to the 3′-most
PASs, reflecting full-length mRNAs, were not affected
by knockdown (Supplemental Fig. S1A), suggesting that
the change was due to ptRNA stabilization as opposed
to increased 3′ processing at the intronic PAS.
We next performed RT-qPCR [oligo(dT)-primed RT and
quantitative PCR (qPCR)] to confirm and extend the re-
sults of 3′READS. To distinguish ptRNAs and full-length
mRNAs, primers were designed as shown in Figure
1G. Consistent with the 3′READS data, levels of both
ptRNAs and uaRNAswere increased byMtr4 knockdown
but not by knockdown of RBM7 or ZCCHC8 (Fig. 1F,H).
In contrast to the uaRNAs, increased levels of two
knownNEXT substrates—RBM39 and FBXO7 PROMPTs
(proRBM39 and proFBXO7, respectively) (Lubas et al.
2011)—were observed in all knockdown cells (Fig. 1H).
Similar results were obtained using a secondMtr4 siRNA
(Supplemental Fig. S1B,C). RT-qPCR also confirmed that
there were no changes in full-length mRNA levels for
genes that displayed elevated ptRNA levels (Fig. 1F, FL
mRNA). The other known Mtr4-containing complex,
TRAMP, appears not to be involved in degradation of
ptRNAs and uaRNAs, as there were no significant chang-
es of the Mtr4 target RNAs after ZCCHC7 knockdown
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Figure 1. Global analysis of poly(A)+ transcript levels following depletion of individualNEXT subunits. (A) Western blot analysis of HeLa
cell extracts after 48 h of transfection of control (Ctrl), Mtr4, RBM7, or ZCCHC8 siRNA. (B) RBM7 mRNA level after 48 h of siRBM7
treatment. RBM7mRNAwas normalized toGAPDHmRNA, and the normalized levels in siCtrl-treated cells were set to 1. Bars represent
mean ± SD. n = 3. An asterisk denotes significant difference from siCtrl (P < 0.05) using an unpaired Student’s t-test. (C ) Schematic of dif-
ferent transcript types analyzed: transcripts using the first (F), middle (M), or last (L) potential PAS in the 3′ untranslated region (UTR); the
single (S; no 3′ UTR APA) PAS in the 3′ UTR; the intronic PAS in the composite terminal exon (Ic); the intronic PAS in the skipped ter-
minal exon (Is); the upstream (not 3′-most) exonic PAS (E); and the upstream antisense transcripts (UA). (D) Changes in relative abundance
of the indicated transcript types following knockdown of indicated NEXT subunits. The percentage of genes showing increases (UP) or
decreases (DWN) of each type of transcript are indicated. False discovery rate < 0.05. (E) Metagene plots of ptRNAs and uaRNAs. Data
are presented as strand-specific reads per million (RPM) at PAS positions within 4 kb upstream of or downstream from the transcription
start site. (F,H) RT-qPCR [oligo(dT)-primed RT and quantitative PCR (qPCR)] analysis of select ptRNAs and corresponding full-length (FL)
mRNAs (F ) and uaRNAs (H) after knockdown of the individual NEXT subunits. Analysis of two representative PROMPTs—proRBM39
and proFBX07—is also shown inH. Values were normalized to GAPDHmRNA, and the normalized levels in siCtrl-treated cells were set
to 1. Bars represent mean ± SD. n = 3. Asterisks denote significant difference from siCtrl (P < 0.05) using an unpaired Student’s t-test. (G)
Diagram of a ptRNA-producing gene and primers used for RT-qPCR. Arrows indicate the positions of primer targeting sites to analyze
ptRNA and full-length mRNA.
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(Supplemental Fig. S1D,E). In contrast and as expected,
the nuclear exosome is required for ptRNA and uaRNA
degradation, as all tested pt/uaRNAs accumulated follow-
ing codepletion of the two catalytic subunits Rrp6 and
Dis3 (Supplemental Fig. S1F,G). Together, these results
indicate that the exosome degrades these RNAs in an
Mtr4-dependent, but NEXT- and TRAMP-independent,
manner.
Identification of Mtr4-interacting proteins
The above results suggested the possible existence of an
additional Mtr4-containing protein complex that func-
tions in ptRNA and/or uaRNA turnover. To investigate
this, we prepared extracts from HEK293 cells stably ex-
pressing N-terminally 3xFlag-tagged Mtr4 (Flag-Mtr4,
with expression equivalent to endogenous Mtr4) (Fig.
Figure 2. Identification of Mtr4-interacting proteins by cofractionation and MS. (A) Western blotting analysis of HEK293 cells and
HEK293 cells stably expressing 3Flag-Mtr4. (Top panel) Blotted with anti-Mtr4 antibodies. (Bottom panel) Blotted with anti-Flag antibod-
ies. (B) Fractions from Superose 6 gel filtration 3Flag-Mtr4-expressing HEK293 cells were analyzed by Western blotting using antibodies
against proteins shown at the right. Approximatemolecular sizes are indicated at the top, and fractions pooled are indicated at the bottom.
(C ) Selected proteins copurifiedwith 3Flag-Mtr4 in the indicated pools. Spectral counts and sequence coverage of knownMtr4-interacting
partners (NEXT, exosome, andNRDE2), proteins detected as complexes (e.g., NuRD and spliceosome), andRNAprocessing or RNA-bind-
ing proteins are shown. A full protein list is in Supplemental Table S1.
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2A) in the presence of RNase A and performed size frac-
tionation using Superose 6 gel filtration chromatography
followed by Western blotting (Fig. 2B). Mtr4 was detected
in all fractions from the void to <158 kDa in a bimodal dis-
tribution with peaks at fraction 31 and at <158 kDa, likely
reflecting the existence ofmultipleMtr4-containing com-
plexes. The NEXT subunit ZCCHC8 eluted at ∼1 MDa,
whereas TRAMP subunits ZCCHC7 and PAPD5 appeared
mainly in the void fractions.
To identify additional Flag-Mtr4-interacting proteins,
we collected three Flag-Mtr4-containing pools (A–C) ac-
cording to the distribution of TRAMP (ZCCHC7 and
PAPD5) and NEXT (ZCCHC8). The pools were subjected
to Flag immunoprecipitation, and the coimmunoprecipi-
tated proteins were identified byMS (Fig. 2C; Supplemen-
tal Table S1). The subunits of NEXT, the exosome, and
cap-binding complex (CBC), which were shown previous-
ly to associate withNEXT (Andersen et al. 2013), were de-
tected in pools A and B. Consistent with a previous report
(Nag and Steitz 2012), various splicing factors also associ-
ated with Flag-Mtr4 in pool B. Pool B also contained
NuRD complex subunits, which function in histone
modification (Xue et al. 1998; Zhang et al. 1998). We
also found several heterogeneous nuclear ribonucleopro-
teins (hnRNPs)—PSF/SFPQ and p54nrb/NONO—in pool
B as well as two other possibly relevant proteins:
NRDE2 and ZFC3H1. Although the role of NRDE2 in hu-
man cells is unknown, the fission yeast homolog Nrl1 in-
teracts physically with an Mtr4-like protein, Mtl1 (Lee
et al. 2013; Aronica et al. 2016), and is involved in suppres-
sion of R-loop formation (Aronica et al. 2016). ZFC3H1 is a
large (∼230-kDa) protein localized in the nucleus and
shown to modulate IL-8 transcription (Tomita et al.
2014). ZFC3H1 is the apparent homolog of the Schizosac-
charomyces pombe protein Red1, which functions in a
distinctMtl1-containing complex and, significantly, plays
essential roles in the degradation of various unstable
RNAs (Lee et al. 2013; Egan et al. 2014; Zhou et al. 2015).
We next performed coimmunoprecipitation (co-IP) ex-
periments to verify several of the interactions suggested
by the above data. We validated RNase-resistant interac-
tions of Mtr4 with ZFC3H1 (Fig. 3A,B), NRDE2, U5-
40K, and hnRNP M (Supplemental Fig. S2). (Note that
ZFC3H1 appears as two major bands of ∼250 and 150
Figure 3. Mtr4-associated ZFC3H1 is required for down-regulation of ptRNAs and uaRNAs but not NEXT substrates. (A) Cell extracts
prepared fromHEK293 cells and HEK293 cells stably expressing 3Flag-Mtr4 were used for immunoprecipitation with anti-Flag antibodies
in the presence of benzonase and RNase A followed by Western blotting with the indicated antibodies. (B) Cell extracts prepared from
HEK293 cells were used for co-IP experiments with anti-ZFC3H1 in the presence of benzonase and RNase A followed byWestern blotting
with antibodies against the proteins indicated at the right. (C ) Western blot analysis of HeLa cell extracts after 72 h of knockdown treat-
ment with the siRNAs indicated at the top; antibodies against the proteins are indicated at the right. (D,E) RT-qPCR analysis of the in-
dicated ptRNAs (D) and the indicated uaRNAs andNEXT substrates proRBM39 and proBIRC4 (E) after the indicated siRNA transfections.
Transcript levelswere normalized toGAPDHmRNA, and the normalized levels in siCtrl-treated cellswere set to 1. Bars representmean ±
SD. n = 3. Asterisks denote significant difference from siCtrl (P < 0.05) using an unpaired Student’s t-test.
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kDa, both of which were decreased by ZFC3H1 knock-
down [Figs. 3C, 6A]. The 150-kDa isoform was more effi-
ciently immunoprecipitated with Mtr4 or ZFC3H1
antibodies [Fig. 3A], whichmay reflect limited epitope ac-
cessibility in the 250-kDa ZFC3H1–Mtr4 complex. The
existence of a 250-kDa ZFC3H1–Mtr4 complex is sup-
ported by the observation that Mtr4 knockdown caused
decreases in both the 250- and 150-kDa isoforms, likely re-
flecting protein destabilization [Figs. 3C, 6A]. The origin
of the smaller species remains to be determined.) Impor-
tantly, neither TRAMP nor NEXT subunits were coim-
munoprecipitated with ZFC3H1 or NRDE2 (Fig. 3B;
Supplemental Fig. S2B,C), indicating that these proteins
form complexes that are distinct from NEXT and
TRAMP. In contrast, hnRNP M and U5-40K coimmuno-
precipitated with ZCCHC7 and PAPD5 but not with
ZCCHC8, suggesting that Mtr4 interacts with these pro-
teins in the context of TRAMP (Supplemental Fig. S2A).
ZFC3H1 is required for repression of ptRNAs
and uaRNAs but not NEXT substrates
Among the verified Mtr4-interacting partners described
above, we decided to focus on ZFC3H1. (While this
work was in progress, Meola et al. [2016] also identified
ZFC3H1 as an Mtr4-interacting protein.) To determine
whether ZFC3H1, like Mtr4, is required for ptRNA and
uaRNA turnover, we depleted ZFC3H1 and evaluated
the accumulation of these RNAs by RT-qPCR (Fig. 3C–
E). Importantly, as with Mtr4 knockdown, both ptRNA
and uaRNA levels were increased byZFC3H1knockdown
(Fig. 3D,E). In contrast, ZFC3H1 knockdown, unlike
NEXT knockdown, had no significant effect on the levels
of two PROMPTs, proRBM39 and proBIRC4, indicating
that ZFC3H1 and NEXT target distinct sets of RNA sub-
strates (Fig. 3E).
Another protein that might be involved in pt/uaRNA
degradation is the nuclear poly(A)-binding protein
(PABPN1). PABPN1 interacts physically with the nuclear
exosome to degrade subsets of polyadenylated lncRNA
species (Beaulieu et al. 2012), and these targets include
both ptRNAs (Li et al. 2015) and uaRNAs (Bresson et al.
2015; Li et al. 2015). Despite the absence of PABPN1 in
our Flag-Mtr4 co-IP/MS (Fig. 2; Supplemental Table S1)
and co-IP/Western blot analyses (Supplemental Fig. S3A,
B), we next investigated whether PABPN1 functions sim-
ilarly to Mtr4/ZFC3H1. RT-qPCR results indicate that
Mtr4/ZFC3H1 and PABPN1 share RNA substrates (Fig.
3C–E; Supplemental Fig. S3C–E), although an exception
was uaIGF2BP1, which was sensitive only to Mtr4/
ZFC3H1 knockdown (Fig. 3E; Supplemental Fig. S3E).
AswithMtr4/ZFC3H1 knockdown, PABPN1 knockdown
had only minimal effect on proRBM39 and proBIRC4 lev-
els (Supplemental Fig. S3E).
Depletion of Mtr4/ZFC3H1 causes cytoplasmic
accumulation of ptRNAs and uaRNAs
We next investigated the consequences of the increased
accumulation of ptRNAs and uaRNAs caused by Mtr4/
ZFC3H1 knockdown. Given that addition of a poly(A)
tail can be sufficient to target mRNAs for nuclear export
(Brodsky and Silver 2000; Fuke and Ohno 2008), we first
investigated whether there were any changes in subcellu-
lar localization of these RNAs in knockdown cells. To this
end, we separated cell compartments into cytoplasmic,
nuclear-soluble, and chromatin fractions. The effective-
ness of our fractionation protocol was verified by Western
blotting: GAPDH, U2AF65, and histoneH3were detected
predominantly in the cytoplasmic, nuclear-soluble, and
chromatin fractions, respectively (Fig. 4A–C). Mtr4 was
predominantly nuclear and evenly distributed in the nu-
clear-soluble and chromatin fractions (Fig. 4A,B), while
ZFC3H1 was almost entirely in the chromatin fraction
(Fig. 4C). NEXT subunit ZCCHC8 and TRAMP subunits
ZCCHC7 and PAPD5 displayed different distributions;
ZCCHC8 was largely nuclear-soluble, whereas ZCCHC7
and PAPD5 were exclusively in the chromatin fraction
(Fig. 4A). PABPN1 was predominantly in the two nuclear
fractions (Fig. 4A).
To investigate ptRNA and uaRNA localization, we an-
alyzed by RT–PCR RNA from fractions prepared as above
from cells treated with Ctrl, Mtr4, or ZFC3H1 siRNAs
(Fig. 4B,C). Specifically, RNA from the cytoplasmic (Fig.
4B,C, lanes 1,2), nuclear-soluble (Fig. 4B,C, lanes 3,4),
and chromatin (Fig. 4B,C, lanes 5,6) fractions of knock-
down cells was analyzed. Effective fractionation was ver-
ified by Western blotting of GAPDH, U2AF65, and
histone H3 as above as well as by RT–PCR of a cytoplas-
mic lncRNA (RPPH1) and a nuclear-insoluble lncRNA
(NEAT1). Moreover, unspliced forms of multiexonic
ptRNAs (CSTF3 and TMED4) were enriched in the chro-
matin fraction, further demonstrating the validity of the
fractionation. In siCtrl cells, all types of Mtr4/ZFC3H1
targets were most abundant in the chromatin fraction
(Fig. 4B,C, cf. lanes 1, 3, and 5). This trend was most pro-
nounced with the single-exonic DAP ptRNA as well as
all uaRNAs, which were almost exclusively in the chro-
matin fraction, whereas multiexonic CSTF3 and
TMED4 ptRNAs were detected in all three fractions.
Most importantly, however, increased accumulation of
all of the ptRNAs and uaRNAs was detected in cytoplas-
mic and nuclear-soluble fractions after Mtr4 or ZFC3H1
knockdown, while levels in the chromatin fraction were
unchanged. These results imply that Mtr4/ZFC3H1 tar-
get transcripts, especially those with single exons, are de-
graded immediately after release from chromatin, and
failure of this surveillance system results in significant ac-
cumulation of these RNAs in the cytoplasm.
Exported ptRNA and uaRNA associate with ribosomes
Wenext investigated the fate of the ua/ptRNAs that accu-
mulate in the cytoplasm in the knockdown cells.Notably,
all of these RNAs contain putative ORFs, and one possi-
bility therefore is that they are bound by ribosomes and
translated. This possibility is supported by the fact that
ptRNAs and uaRNAs have very long, ∼300-nucleotide
poly(A) tails, as determined by RL-PAT assays (Supple-
mental Fig. S4). To investigate the association of ptRNAs
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and uaRNAs with ribosomes, we first performed poly-
some fractionation by sedimenting cytoplasmic extracts
prepared from siRNA-treated cells through 15%–45%
sucrose gradients (Fig. 5A) and then evaluated the distri-
bution of individual Mtr4 target transcripts by RT–PCR
(Fig. 5B–D; quantitation in Supplemental Fig. S5). In Ctrl
siRNA-treated cells, CSTF3 and TMED4 ptRNAs were
detected mainly in polysomes, while the DAP ptRNA
was found in monosomes to light polysomes (Fig. 5B).
All four uaRNAs analyzed (ZNF207, IGF2BP1, IGF2BP3,
and MAN1A2), although present at only low levels in
the cytoplasm, were distributed between free cytosolic
to light polysome fractions (Fig. 5C). While Mtr4 knock-
down in general did not cause significant changes in the
distribution of these RNAs, all of the ptRNAs and ua-
RNAs that accumulated in the cytoplasm associated
with ribosomes, and the absolute amount of ribosome-
bound RNA thus increased in all cases. We also analyzed
the polysome profile of two full-length mRNAs (GAPDH
and CSTF3), and, in contrast to the ptRNAs and uaRNAs,
both shifted to lighter fractions following Mtr4 knock-
down (Fig. 5D).
We next investigatedwhether the ptRNAs and uaRNAs
were indeed associated with active ribosomes. To this
end, we treated cells with the eIF2–GTP–tRNAiMet ter-
nary complex inhibitor BTdCPU, which blocks formation
of the preinitiation complex (Chen et al. 2011), and sub-
jected cell extracts to sucrose gradient analysis as above.
UV absorption profiles showed a sharp inhibition of trans-
lation after 3 h of BTdCPU treatment (Fig. 5A; Supple-
mental Fig. S6A, +BTdCPU). RT–PCR analysis of the
individual Mtr4 target RNAs revealed in all cases a shift
of peak positions from heavy to light fractions following
BTdCPU treatment (Fig. 5B–D), providing evidence that
the RNAswere associatedwith active polysomes. Togeth-
er, our results indicate thatMtr4 target transcripts that es-
caped RNA surveillance in the nucleus and were exported
to the cytoplasmwere then bound by ribosomes and likely
translated.
Despite the increased association of uaRNAs and
ptRNAs with ribosomes in the Mtr4 knockdown cells,
we detected an unexpected decrease in polysomes. Specif-
ically, analysis of the UV absorption profiles revealed that
48 h of Mtr4 siRNA treatment caused a reduction in poly-
somes, especially in heavier polysomes (Fig. 5A; Supple-
mental Fig. S6A). Notably, this is consistent with the
behavior of the two full-length mRNAs analyzed (see
above). An even more robust reduction in polysomes
was evident after 72 h ofMtr4 knockdown, again especial-
ly notable in the heavy polysome fractions (Supplemental
Fig. S6B). A second Mtr4 siRNA gave similar results (Sup-
plemental Fig. S6C). Also of note, althoughMtr4-depleted
cells showed reduced growth and morphological changes
after 72 h, ptRNA and uaRNA levels continued to in-
crease even after 96 h of knockdown (Supplemental Fig.
S6D). These findings together indicate that normally un-
stable, nuclear, and hence untranslated lncRNAs associ-
ate with active ribosomes following Mtr4 knockdown,
but, paradoxically, this correlates with an overall reduc-
tion in polysomes and hence, very likely, translation.
To verify that Mtr4 knockdown indeed led to a
global reduction of translation and determine whether
ZFC3H1 knockdown might have similar effects, we per-
formed puromycin incorporation assays. Puromycin is a
chain terminator that is incorporated into growing na-
scent polypeptide chains and thus can be used to label na-
scent polypeptides (Schmidt et al. 2009). We treated cells
with low concentrations of puromycin (1 µg/mL), and
translation efficiencywas evaluated by detecting puromy-
cilated nascent chains using anti-puromycin antibodies
Figure 4. Mtr4 knockdown causes cyto-
plasmic accumulation of stabilized ptRNAs
and uaRNAs. (A) Western blotting of sub-
cellular fractions prepared from HeLa cells.
Proteins fromwhole-cell extract (WCE), cy-
toplasm (Cyt), nuclear-soluble (Nuc), and
nuclear-insoluble chromatin (Chr) fractions
were analyzed using antibodies directed
against the proteins listed on the right. (B,
C ) Subcellular fractionation was performed
after 72 h of siMtr4 (B) or siZFC3H1 (C )
treatment, and total RNAs were isolated
from each fraction, as indicated at the top.
cDNA was synthesized using random or
oligo(dT) primer, and the indicated tran-
scripts (shown at the left) were analyzed
by PCR. Gels were prestained with ethid-
ium bromide (EtBr). RPPH1 and NEAT1
RNAswere amplified using random-primed
RT products and served as cytoplasmic and
nuclear-insoluble markers. Other RNAs
were amplified using oligo(dT)-primed RT
products.
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for Western blotting of whole-cell lysates (Fig. 6A, quanti-
tation in B). Puromycin incorporation was completely
blocked by pretreatment with cycloheximide (CHX) (Fig.
6A, lane 3), confirming that this method allowed us to an-
alyze newly synthesized proteins. In agreement with the
polysome fractionation data, efficiency of puromycin in-
corporation was substantially lower after Mtr4 or
ZFC3H1 knockdown (Fig. 6A, cf. lanes 2 and 4,8). Note
that siZFC3H1 treatment was less toxic than siMtr4:
We observed only a small reduction in cell proliferation
and slight morphological changes. Importantly, depletion
of NEXT and TRAMP subunits RBM7, ZCCHC8, and
ZCCHC7 did not cause a significant decrease in puromy-
cin incorporation (Fig. 6A, lanes 5–7).
Next, we wished to address the possibility that the re-
duction in polysomes and translation in the Mtr4/
ZFC3H1 knockdown cells might reflect another function
of the proteins. Specifically, aberrant unprocessed pre-
rRNAs have been observed to accumulate in Mtr4-com-
promised cells (Schilders et al. 2007; Tafforeau et al.
2013). We also detected pre-rRNAs by Northern blotting
using probes hybridizing to 3′ extended sequences of
5.8S (ITS2) and 18S (ITS1) rRNAs in Mtr4-depleted cells
(Supplemental Fig. S7A). However, Northern blotting us-
ing probes that detect both mature and unprocessed
rRNAs revealed that the amount of unprocessed rRNAs
relative to the mature species was extremely low: The un-
processed pre-rRNAs were detectable only when blots
were overexposed such that signals for mature rRNAs
were saturated and no longer in a quantitative range (Sup-
plemental Fig. S7B, 5.8S and 18S). In addition, there were
no detectable effects on the levels of mature rRNAs.
Moreover, ZFC3H1 knockdown, which also caused
reduced translation, did not lead to accumulation of aber-
rant pre-rRNAs or decrease ofmature rRNAs (Supplemen-
tal Fig. S7B). These findings and other results discussed
Figure 5. Cytoplasmic ptRNAs and uaRNAs
associatewith active ribosomes but lead to re-
duced global translation. (A) UV absorption
profiles at 254 nm of 15%–45% sucrose gradi-
ents. HeLa cells were transfected with either
control siRNA (siCtrl) or Mtr4 siRNA
(siMtr4) for 48 h, and cytoplasmic extracts
were prepared from cells with or without 50
µM/mL BTdCPU for 3 h. (B–D) RNAs extract-
ed from each fraction as in A were used for
oligo(dT)-primed cDNA synthesis, and the in-
dicated transcripts were analyzed by RT–
PCR. Gels were prestained with EtBr. Ribo-
some/polysome-associated fractions are high-
lighted with a gray box. An asterisk marks
primer dimers.
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below argue strongly that the effects of Mtr4/ZFC3H1
knockdown on translation are not due to defects in ribo-
some assembly.
Together, our experiments revealed an unexpected role
for Mtr4–ZFC3H1 in preventing global disruption of
mRNA association with polysomes and subsequent
translation.
Discussion
It is becoming increasingly clear that a much larger frac-
tion of the human genome is transcribed than previously
appreciated. Much of this “non-mRNA” transcription is
by RNA polymerase II, and the RNAs produced are fre-
quently subject to the processing reactions that typically
give rise to mRNAs, such as splicing and polyadenylation
(Jensen et al. 2013). However, unlike mRNAs, these
RNAs are often retained in the nucleus and rapidly turned
over. While some of the key factors in this process are
known, such as the nuclear exosome and NEXT complex
(Lubas et al. 2011;Meola et al. 2016; for review, see Zinder
andLima 2017), it is notwell understood howandwhether
the degradationof theseRNAs is coordinated andwhat the
consequences might be if their turnover is prevented. In
this study, we identified Mtr4 together with ZFC3H1 as a
potential “master regulator” of polyadenylated lncRNA
metabolism and showed that when its activity is reduced,
normallyunstable lncRNAsaccumulateandaretransport-
ed to the cytoplasm, where they appear to “swamp” ribo-
somes and thereby inhibit translation globally (Fig. 7).
Based on these properties, we refer to the Mtr4/ZFC3H1
complex as the “polysome protector complex” (PPC).
ptRNAs and uaRNAs are targeted for turnover by the
PPC and not by either of the other characterized Mtr4-
containing complexes—NEXT or TRAMP. A large major-
ity of these RNAs contain a PAS at their 3′ end, implying
that the canonical or very similar pre-mRNA3′ processing
machinery is used for their polyadenylation. However, in
contrast to mRNAs (which are generally more stable, effi-
ciently exported to the cytoplasm, and translated), ua-
RNAs and ptRNAs as well as many other lncRNAs are
typically rapidly degraded in the nucleus (Andersson
et al. 2014b; Li et al. 2015; Schlackow et al. 2017). While
neither NEXT nor TRAMP is required for ptRNA and
uaRNA turnover, the nuclear exosome is. Thus, the PPC
is distinct fromNEXT and TRAMP, suggesting that these
complexes target distinct sets of RNA substrates for deg-
radation by the exosome. Importantly, though, only the
PPC prevents accumulation and transport of lncRNAs
from the nucleus that is sufficient to disrupt normal trans-
lation, as knockdown of NEXT/TRAMP subunits did not
detectably affect translation.
While this work was in preparation, Meola et al. (2016)
reported that Mtr4 and ZFC3H1 together with PABPN1
form a complex that preferentially degrades polyadeny-
lated lncRNAs such as snoRNA host gene (SNHG) tran-
scripts. They also showed that ZFC3H1 and PABPN1
knockdown resulted in the accumulation of subsets of
uaRNAs and eRNAs, There are similarities as well as dif-
ferences between our results and those of Meola et al.
(2016). For example, in addition to uaRNAs, we identified
ptRNAs as Mtr4/ZFC3H1 substrates and, notably, found
that these RNAs had very long poly(A) tails and were
not substrates for NEXT-mediated degradation. Also,
while we did not detect an interaction between PABPN1
and Mtr4/ZFC3H1, we did observe the accumulation of
most, but not all, ptRNAs and uaRNAs tested following
PABPN1 knockdown. Finally and most importantly, we
demonstrated that an important function of Mtr4/
ZFC3H1 involves the maintenance of polysome integrity
by preventing the accumulation of polyadenylated
lncRNAs in the cytoplasm.
Figure 6. Mtr4/ZFC3H1 depletion causes global reduction of
translation. (A) Puromycin incorporation assay. HeLa cells trans-
fected with the indicated siRNAs for 48 h were treated with 1 µg/
mL puromycin for 30 min. (Lane 3) CHX treatment was per-
formed 10 min prior to puromycin addition. Cell lysates were re-
solved by SDS-PAGE, and puromycilated proteins were detected
using an anti-puromycin antibody. (B) Puromycin-incorporated
protein levels as in Awere quantitated using LI-COR Image Stu-
dio software and normalized by GAPDH levels. The normalized
levels in lane 2were set to 1. Bars represent mean ± SD. n = 3. As-
terisks denote significant difference from lane 2 (P < 0.05) using
an unpaired Student’s t-test.
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The fact that Mtr4 participates in multiple distinct
complexes is reminiscent ofMtr4 proteins in fission yeast.
S. pombe has twoMtr4 paralogs: Mtr4 andMtl1. Mtr4 is a
TRAMP component (Zhang et al. 2011), whereas Mtl1
forms a core complex with Red1, called MTREC (Mtl1–
Red1 core) or NURS (nuclear RNA silencing) (Lee et al.
2013; Egan et al. 2014; Zhou et al. 2015). As mentioned
above, Red1 is the fission yeast homolog of ZFC3H1 and
is essential for exosomal decay of various RNAs, includ-
ing CUTs (cryptic unstable transcripts), which are similar
to uaRNAs and PROMPTs inmammals;meioticmRNAs;
and unspliced pre-mRNAs (Lee et al. 2013; Egan et al.
2014; Zhou et al. 2015). Specificity for RNA targeting by
MTREC/NURS is determined by at least three distinct
submodule complexes (Zhou et al. 2015). Further studies
are required to determine whether the PPC also uses asso-
ciated proteins to distinguish specific RNA substrates.
The global reduction of translation that we observed in
PPC-depleted cells highlights the importance of rapidly
degrading naturally unstable nuclear lncRNAs. Since fail-
ure of RNA surveillance by PPC depletion leads to in-
creased accumulation of cytoplasmic polyadenylated
RNAs that have the ability to recruit ribosomes, we pro-
pose that heavy polysome formation on mRNAs is ham-
pered by “dilution of ribosomes” by the accumulated
normally unstable nuclear “noncoding” RNAs in the cy-
toplasm (Fig. 7). Translation or ribosome binding of
lncRNAs, which contain small ORFs (sORFs) and thus
possibly produce micropeptides (Slavoff et al. 2013;
Ruiz-Orera et al. 2014; Raj et al. 2016) has been reported
in multiple species, including yeast (Ingolia et al. 2014;
Smith et al. 2014), fruit flies (Dunn et al. 2013; Aspden
et al. 2014), zebrafish (Chew et al. 2013; Bazzini et al.
2014), and mammals (Chew et al. 2013; Zhou et al.
2013; Ingolia et al. 2014; van Heesch et al. 2014; Fields
et al. 2015; Ji et al. 2015; Calviello et al. 2016; for review,
see Ingolia 2016). Moreover, a recent study provided evi-
dence that a vast majority of monosomes is actively elon-
gating and translating sORFs (Heyer and Moore 2016).
Thus, ribosome binding/translation of some lncRNAs oc-
curs and appears compatible with efficient cellular pro-
tein synthesis. However, our data provide evidence that
when such RNAs are globally stabilized and accumulate
in the cytoplasm, they “overwhelm” the system, and
translation of mRNAs is repressed (Fig. 7). The fact that
Mtr4/ZFC3H1 substrates have long poly(A) tails, which
is in contrast to NEXT targets that largely lack poly(A)
tails (Meola et al. 2016), may help explain their efficient
ribosome association (Peng et al. 2008; Park et al. 2016).
It is noteworthy that although eRNAs are largely nonpo-
lyadenylated (Djebali et al. 2012; Andersson et al.
2014a), we recently identified a class of poly(A)+ eRNAs
that are stabilized by Mtr4/ZFC3H1 knockdown. These
eRNAs can also be transported to the cytoplasm and asso-
ciate with ribosomes (K Ogami, Y Chen, and JL Manley,
unpubl.), increasing the pool of lncRNAs that require sur-
veillance by the PPC. Our results thus highlight how crit-
ical it is that such lncRNAs be degraded rapidly in the
nucleus because, if they survive surveillance by the
PPC, they become toxic.
Could another function of Mtr4 or ZFC3H1 be respon-
sible for the disruption of translation that we observed?
As noted above, Mtr4 is known to function in the matura-
tion of 5.8S and 18S rRNA from cleaved rRNA precursors
(de laCruz et al. 1998; Schilders et al. 2007; Tafforeau et al.
2013). Might defects in rRNA processing contribute to re-
duced translation in Mtr4-deficient cells? We consider
this unlikely for several reasons: First, since mature
rRNAs are abundant and very stable, with half-lives that
are days long (Yi et al. 1999; Defoiche et al. 2009), it would
be unlikely that mature rRNA levels decrease sufficiently
to affect ribosome levels and perturb translation. Our find-
ing that the amount of unprocessed pre-rRNA that accu-
mulated following Mtr4 knockdown was extremely
small and that levels of 5.8S and 18S rRNAs were
Figure 7. Model for the role of theMtr4/ZFC3H1 complex in the
turnover of nuclear polyadenylated transcripts and how its loss af-
fects translation. Model depicting the impact of PPC deficiency
on polyadenylated transcriptomes and global translation. Loss
of the PPC results in stabilization of ptRNAs and uaRNAs,which
are normally rapidly degraded in the nucleus, and these RNAs are
then transported to the cytoplasm. The exported RNAs become
ribosome-associated and overwhelm the translational machin-
ery, which leads to disruption of the quantitative balance be-
tween available ribosomes and translatable RNAs. See the text
for details.
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essentially unaffected is consistent with this. Second,
while ZFC3H1 knockdown was shown previously to re-
sult in reductions in 47S and 45S pre-rRNAs (Tafforeau
et al. 2013), our data showed no changes in downstream
pre-rRNA and mature rRNA levels following ZFC3H1
knockdown. Third, unprocessed pre-5.8S rRNA in fact as-
sembles into 60S ribosomes (Briggs et al. 1998), and the re-
sulting immature 60S particles engage in apparently
normal translation (Rodriguez-Galan et al. 2015). Indeed,
polysome disassembly has not been observed in yeast or
mammals under conditions that allow accumulation of
aberrant pre-rRNA (Briggs et al. 1998; Strezoska et al.
2000). It is thus unlikely that defective pre-rRNA process-
ing is responsible for the impaired polysome formation/
translation that we observed in Mtr4/ZFC3H1 knock-
down cells. Indeed, the fact that the excess uaRNAs and
ptRNAs that accumulated in Mtr4 knockdown cells asso-
ciated with active ribosomes further argues against this
possibility. Mtr4-depleted cells can also accumulate ma-
ture and 3′ extended snRNA (Hrossova et al. 2015; Lubas
et al. 2015) and pri-miRNA5′ by-products (Dorweiler et al.
2014; Lubas et al. 2015). However, accumulation of these
transcripts does not contribute to the decreased transla-
tion that we observed, since these RNAs are NEXT sub-
strates (Hrossova et al. 2015; Lubas et al. 2015; K Ogami,
Y Chen, M Hoque, W Li, B Tian, and JL Manley, unpubl.),
and NEXT subunit knockdown had no effect on protein
synthesis.
Our model implies that ribosomes must not be present
in significant excess or they would otherwise be able to
handle the increase in substrates produced when the
PPC is depleted. Indeed, studies in yeast have suggested
that ribosomes in fact are limiting for translation (Chu
and von der Haar 2012; Shah et al. 2013). A similar situa-
tion likely exists in human cells. A good example is virus
infection. In infected cells, there is often a competition be-
tween viral and cellular RNAs for limiting translation
components. To overcome this, some viruses alter the bal-
ance of viral and cellular mRNA availability for transla-
tion by decreasing cytoplasmic cellular mRNA levels by
stimulation ofmRNA turnover or inhibition ofmRNAex-
port (for review, see Walsh and Mohr 2011). For example,
herpes simplex virus 1 expresses the endonuclease virion
host shutoff (vhs) to accelerate cellular mRNA decay,
thereby preventing mRNA overload in infected cells
(Dauber et al. 2014). Viral mRNAs associated with poly-
somes dramatically decrease in the absence of vhs, indi-
cating that the total amount of translatable RNA needs
to be regulated to ensure optimal translation of viral
mRNAs.
In conclusion, we identified a complex containing the
RNA helicase Mtr4 and the zinc finger protein ZFC3H1.
This complex, dubbed the PPC, functions in nuclear sur-
veillance of certain unstable polyadenylated lncRNAs to
prevent their accumulation, export to the cytoplasm,
and consequent disruption of protein synthesis. Our find-
ings are significant because they provide an explanation of
why so many lncRNAs are degraded in the nucleus essen-
tially as soon as they are synthesized, as they otherwise
have the potential to escape from the nucleus and over-
whelm the cell’s translational capacity. While it will be
important in the future to learn more about the PPC
(e.g., precisely how it functions and whether it can be reg-
ulated), our results have uncovered a new and unexpected
function for nuclear RNA surveillance.
Materials and methods
Primers and siRNAs
All primers and siRNAs used in this study are listed in Supple-
mental Table S2. siRNAs against Rrp6 and Dis3 were described
previously (Richard et al. 2013; Di Giammartino et al. 2014).
siMtr4 s223606 was obtained from Thermo Fischer Scientific.
Cell culture and siRNA transfections
HeLa cells were cultured inDMEMsupplementedwith 10%FBS.
The siRNAswere transfected usingDharmaFECT 1 (GEDharma-
con) at 20 nM and maintained for 48, 72, or 96 h as indicated. To
maintain high knockdown efficiency after 96 h, the siRNA trans-
fection was repeated 48 h after the first transfection with half the
amount of siRNA, and cells were harvested 48 h after the second
transfection.
Antibodies
Mtr4 (NB100-1574), ZCCHC8 (NB100-94995), ZCCHC7 (NBP1-
89175), Dis3 (H00022894-B01P), and Rrp6 (NBP1-32870) antibod-
ies were from Novus Biologicals. ZFC3H1 (Bethyl Laboratories,
A301-456A), hnRNP M (Bethyl Laboratories, A303-910A),
NRDE2 (Proteintech, 24968-1-AP), U2AF65 (Sigma, U4758), his-
tone H3 (Abcam,ab1791), and puromycin (Kerafast, 3RH11) were
also used in this study. PAPD5 antibody was a generous gift from
Dr. Shin-ichi Hoshino (Ogami et al. 2013).
RT-qPCR
Total RNA was isolated using TRIzol according to the manufac-
turer’s instructions followed by DNase I digestion for 30 min at
37°C. Twomicrograms of DNase I-treated RNAwas reverse-tran-
scribed with oligo(dT) primer using Maxima RT. Reactions were
diluted 15 times in water, and qPCR was performed with the
primers listed in Supplemental Table S1 and Power SYBR using
StepOnePlus (Applied Biosystems). All data were normalized to
GAPDH mRNA levels. Reagents for RT-qPCR were all from
Thermo Fischer Scientific.
3′READS
Total RNA was purified from control and siRNA-treated cells.
RNA integrity was analyzed by using Agilent Bioanalyzer. Sam-
ples with an RNA integrity number (RIN) >9.0 were subjected
to 3′READS analysis following the protocol described in Hoque
et al. (2014). Briefly, after RNA fragmentation, poly(A)+ RNA frag-
ments were captured on magnetic beads coated with a chimeric
oligonucleotide (oligo CU5T45), which contained 45 thymidines
at the 5′ portion and five uridines at the 3′ portion, and subjected
to RNase H digestion, which removed the bulk of the poly(A) tail
and eluted RNA from beads. Eluted RNAwas ligated to 5′ and 3′
adapters followed by reverse transcription, PCR amplification,
and deep sequencing on an Illumina platform. 3′READS data
were analyzed as described (Li et al. 2015).
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Gel filtration
HEK293 or HEK293/3Flag-Mtr4 cells from 10 10-cm dishes were
washed twice with PBS and lysed in lysis buffer (20mMTris-HCl
at pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1× prote-
ase inhibitor cocktail [Biotools], 100 µg/mL RNase A) for 10 min
at room temperature and 15 min on ice. Lysates were sonicated
and cleared by centrifugation at 15,000 rpm in an Eppendorf cen-
trifuge 5424 for 20 min at 4°C. The supernatants were filtered us-
ing Spin-X 0.45 µM cellulose acetate membrane (Sigma) at
16,000g for 10 min at 4°C prior to applying to a Superose 6 col-
umn. Gel filtration was performed in FPLC buffer (50 mM Tris-
HCl at pH 8.0, 150 mM NaCl, 0.5% NP-40) with a flow rate of
0.15 mL/min. Eluates were collected every 5 min.
MS analysis
Pooled FPLC fractions 26–33 (pool A), 34–42 (pool B), and 43–50
(pool C) were mixed with anti-Flag M2 magnetic beads for 2
h. Beads were then washed three times with wash buffer (20
mM Tris-HCl at pH 8.0, 300 mM NaCl, 0.5% NP-40, 0.5 mM
EDTA). Proteins remaining on the resin were eluted using 100
µL of 150 µg/mL 3Flag peptide (ApexBio) three times and precip-
itated in 23% TCA and washed with cold acetone. Proteins were
reduced with 5 mM Tris (2-carboxyethyl) phosphine hydrochlo-
ride (Sigma) and alkylated with 55mM 2-chloroacetamide (Fluka
Analytical). Proteins were digested for 18 h at 37°C in 2 M urea,
100 mM Tris (pH 8.5), and 1 mM CaCl2 with 2 µg of trypsin
(Promega). Multidimensional protein identification technology
(MudPIT) analysis was performed using an Eksigent nanoLC
pump and a Thermo LTQ-Orbitrap using an in-house built elec-
trospray stage (Wolters et al. 2001).
Protein and peptide identification and protein quantitation
were done with Integrated Proteomics Pipeline (IP2; Integrated
Proteomics Applications, Inc., http://www.integratedproteomics.
com). Tandem mass spectra were extracted from raw files using
RawConverter (He et al. 2015) andwere searched against aUniProt
human database with reversed sequences using ProLuCID (Peng
et al. 2003; Xu et al. 2015). The search space included all fully tryp-
tic and half-tryptic peptide candidates. Peptide candidates were fil-
tered using DTASelect with the following parameters: -p 2 -y 1
--trypstat --extra --pI -DM 10 --DB --dm -in --brief --quiet (Tabb
et al. 2002).
Co-IP
HEK293 or HEK293/3Flag-Mtr4 cells grown in two 10-cm dishes
were washed twice with PBS and lysed in lysis buffer (20 mM
Tris-HCl at pH 8.0, 300 mM NaCl, 1.5 mM MgCl2, 0.5 mM
EDTA, 0.5%NP-40, 1× protease inhibitor cocktail, 10 µg/mLRN-
ase A, >250 U/mL benzonase) for 20 min on ice. The lysates were
sonicated and then centrifuged in an Eppendorf centrifuge 5424 at
15,000 rpm for 20min at 4°C, and supernatantswere rotated with
either anti-Flag M2 magnetic beads (Sigma) for 1 h or protein G
beads (GE healthcare) in the presence of antibodies for 4 h. The
beads were then washed three times with lysis buffer, and pro-
teins retained on the resin were subjected to Western blot
analysis.
Subcellular fractionation
Seventy-two hours after siRNA transfection, HeLa cells grown in
a 10-cm dish were washed twice with PBS and collected by scrap-
ing and centrifugation. Cell pellets were resuspended in 400 µL of
swelling buffer (10 mM Tris-HCl at pH 8.0, 1.5 mM MgCl2, 10
mMKCl, 5 U of RNasin, 1× protease inhibitor cocktail) and incu-
bated for 15 min on ice. Cells were homogenized by passing a 26-
gauge needle attached to a 1-mL syringe until >90% of cells were
disrupted (typically 10∼20 strokes). Half of the lysate was kept in
a new tube and used as whole-cell lysate. The rest of the 200 µL of
lysatewas mixed with 2 µL of 10%NP-40, gently tapped, and im-
mediately centrifuged in an Eppendorf centrifuge 5424 at 6,000
rpm for 5 min. The supernatant was kept in a new tube and
used as cytoplasmic fraction. The pellet was washed once with
swelling buffer, resuspended in 100 µL of glycerol buffer (20
mMTris-HCl at pH 8.0, 75 mMNaCl, 0.5 mM EDTA, 50% glyc-
erol, 0.85mMDTT, 5U of RNasin, 1× protease inhibitor cocktail)
by pipetting, and then mixed with 100 µL of nucleus lysis buffer
(20 mMHEPES-NaOH at pH 7.6, 7.5 mMMgCl2, 0.2 mM EDTA,
300 mMNaCl, 1 M urea, 1%NP-40, 1 mMDTT, 5 U of RNasin,
1× protease inhibitor cocktail). The mixture was pulse-vortexed
three times, incubated for 1 min on ice, and then centrifuged in
an Eppendorf centrifuge 5424 at 14,000 rpm for 2min. The super-
natant was used as nuclear-soluble fraction. The pellet was
washed once with a 1:1 mixture of glycerol/nucleus lysis buffer
and then resuspended in 200 µL of water. RNAwas extracted us-
ing TRIzol, DNase I-treated, and then reverse-transcribed with
oligo(dT) or random primer using Maxima RT.
Polysome fractionation
HeLa cells were transfected with either siCtrl or siMtr4 and
maintained in the same medium for the indicated times in five
10-cm dishes. On the day of harvest (∼80% confluency), cells
were treated with either 50 µM BTdCPU or 100 µg/mL CHX for
3 h and 5 min, respectively, at 37°C. Cells were washed once
with ice-cold PBS containing either 50 µM BTdCPU (Millipore)
or 100 µg/mL CHX and then resuspended in 400 µL of polysome
lysis buffer (20 mM HEPES-NaOH at pH 7.6, 150 mM NaCl, 15
mM MgCl2, 0.5% NP-40, 80 U RNasin, 1× protease inhibitor
cocktail) containing either 50 µM BTdCPU or 100 µg/mL CHX.
After 10 min of incubation on ice, the lysates were centrifuged
at 3000 rpm for 5 min, and the supernatant was centrifuged at
15,000 rpm for 5 min in a new tube. The supernatant was loaded
onto 15%–45% sucrose gradients (20 mM HEPES-NaOH at pH
7.6, 150 mM NaCl, 5 mM MgCl2, 100 µg/mL CHX) followed by
centrifugation at 39,000 rpm for 90 min using an SW41Ti rotor.
Fractions (200 µL each) were manually collected, and A254 was
determined using a Nanodrop spectrophotometer. RNA was ex-
tracted by mixing with 1 vol of TRIzol, isopropanol-precipitated
in the presence of GeneElute-LPA (Sigma), and then reverse-tran-
scribed with oligo(dT) primer using Maxima RT. To avoid effi-
ciency differences in RT reactions, RNA amounts were
equalized by adding purified yeast RNA (Thermo Fisher Scien-
tific).No PCRproductswere generatedwhenyeastRNARTprod-
ucts alone were amplified with the primers used in this study.
Puromycin incorporation assay
siRNA-transfected HeLa cells (∼50% confluent) were treated
with 1 µg/mL puromycin for 30 min to label nascent polypep-
tides. CHX treatment was done at 10 µg/mL 10 min prior to add-
ing puromycin. Puromycilated proteins were resolved by SDS-
PAGE and detected by Western blotting using anti-puromycin
antibody.
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Figure S1. Mtr4 controls pt- and ua-RNA expression via a NEXT and 
TRAMP-independent mechanism. 
(A) UCSC genome browser screenshot of a representative example of RNA-Seq data at 
CSTF3 locus. (B) Western blot analysis of HeLa cell extracts after 48 hours KD of Mtr4 
using a second Mtr4 siRNA, s223606. (C) RT-qPCR analysis of ptRNA and uaRNA after 
Mtr4 KD using s223606. proRBM39 was included as a positive control of RNA 
accumulation after Mtr4 depletion. Transcript levels were normalized to GAPDH mRNA, 
and normalized levels in siCtrl-treated cells were set to 1. Bars represent mean ± SD (n=3), 
and asterisks denotes significant difference from siCtrl (P<0.05) using an unpaired Student's 
t-test. (D) Western blot analysis of HeLa cell extracts after 96 hours KD of ZCCHC7. (E) 
RT-qPCR analysis of ptRNA, full-length mRNA (FL mRNA) and uaRNAs. RNA levels were 
normalized to GAPDH mRNA, and the normalized levels in siCtrl-treated cells were set to 1. 
Bars represent mean ± SD (n=3), and asterisks denote significant difference from siCtrl 
(P<0.05) using an unpaired Student's t-test. (F) Western blot analysis of HeLa cell extracts 
after 96 hours KD of the nuclear exosome catalytic subunits Dis3 and Rrp6. (G) RT-qPCR 
analysis of ptRNA and uaRNA after depletion of Dis3/Rrp6. Transcript levels were 
normalized to GAPDH mRNA, and the normalized levels in siCtrl-treated cells were set to 1. 
Bars represent mean ± SD (n=3), and asterisks denote significant difference from siCtrl 





Figure S2. Co-IP analysis of Mtr4 complexes. 
(A, B) HeLa cells were transfected with the indicated plasmids for 30 hours, and cell extracts 
were used for IP with anti-Flag in the presence of Benzonase and RNase A followed by 
western blotting with antibodies against the proteins indicated on the right. Note that the 
interaction of TRAMP with U5-40K and hnRNP M was observed only when nuclear extracts 
prepared using high salt buffer were used. (C) Cell extracts prepared from HEK293 cells 
were used for co-IP with anti-ZCCHC8 antibodies in the presence of Benzonase and RNase 
A followed by western blotting with antibodies against the proteins indicated on the right. 
 
Figure S3. Effects of PABPN1 knockdown on pt- and ua-RNAabundances. 
(A) Cell extracts prepared from HEK293 and HEK293 cells stably expressing 3FLAG-Mtr4 
were used for IP with anti-Flag antibodies in the presence of Benzonase and RNase A 
followed by western blotting with the indicated antibodies. (B) Cell extracts prepared from 
HEK293 cells were used for co-IP experiment with anti-ZFC3H1 in the presence of 
Benzonase and RNase A followed by western blotting with antibodies against the proteins 
indicated on the right. (C) Western blot analysis of HeLa cell extracts after 72 hours KD 
treatment with the siRNAs indicated at the top, with antibodies against the proteins indicated 
on the right. (D, E) RT-qPCR analysis of indicated ptRNAs (D) and indicated uaRNAs and 
NEXT substrates proRBM39 and proBIRC4 (E) after the indicated siRNA transfections. 
Transcript levels were normalized to GAPDH mRNA, and the normalized levels in 
siCtrl-treated cells were set to 1. Bars represent mean ± SD (n=3), and asterisks denote 





Figure S4. Poly(A) tail length analysis of pt- and ua-RNAs by RNA ligation coupled 
poly(A) test (RL-PAT) assay. 
(A) Schematic illustration of the RL-PAT assay. RNAs were ligated with the anchor 
oligonucleotide and reverse-transcribed using the primer complementary to the anchor 
sequence. The resulting cDNA was subjected to semi-nested PCR, and PCR products were 
resolved in 2.0% agarose gels prestained with EtBr. (B) RL-PAT assay analysis of pt- and 
ua-RNAs following either control siRNA (siCtrl) or Mtr4 siRNA (siMtr4) treatment of HeLa 
cells for 72 hours. RNAs digested with RNase H in the presence of oligo(dT) were analyzed 
to mark positions of deadenylated RNAs (lanes 3 and 4).  
 
Figure S5. Quantitation of polysome fractionation after Mtr4 knockdown. 
Band strength in each fraction in Figure 6B-6D was quantitated using Image-studio software 
LICOR. Absolute signal values after background subtraction are plotted. Ribosome-bound 
and -free fractions are indicated by a red dashed line. 
 
Figure S6. Polysome fractionation after Mtr4 knockdown. 
(A) Agarose gel electrophoresis-EtBr staining analysis of extracted RNAs from sucrose 
gradient fractions, corresponding to Figure 6A. (B) UV absorption profiles at 254 nm (upper) 
and agarose gel electrophoresis-EtBr staining analysis (below) of sucrose gradients. HeLa 
cells were transfected with either control (Ctrl) or Mtr4 siRNA for 72 hours, and cytoplasmic 
extracts were separated using 15-45% sucrose gradients. (C) UV absorption profiles at 254 
nm of sucrose gradients of samples from Mtr4 KD using a second siRNA, s223606. HeLa 




extracts were resolved using 15-45% sucrose gradients. (D) RT-qPCR analysis of ptRNA and 
uaRNA after the indicated hours of Mtr4 KD. Transcript levels were normalized to GAPDH 
mRNA, and the normalized levels in siCtrl-treated cells were set to 1.  
 
Figure S7. Northern blotting analysis of pre-rRNA processing. 
(A) Schematic of the human pre-rRNA showing the positions of the oligonucleotide probes. 
(B) Northern blot analysis of HeLa RNA extracts after 72 hours treatment of the indicated 
siRNAs. Unprocessed and mature rRNAs were detected using the indicated probes. Arrows 
and asterisks indicate accumulated precursors and mature rRNAs, respectively. 
 
MATERIALS AND METHODS 
Northern blotting 
Northern blotting conditions were adapted from Wang and Pestov (2016). In brief, total RNA 
was extracted with TRIzol (Invitrogen) from untransfected HeLa cells or 72h after 
transfection with siRNAs. One (for 18S), 2 (for ITS1) or 8 (for 5.8S and ITS2) µg of total 
RNAs were separated on a 1% (for 18S and ITS1) or 1.8% (for 5.8S and ITS2) formaldehyde  
agarose gel using a Tricine-triethanolamine buffer. After O/N passive transfer to Hybond N+ 
membranes, blots were hybridized with 32P-labeled oligo probes in hybridization solution (5
SSC, 5Denhardt’s solution, 0.5% SDS). After O/N incubation at 37°C, blots were 
washed in 2XSSC/0.1% SDS at RT for 10 min, in 2XSSC/0.1% SDS at 42°C for 10 min, in 
1XSSC/0.1% SDS at 42°C for 10 min followed by 1XSSC/0.1% SDS at 42°C for 20 min and 
autoradiography. 




DNase I-treated total RNAs were ligated with KO109 5'-Phospho-CGC GGC CGC GGA 
GCT CGC- NH2-3' oligonucleotide using T4 RNA ligase 1 (New England Biolabs) in the 
presence of 15% PEG8000 at 14°C for 30 min, and reverse-transcribed with KO108 5'-GCG 
AGC TCC GCG GCC GCG-3' using Maxima Reverse Transcriptase (Thermo Fischer 
Scientific). Semi-nested PCR was performed using gene-specific forward primers (Table S2) 
and KO105 5'-GCG AGC TCC GCG GCC GCG TTT TT-3' reverse primer. PCR products 
were resolved in 2.0% agarose gel prestained with EtBr. To remove poly(A) tails, 10 µg of 
DNase I-treated RNAs were mixed with 50 pmol of oligo(dT)18 in RNase H buffer (50 mM 
Tris-HCl (pH 7.4), 100 mM NaCl, 10 mM MgCl2) and incubated at 85°C for 5 min, 42 °C for 
10 min, and then incubated in the presence of 2U Hybridase-Thermostable RNase H 
(Epicentre) at 42°C for 30 min. RNase H-treated RNAs were isolated using TRIzol. 
 
SUPPLEMENTAL REFFERENCE 
Wang M, Pestov DG 2016. Quantitative northern blot analysis of mammalian rRNA 
processing. Methods Mol Biol 1455:147-157. 
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Table S1. Proteins identified in gel filtration-coupled co-IP and MS analysis 
Accession Description 
A B C 
293 Mtr4 293 Mtr4 293 Mtr4 
P42285 SKIV2L2  0(0%) 161(29.9%) 0(0%) 282(59.1%) 0(0%) 117(38.5%) 
Q6NZY4 ZCCHC8 0(0%) 23(19.8%) 0(0%) 120(51.8%) 0(0%) 0(0%) 
O60293 ZFC3H1  0(0%) 10(4.1%) 0(0%) 60(18.2%) 0(0%) 0(0%) 
P21333 FLNA  0(0%) 4(1.6%) 0(0%) 60(17.7%) 0(0%) 0(0%) 
Q14152 EIF3A  0(0%) 0(0%) 0(0%) 45(17.6%) 0(0%) 0(0%) 
Q9P2R3 ANKFY1 0(0%) 0(0%) 0(0%) 44(16.6%) 0(0%) 0(0%) 
Q9Y580 RBM7  0(0%) 8(16.2%) 0(0%) 34(51.8%) 0(0%) 0(0%) 
P78371 CCT2  0(0%) 0(0%) 0(0%) 42(40.2%) 0(0%) 0(0%) 
P55884 EIF3B  0(0%) 0(0%) 0(0%) 41(29.6%) 0(0%) 0(0%) 
Q9H7Z3 NRDE2  0(0%) 0(0%) 0(0%) 16(17.2%) 0(0%) 12(5.3%) 
Q01780 EXOSC10 0(0%) 6(8.1%) 0(0%) 22(18.3%) 0(0%) 0(0%) 
P55072 VCP  0(0%) 0(0%) 0(0%) 26(24.8%) 0(0%) 0(0%) 
P49368 CCT3  0(0%) 0(0%) 0(0%) 24(29.2%) 0(0%) 2(3.3%) 
P68363 TUBA1B  0(0%) 4(11.8%) 0(0%) 22(19.3%) 0(0%) 0(0%) 
Q71U36 TUBA1A  0(0%) 4(11.8%) 0(0%) 21(16.2%) 0(0%) 0(0%) 
Q9BQE3 TUBA1C  0(0%) 4(11.8%) 0(0%) 21(14%) 0(0%) 0(0%) 
P17987 TCP1  0(0%) 0(0%) 0(0%) 24(18.9%) 0(0%) 0(0%) 
Q6PEY2 TUBA3E 0(0%) 2(8.4%) 0(0%) 21(16.2%) 0(0%) 0(0%) 
Q13748 TUBA3C  0(0%) 2(8.4%) 0(0%) 21(16.2%) 0(0%) 0(0%) 
Q13347 EIF3I  0(0%) 0(0%) 0(0%) 23(46.8%) 0(0%) 0(0%) 
P50991 CCT4  0(0%) 0(0%) 0(0%) 22(26.3%) 0(0%) 0(0%) 
P68366 TUBA4A  0(0%) 0(0%) 0(0%) 22(19.4%) 0(0%) 0(0%) 
Q99832 CCT7 0(0%) 0(0%) 0(0%) 21(27.4%) 0(0%) 0(0%) 
B5ME19 EIF3CL 0(0%) 0(0%) 0(0%) 20(17.3%) 0(0%) 0(0%) 
Q99613 EIF3C  0(0%) 0(0%) 0(0%) 20(17.3%) 0(0%) 0(0%) 
Q00839 HNRNPU  0(0%) 8(8.5%) 0(0%) 11(12.4%) 0(0%) 0(0%) 
Q07020 RPL18 0(0%) 16(26.6%) 0(0%) 3(11.7%) 0(0%) 0(0%) 
Q02878 RPL6  0(0%) 12(14.2%) 0(0%) 7(16.7%) 0(0%) 0(0%) 
P62913 RPL11 0(0%) 14(17.4%) 0(0%) 5(16.9%) 0(0%) 0(0%) 
Q13200 PSMD2  0(0%) 0(0%) 0(0%) 19(16.5%) 0(0%) 0(0%) 
P05387 RPLP2  0(0%) 14(691.6%) 0(0%) 3(46.1%) 0(0%) 0(0%) 
218
P62266 RPS23  0(0%) 14(23.1%) 0(0%) 3(13.3%) 0(0%) 0(0%) 
P62241 RPS8 0(0%) 11(31.7%) 0(0%) 6(13%) 0(0%) 0(0%) 
Q5RKV6 EXOSC6  0(0%) 4(18%) 0(0%) 7(12.9%) 0(0%) 6(10.3%) 
Q5VTE0 EEF1A1P5 0(0%) 4(5%) 0(0%) 13(16.5%) 0(0%) 0(0%) 
P68104 EEF1A1  0(0%) 4(5%) 0(0%) 13(16.5%) 0(0%) 0(0%) 
Q9BXP5 SRRT  0(0%) 0(0%) 0(0%) 16(8.2%) 0(0%) 0(0%) 
P62424 RPL7A 0(0%) 12(23.7%) 0(0%) 4(7.1%) 0(0%) 0(0%) 
Q13162 PRDX4  0(0%) 0(0%) 0(0%) 11(38.4%) 0(0%) 5(7.7%) 
P60228 EIF3E  0(0%) 0(0%) 0(0%) 15(21.1%) 0(0%) 0(0%) 
P11940 PABPC1 0(0%) 0(0%) 0(0%) 15(14.8%) 0(0%) 0(0%) 
Q13310 PABPC4  0(0%) 0(0%) 0(0%) 15(14.1%) 0(0%) 0(0%) 
O75821 EIF3G 0(0%) 0(0%) 0(0%) 15(37.2%) 0(0%) 0(0%) 
O00231 PSMD11  0(0%) 0(0%) 0(0%) 14(19.4%) 0(0%) 0(0%) 
Q13868 EXOSC2 0(0%) 7(14.3%) 0(0%) 7(27%) 0(0%) 0(0%) 
P40227 CCT6A  0(0%) 0(0%) 0(0%) 14(18.5%) 0(0%) 0(0%) 
P06576 ATP5B  0(0%) 0(0%) 0(0%) 14(14.2%) 0(0%) 0(0%) 
P26641 EEF1G  0(0%) 0(0%) 0(0%) 14(16.9%) 0(0%) 0(0%) 
P78527 PRKDC  0(0%) 0(0%) 0(0%) 13(3.5%) 0(0%) 0(0%) 
O43242 PSMD3 0(0%) 0(0%) 0(0%) 12(18.9%) 0(0%) 0(0%) 
P39023 RPL3 0(0%) 0(0%) 0(0%) 12(22.8%) 0(0%) 0(0%) 
P61353 RPL27 0(0%) 7(20.6%) 0(0%) 5(23.5%) 0(0%) 0(0%) 
P46781 RPS9  0(0%) 5(16%) 0(0%) 7(13.9%) 0(0%) 0(0%) 
O15371 EIF3D  0(0%) 0(0%) 0(0%) 12(18.1%) 0(0%) 0(0%) 
O75643 SNRNP200 0(0%) 0(0%) 0(0%) 12(5.9%) 0(0%) 0(0%) 
P36578 RPL4  0(0%) 7(6.6%) 0(0%) 5(13.1%) 0(0%) 0(0%) 
Q9Y262 EIF3L  0(0%) 0(0%) 0(0%) 12(8.7%) 0(0%) 0(0%) 
Q9Y3B2 EXOSC1  0(0%) 2(15.9%) 0(0%) 9(11.8%) 0(0%) 0(0%) 
Q9NQT4 EXOSC5  0(0%) 0(0%) 0(0%) 11(28.9%) 0(0%) 0(0%) 
Q09161 NCBP1  0(0%) 2(2.9%) 0(0%) 9(10.9%) 0(0%) 0(0%) 
P05388 RPLP0  0(0%) 11(30.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P62249 RPS16 0(0%) 0(0%) 0(0%) 11(37.7%) 0(0%) 0(0%) 
P62753 RPS6  0(0%) 7(20.1%) 0(0%) 4(16.9%) 0(0%) 0(0%) 
P33176 KIF5B  0(0%) 0(0%) 0(0%) 10(10%) 0(0%) 0(0%) 
P50914 RPL14  0(0%) 6(8.8%) 0(0%) 4(5.6%) 0(0%) 0(0%) 
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P38646 HSPA9 0(0%) 0(0%) 0(0%) 10(10.6%) 0(0%) 0(0%) 
Q13263 TRIM28  0(0%) 0(0%) 0(0%) 10(17.4%) 0(0%) 0(0%) 
Q15024 EXOSC7  0(0%) 5(20.6%) 0(0%) 5(18.6%) 0(0%) 0(0%) 
P52272 HNRNPM  0(0%) 4(4%) 0(0%) 5(5.2%) 0(0%) 0(0%) 
P60866 RPS20  0(0%) 2(19.3%) 0(0%) 7(22.7%) 0(0%) 0(0%) 
P10809 HSPD1 0(0%) 0(0%) 0(0%) 9(14%) 0(0%) 0(0%) 
Q99547 MPHOSPH6 0(0%) 0(0%) 0(0%) 6(30.6%) 0(0%) 3(13.8%) 
Q8NHW5 RPLP0P6 0(0%) 9(18.3%) 0(0%) 0(0%) 0(0%) 0(0%) 
P31943 HNRNPH1  0(0%) 4(6%) 0(0%) 5(15.6%) 0(0%) 0(0%) 
Q9NQT5 EXOSC3  0(0%) 0(0%) 0(0%) 6(28.7%) 0(0%) 2(7.3%) 
P07910 HNRNPC  0(0%) 8(19.9%) 0(0%) 0(0%) 0(0%) 0(0%) 
P11021 HSPA5 0(0%) 0(0%) 0(0%) 8(14.1%) 0(0%) 0(0%) 
P23246 SFPQ 0(0%) 0(0%) 0(0%) 8(7.8%) 0(0%) 0(0%) 
P15880 RPS2 0(0%) 3(7.5%) 0(0%) 5(12.6%) 0(0%) 0(0%) 
P29692 EEF1D  0(0%) 0(0%) 0(0%) 8(23.5%) 0(0%) 0(0%) 
O15397 IPO8 0(0%) 0(0%) 0(0%) 8(9.8%) 0(0%) 0(0%) 
Q99460 PSMD1 0(0%) 0(0%) 0(0%) 8(11.9%) 0(0%) 0(0%) 
Q92769 HDAC2 0(0%) 0(0%) 0(0%) 8(11.9%) 0(0%) 0(0%) 
P51665 PSMD7 0(0%) 0(0%) 0(0%) 8(14.2%) 0(0%) 0(0%) 
Q9Y4E8 USP15  0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 7(6.8%) 
Q9NPD3 EXOSC4  0(0%) 0(0%) 0(0%) 7(13.9%) 0(0%) 0(0%) 
Q9H361 PABPC3 0(0%) 0(0%) 0(0%) 7(2.2%) 0(0%) 0(0%) 
P62195 PSMC5  0(0%) 0(0%) 0(0%) 7(21.2%) 0(0%) 0(0%) 
P62280 RPS11  0(0%) 5(21.5%) 0(0%) 2(18.4%) 0(0%) 0(0%) 
Q16576 RBBP7  0(0%) 0(0%) 0(0%) 7(7.1%) 0(0%) 0(0%) 
Q32P51 HNRNPA1L2 0(0%) 0(0%) 0(0%) 7(10.3%) 0(0%) 0(0%) 
P06702 S100A9  0(0%) 0(0%) 0(0%) 7(34.2%) 0(0%) 0(0%) 
P18124 RPL7  0(0%) 7(19.4%) 0(0%) 0(0%) 0(0%) 0(0%) 
P24534 EEF1B2  0(0%) 0(0%) 0(0%) 7(34.2%) 0(0%) 0(0%) 
Q08211 DHX9  0(0%) 0(0%) 0(0%) 7(4.2%) 0(0%) 0(0%) 
O94776 MTA2  0(0%) 0(0%) 0(0%) 6(9.7%) 0(0%) 0(0%) 
Q6P2Q9 PRPF8 0(0%) 0(0%) 0(0%) 6(3.9%) 0(0%) 0(0%) 
P43686 PSMC4 0(0%) 0(0%) 0(0%) 6(22.7%) 0(0%) 0(0%) 
P55795 HNRNPH2  0(0%) 4(6%) 0(0%) 2(5.1%) 0(0%) 0(0%) 
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P05141 SLC25A5  0(0%) 0(0%) 0(0%) 6(11.7%) 0(0%) 0(0%) 
P49327 FASN  0(0%) 0(0%) 0(0%) 6(4.1%) 0(0%) 0(0%) 
P07437 TUBB 0(0%) 0(0%) 0(0%) 6(28.2%) 0(0%) 0(0%) 
Q09028 RBBP4  0(0%) 0(0%) 0(0%) 6(12.2%) 0(0%) 0(0%) 
O00303 EIF3F  0(0%) 0(0%) 0(0%) 6(9.2%) 0(0%) 0(0%) 
P27635 RPL10  0(0%) 2(11.7%) 0(0%) 4(28%) 0(0%) 0(0%) 
P62191 PSMC1  0(0%) 0(0%) 0(0%) 6(11.6%) 0(0%) 0(0%) 
P62333 PSMC6  0(0%) 0(0%) 0(0%) 6(20.8%) 0(0%) 0(0%) 
P27708 CAD  0(0%) 0(0%) 0(0%) 6(3.9%) 0(0%) 0(0%) 
P46777 RPL5  0(0%) 6(16.8%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q15008 PSMD6  0(0%) 0(0%) 0(0%) 6(12.9%) 0(0%) 0(0%) 
P54105 CLNS1A  0(0%) 0(0%) 0(0%) 6(24.1%) 0(0%) 0(0%) 
P53621 COPA 0(0%) 0(0%) 0(0%) 6(5.4%) 0(0%) 0(0%) 
P08238 HSP90AB1  0(0%) 0(0%) 0(0%) 4(7.9%) 0(0%) 2(2.9%) 
P08670 VIM  0(0%) 0(0%) 0(0%) 6(16.5%) 0(0%) 0(0%) 
P35580 MYH10  0(0%) 0(0%) 0(0%) 5(3.4%) 0(0%) 0(0%) 
Q9BYE4 SPRR2G 0(0%) 0(0%) 0(0%) 5(30.1%) 0(0%) 0(0%) 
P47914 RPL29 0(0%) 5(14.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
O60812 HNRNPCL1  0(0%) 5(17.1%) 0(0%) 0(0%) 0(0%) 0(0%) 
P43243 MATR3 0(0%) 0(0%) 0(0%) 5(5%) 0(0%) 0(0%) 
P62263 RPS14  0(0%) 0(0%) 0(0%) 5(29.1%) 0(0%) 0(0%) 
P25398 RPS12  0(0%) 0(0%) 0(0%) 5(40.9%) 0(0%) 0(0%) 
Q13547 HDAC1  0(0%) 0(0%) 0(0%) 5(8.3%) 0(0%) 0(0%) 
P62701 RPS4X 0(0%) 5(14.8%) 0(0%) 0(0%) 0(0%) 0(0%) 
P35325 SPRR2B 0(0%) 0(0%) 0(0%) 5(30.6%) 0(0%) 0(0%) 
P35326 SPRR2A  0(0%) 0(0%) 0(0%) 5(30.6%) 0(0%) 0(0%) 
P17980 PSMC3  0(0%) 0(0%) 0(0%) 5(15.9%) 0(0%) 0(0%) 
P68371 TUBB4B  0(0%) 0(0%) 0(0%) 5(24%) 0(0%) 0(0%) 
P46779 RPL28  0(0%) 5(17.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
P40429 RPL13A 0(0%) 5(9.9%) 0(0%) 0(0%) 0(0%) 0(0%) 
P12236 SLC25A6  0(0%) 0(0%) 0(0%) 5(8.4%) 0(0%) 0(0%) 
P12235 SLC25A4  0(0%) 0(0%) 0(0%) 5(8.4%) 0(0%) 0(0%) 
P20930 FLG  0(0%) 0(0%) 0(0%) 5(1%) 0(0%) 0(0%) 
P22532 SPRR2D 0(0%) 0(0%) 0(0%) 5(30.6%) 0(0%) 0(0%) 
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P22531 SPRR2E 0(0%) 0(0%) 0(0%) 5(30.6%) 0(0%) 0(0%) 
Q9BRS2 RIOK1 0(0%) 0(0%) 0(0%) 4(12.3%) 0(0%) 0(0%) 
P31151 S100A7  0(0%) 0(0%) 0(0%) 4(35.6%) 0(0%) 0(0%) 
Q14683 SMC1A 0(0%) 0(0%) 0(0%) 4(2.4%) 0(0%) 0(0%) 
Q58FF7 HSP90AB3P 0(0%) 0(0%) 0(0%) 2(4.2%) 0(0%) 2(3.5%) 
Q07866 KLC1 0(0%) 0(0%) 0(0%) 4(2.4%) 0(0%) 0(0%) 
Q00610 CLTC  0(0%) 0(0%) 0(0%) 4(3.8%) 0(0%) 0(0%) 
P35998 PSMC2  0(0%) 0(0%) 0(0%) 4(12.2%) 0(0%) 0(0%) 
Q9BVA1 TUBB2B  0(0%) 0(0%) 0(0%) 4(18%) 0(0%) 0(0%) 
O43852 CALU 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 4(14.3%) 
P23458 JAK1 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 4(2.9%) 
P04350 TUBB4A 0(0%) 0(0%) 0(0%) 4(20%) 0(0%) 0(0%) 
O43143 DHX15 0(0%) 2(3.3%) 0(0%) 2(3%) 0(0%) 0(0%) 
A6NHT5 HMX3 0(0%) 4(4.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
P05109 S100A8  0(0%) 0(0%) 0(0%) 4(20.4%) 0(0%) 0(0%) 
Q8WXI9 GATAD2B  0(0%) 0(0%) 0(0%) 4(6.7%) 0(0%) 0(0%) 
Q7L2H7 EIF3M  0(0%) 0(0%) 0(0%) 4(15.5%) 0(0%) 0(0%) 
Q9H0B6 KLC2  0(0%) 0(0%) 0(0%) 4(2.3%) 0(0%) 0(0%) 
O00487 PSMD14  0(0%) 0(0%) 0(0%) 4(10%) 0(0%) 0(0%) 
P62081 RPS7  0(0%) 0(0%) 0(0%) 4(13.4%) 0(0%) 0(0%) 
Q13885 TUBB2A  0(0%) 0(0%) 0(0%) 4(18%) 0(0%) 0(0%) 
P25787 PSMA2 0(0%) 0(0%) 0(0%) 4(23.5%) 0(0%) 0(0%) 
Q6PKG0 LARP1 0(0%) 0(0%) 0(0%) 4(2.8%) 0(0%) 0(0%) 
Q15750 TAB1  0(0%) 0(0%) 0(0%) 4(9.3%) 0(0%) 0(0%) 
Q06265 EXOSC9  0(0%) 4(5.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q8NC51 SERBP1 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 4(7.1%) 
Q15029 EFTUD2  0(0%) 0(0%) 0(0%) 4(3.2%) 0(0%) 0(0%) 
P26640 VARS  0(0%) 0(0%) 0(0%) 4(3%) 0(0%) 0(0%) 
P14625 HSP90B1  0(0%) 0(0%) 0(0%) 2(3.5%) 0(0%) 2(5.1%) 
Q14315 FLNC  0(0%) 0(0%) 0(0%) 3(1.2%) 0(0%) 0(0%) 
Q14697 GANAB  0(0%) 0(0%) 0(0%) 3(1.8%) 0(0%) 0(0%) 
Q5T750 XP32  0(0%) 0(0%) 0(0%) 3(6.4%) 0(0%) 0(0%) 
P05023 ATP1A1  0(0%) 0(0%) 0(0%) 3(3%) 0(0%) 0(0%) 
Q99623 PHB2 0(0%) 0(0%) 0(0%) 3(11%) 0(0%) 0(0%) 
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P07814 EPRS  0(0%) 0(0%) 0(0%) 3(3.2%) 0(0%) 0(0%) 
Q99873 PRMT1 0(0%) 0(0%) 0(0%) 3(7.5%) 0(0%) 0(0%) 
Q16531 DDB1  0(0%) 0(0%) 0(0%) 3(2.8%) 0(0%) 0(0%) 
P60900 PSMA6  0(0%) 0(0%) 0(0%) 3(8.9%) 0(0%) 0(0%) 
Q13435 SF3B2 0(0%) 0(0%) 0(0%) 3(4.9%) 0(0%) 0(0%) 
P25705 ATP5A1  0(0%) 0(0%) 0(0%) 3(4.3%) 0(0%) 0(0%) 
Q04637 EIF4G1  0(0%) 0(0%) 0(0%) 3(1.8%) 0(0%) 0(0%) 
P61626 LYZ  0(0%) 0(0%) 0(0%) 3(30.4%) 0(0%) 0(0%) 
Q13330 MTA1 0(0%) 0(0%) 0(0%) 3(4.5%) 0(0%) 0(0%) 
P46778 RPL21 0(0%) 0(0%) 0(0%) 3(16.2%) 0(0%) 0(0%) 
P61247 RPS3A 0(0%) 0(0%) 0(0%) 3(10.2%) 0(0%) 0(0%) 
P61163 ACTR1A  0(0%) 0(0%) 0(0%) 3(8.8%) 0(0%) 0(0%) 
Q15233 NONO  0(0%) 0(0%) 0(0%) 3(11.9%) 0(0%) 0(0%) 
P51991 HNRNPA3 0(0%) 0(0%) 0(0%) 3(9.5%) 0(0%) 0(0%) 
Q9NY65 TUBA8  0(0%) 0(0%) 0(0%) 3(10.5%) 0(0%) 0(0%) 
P20700 LMNB1 0(0%) 0(0%) 0(0%) 3(10.1%) 0(0%) 0(0%) 
Q92526 CCT6B  0(0%) 0(0%) 0(0%) 3(2.5%) 0(0%) 0(0%) 
P63151 PPP2R2A  0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 3(3.4%) 
Q9UNM6 PSMD13 0(0%) 0(0%) 0(0%) 3(8.2%) 0(0%) 0(0%) 
Q9Y265 RUVBL1  0(0%) 0(0%) 0(0%) 3(4.8%) 0(0%) 0(0%) 
P35579 MYH9  0(0%) 0(0%) 0(0%) 2(1.3%) 0(0%) 0(0%) 
Q14406 CSHL1 0(0%) 2(3.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P28074 PSMB5  0(0%) 0(0%) 0(0%) 2(10.6%) 0(0%) 0(0%) 
P28070 PSMB4  0(0%) 0(0%) 0(0%) 2(11.4%) 0(0%) 0(0%) 
Q9BUA3 C11orf84  0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 2(3.1%) 
Q14008 CKAP5  0(0%) 0(0%) 0(0%) 2(1.8%) 0(0%) 0(0%) 
Q9UBQ5 EIF3K  0(0%) 0(0%) 0(0%) 2(13.3%) 0(0%) 0(0%) 
O43809 NUDT21  0(0%) 0(0%) 0(0%) 2(10.6%) 0(0%) 0(0%) 
P69849 NOMO3 0(0%) 0(0%) 0(0%) 2(1.9%) 0(0%) 0(0%) 
P55036 PSMD4  0(0%) 0(0%) 0(0%) 2(4.8%) 0(0%) 0(0%) 
Q9H853 TUBA4B 0(0%) 0(0%) 0(0%) 2(11.6%) 0(0%) 0(0%) 
P13010 XRCC5  0(0%) 0(0%) 0(0%) 2(2.9%) 0(0%) 0(0%) 
P49207 RPL34  0(0%) 2(15.4%) 0(0%) 0(0%) 0(0%) 0(0%) 
P07900 HSP90AA1  0(0%) 0(0%) 0(0%) 2(3.3%) 0(0%) 0(0%) 
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Q7Z406 MYH14 0(0%) 0(0%) 0(0%) 2(1.1%) 0(0%) 0(0%) 
Q7Z6Z7 HUWE1  0(0%) 0(0%) 0(0%) 2(0.6%) 0(0%) 0(0%) 
P49792 RANBP2 0(0%) 0(0%) 0(0%) 2(0.6%) 0(0%) 0(0%) 
P62140 PPP1CB  0(0%) 0(0%) 0(0%) 2(9.2%) 0(0%) 0(0%) 
P62244 RPS15A 0(0%) 0(0%) 0(0%) 2(12.3%) 0(0%) 0(0%) 
O00571 DDX3X  0(0%) 0(0%) 0(0%) 2(4.2%) 0(0%) 0(0%) 
P62314 SNRPD1  0(0%) 0(0%) 0(0%) 2(10.9%) 0(0%) 0(0%) 
P60842 EIF4A1  0(0%) 0(0%) 0(0%) 2(7.6%) 0(0%) 0(0%) 
P60660 MYL6 0(0%) 0(0%) 0(0%) 2(15.9%) 0(0%) 0(0%) 
Q13509 TUBB3 0(0%) 0(0%) 0(0%) 2(6.4%) 0(0%) 0(0%) 
P62851 RPS25  0(0%) 2(15.2%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q86SG5 S100A7A  0(0%) 0(0%) 0(0%) 2(23.8%) 0(0%) 0(0%) 
P61313 RPL15 0(0%) 2(10.3%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q96L21 RPL10L  0(0%) 0(0%) 0(0%) 2(8.9%) 0(0%) 0(0%) 
P01243 CSH1 0(0%) 2(3.7%) 0(0%) 0(0%) 0(0%) 0(0%) 
P01241 GH1 0(0%) 2(3.7%) 0(0%) 0(0%) 0(0%) 0(0%) 
P01242 GH2  0(0%) 2(3.7%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q13283 G3BP1  0(0%) 0(0%) 0(0%) 2(4.1%) 0(0%) 0(0%) 
Q15393 SF3B3  0(0%) 2(2.2%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q15459 SF3A1  0(0%) 0(0%) 0(0%) 2(4.8%) 0(0%) 0(0%) 
P46821 MAP1B 0(0%) 0(0%) 0(0%) 2(1%) 0(0%) 0(0%) 
P61254 RPL26  0(0%) 2(11%) 0(0%) 0(0%) 0(0%) 0(0%) 
P83731 RPL24  0(0%) 2(13.4%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q15155 NOMO1  0(0%) 0(0%) 0(0%) 2(1.9%) 0(0%) 0(0%) 
O15523 DDX3Y 0(0%) 0(0%) 0(0%) 2(4.2%) 0(0%) 0(0%) 
Q96DI7 SNRNP40  0(0%) 0(0%) 0(0%) 2(5.9%) 0(0%) 0(0%) 
Q99417 MYCBP  0(0%) 0(0%) 0(0%) 2(19.4%) 0(0%) 0(0%) 
P53618 COPB1  0(0%) 0(0%) 0(0%) 2(3.6%) 0(0%) 0(0%) 
Q92616 GCN1L1  0(0%) 0(0%) 0(0%) 2(1%) 0(0%) 0(0%) 
Q9UQE7 SMC3 0(0%) 0(0%) 0(0%) 2(1.6%) 0(0%) 0(0%) 
Q9NYJ8 TAB2  0(0%) 0(0%) 0(0%) 2(3.5%) 0(0%) 0(0%) 
P26373 RPL13  0(0%) 2(8.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
P18077 RPL35A 0(0%) 2(16.4%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q5JPE7 NOMO2  0(0%) 0(0%) 0(0%) 2(1.8%) 0(0%) 0(0%) 
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Q9UNX3 RPL26L1  0(0%) 2(11%) 0(0%) 0(0%) 0(0%) 0(0%) 
P36542 ATP5C1  0(0%) 0(0%) 0(0%) 2(7%) 0(0%) 0(0%) 
P57052 RBM11  0(0%) 0(0%) 0(0%) 2(3.9%) 0(0%) 0(0%) 
Q9Y295 DRG1  0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 2(4.6%) 
P61978 HNRNPK  0(0%) 0(0%) 0(0%) 2(3.2%) 0(0%) 0(0%) 
O75369 FLNB 0(0%) 0(0%) 0(0%) 2(0.9%) 0(0%) 0(0%) 
P50990 CCT8  0(0%) 0(0%) 0(0%) 39(38%) 2(4.7%) 5(2.6%) 
P39019 RPS19 2(11%) 0(0%) 0(0%) 22(34.5%) 0(0%) 0(0%) 
P0CG48 UBC  2(3.6%) 4(3.6%) 0(0%) 6(3.2%) 0(0%) 0(0%) 
P0CG47 UBB  2(10.9%) 4(10.9%) 0(0%) 6(9.6%) 0(0%) 0(0%) 
P62979 RPS27A 2(16%) 4(16%) 0(0%) 6(14.1%) 0(0%) 0(0%) 
P62987 UBA52 2(19.5%) 4(19.5%) 0(0%) 6(17.2%) 0(0%) 0(0%) 
P09651 HNRNPA1  2(7.5%) 0(0%) 0(0%) 9(13.2%) 0(0%) 0(0%) 
P62888 RPL30 2(14.8%) 7(32.2%) 0(0%) 2(20.9%) 0(0%) 0(0%) 
Q8NHM4 PRSS3P2 2(14.6%) 2(12.1%) 0(0%) 0(0%) 0(0%) 0(0%) 
P47929 LGALS7 2(18.4%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q53GS9 USP39 2(3.7%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q7Z7F7 MRPL55  0(0%) 0(0%) 0(0%) 0(0%) 2(11.7%) 0(0%) 
Q86YZ3 HRNR 2(1.7%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q92620 DHX38 2(2.1%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
P23396 RPS3 3(14.4%) 4(17.7%) 0(0%) 15(35.8%) 0(0%) 0(0%) 
P32969 RPL9  3(12%) 4(5.7%) 0(0%) 12(37.5%) 0(0%) 0(0%) 
P54652 HSPA2  0(0%) 0(0%) 0(0%) 7(4.5%) 3(3.9%) 0(0%) 
P35268 RPL22 3(18.8%) 4(19.5%) 0(0%) 0(0%) 0(0%) 0(0%) 
P01040 CSTA  3(30.6%) 2(30.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q15208 STK38  0(0%) 0(0%) 0(0%) 0(0%) 3(11.6%) 0(0%) 
P81605 DCD 4(37.3%) 2(12.7%) 0(0%) 19(531.6%) 0(0%) 2(23.6%) 
P11142 HSPA8  0(0%) 4(4.2%) 0(0%) 16(13.3%) 4(5.4%) 0(0%) 
P48643 CCT5  0(0%) 0(0%) 3(2.2%) 53(51.8%) 2(5.2%) 6(2.2%) 
P34931 HSPA1L 2(3.9%) 7(6.1%) 0(0%) 3(5.5%) 3(4.2%) 0(0%) 
P30050 RPL12  2(18.8%) 0(0%) 0(0%) 9(14.5%) 3(18.2%) 0(0%) 
P02768 ALB 5(5.1%) 2(2.8%) 0(0%) 5(3.9%) 0(0%) 0(0%) 
P62857 RPS28  5(33.3%) 0(0%) 0(0%) 2(23.2%) 0(0%) 0(0%) 
Q16875 PFKFB3  0(0%) 0(0%) 0(0%) 0(0%) 7(7.1%) 0(0%) 
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P22626 HNRNPA2B1 8(16.4%) 9(25.8%) 0(0%) 31(30.9%) 0(0%) 8(9.1%) 
P48741 HSPA7 0(0%) 0(0%) 0(0%) 10(3.3%) 8(6.8%) 0(0%) 
Q9BYX7 POTEKP 9(6.7%) 8(6.7%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q6S8J3 POTEE  9(2.3%) 8(2.3%) 0(0%) 0(0%) 0(0%) 0(0%) 
A5A3E0 POTEF 9(2.3%) 8(2.3%) 0(0%) 0(0%) 0(0%) 0(0%) 
Q9Y657 SPIN1  0(0%) 0(0%) 0(0%) 0(0%) 9(6.5%) 4(6.5%) 
P17066 HSPA6 2(4.5%) 7(4.5%) 0(0%) 10(1.9%) 9(6.4%) 0(0%) 
P62736 ACTA2  11(9.5%) 8(6.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P68133 ACTA1  11(9.5%) 8(6.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P68032 ACTC1  11(9.5%) 8(6.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P63267 ACTG2  11(9.6%) 8(6.6%) 0(0%) 0(0%) 0(0%) 0(0%) 
P08107 HSPA1A  4(8.7%) 22(15.6%) 0(0%) 58(31.8%) 11(10.9%) 0(0%) 
P60709 ACTB  15(17.1%) 9(12.3%) 0(0%) 4(12.8%) 0(0%) 0(0%) 
P63261  ACTG1  15(17.1%) 9(12.3%) 0(0%) 4(12.8%) 0(0%) 0(0%) 
O75688 PPM1B  0(0%) 0(0%) 0(0%) 0(0%) 17(26.7%) 0(0%) 
Q9BQA1 WDR77  0(0%) 0(0%) 10(9.4%) 103(81.7%) 9(17.3%) 0(0%) 
Q8WWY3 PRPF31 0(0%) 0(0%) 0(0%) 17(26.9%) 19(19.6%) 3(9.6%) 
P69905 HBA1 21(23.9%) 17(28.2%) 0(0%) 0(0%) 0(0%) 0(0%) 
P02042 HBD 25(25.2%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
P68871 HBB 40(591.2%) 19(10.9%) 0(0%) 0(0%) 0(0%) 0(0%) 
P98175 RBM10  40(19.9%) 2(3.2%) 0(0%) 51(21.3%) 21(10.8%) 47(11.6%) 
O14744 PRMT5  7(7.2%) 5(3%) 41(11%) 246(64.1%) 37(28.9%) 13(6.3%) 













Table S2. Primers and siRNAs used in this study 
 
1) Primers for RT-PCR  
Sense (5'-3') antisense(5'-3') 
KO-009 RBM7 S CAGGTACGAAAGGACTATGG KO-010 RBM7 AS GTCTCAAAGCACTGTTCATCAC 
KO-060 GAPDH S ACGACCACTTTGTCAAGCTC KO-061 GAPDH AS TTCCTCTTGTGCTCTTGCTG 
KO-064 CSTF3 int pA S CTGGAAACTGTACATTGAAGCAGAG KO-065 CSTF3 int pA AS TCCTCCTTGTCCTAATTGGCTAT 
KO-066 CSTF3 last pA S GCCTCTGCAGAAAACTCCTG KO-067 CSTF3 last pA AS CCATGTGATAGAGGCACCAA 
KO-068 DIDO1 int pA S CCAAACTCTTGCCCTTTGAG KO-069 DIDO1 int pA AS TCCTAACTCCTGCTCCCAGA 
KO-070 DIDO1 last pA S TTGGTGTTGAAAGCCAAGTG KO-071 DIDO1 last pA AS CCTTCTCATCGTACTAGATGTTGG 
KO-072 DAP int pA S CGGCCCACTACACTAAAGGA KO-073 DAP int pA AS TGAGCATTGAGGCACAAGTC 
KO-074 DAP last pA S GCCTTTCTGGTGCTGTTCTC KO-075 DAP last pA AS TTTCAAGTGTGAGGCTGTGC 
KO-091 TMED4 int pA S CAGTTGCTTGATCAGGTGGA KO-092 TMED4 int pA AS AGCTGATCTCCCAAGCAGAA 
KO-093 TMED4 last pA S CACTTGCTGACCCTGGTTCT KO-094 TMED4 last pA AS GGAAAATCACTCGAGGCAAA 
KO-095 CD55 int pA S TTGCCAGAGTGCAGAGGTAA KO-096 CD55 int pA AS TGAAAGGTGGGTTTGCTACA 
KO-097 CD55 last pA S GGCAGTCCTGGAATCACATT KO-098 CD55 last pA AS TTTTCCTCGTGATCCCATTC 
KO-116 ZNF207 UA S TGGGCGCTGTCTCTATCTTT KO-126 ZNF207 UA AS GCATGCGAATGGAAAACAG 
KO-118 IGF2BP1 UA S ACGTGGCTGGGTAGAACAAA KO-119 IGF2BP1 UA AS AGAAATGGGGCTGGGACTTA 
KO-120 AIFM1 UA S CCATGCTTAAGTCCAGATGCT KO-121 AIFM1 UA AS CCCTCACAATGGTTCGACTT 
KO-189 proRBM39 S CATTTTTGAAGGAACGGTAG KO-188 proRBM39 AS GGAAATAGTGGAGAAAAGCA 
KO-190 proBIRC4 S ATCCATCATCTCACCACATT KO-191 proBIRC4 AS CTGGTCATACCCTGGATTTA 
KO-217 proFBXO7 S TTGGGGTGATTGTTATGCAG KO-218 proFBXO7 AS AGGCCTCAATGAGCTGTGAT 
KO-256 CSTF3 exon2 S GGTGAAGAAAGCGGAAAAGA KO-065 CSTF3 int pA AS TCCTCCTTGTCCTAATTGGCTAT 
KO-257 TMED4 exon3 S TACCAGGATGGCTCTCTTCG KO-092 TMED4 int pA AS AGCTGATCTCCCAAGCAGAA 
KO-261 NEAT1 S TTGGTTCTGAGCTGCGTCTA KO-262 NEAT1 AS GTGCTGTAAAGGGGAAGAAA 










2) Primers for RL-PAT assay 
primary PCR secondary PCR 
KO-064 CSTF3 int pA S CTGGAAACTGTACATTGAAGCAGAG KO-106 CSTF3 int PAT 2nd GCCAATTAGGACAAGGAGGATT 
KO-419 DIDO1 int PAT 1st GCTCTTCTGGGAAGAATGTTTG KO-420 DIDO1 int PAT 2nd TGTCAGGTAAGCATTTCTTCAGT 
KO-418 TMED4 int PAT 1st GTTCTCACAGTTCATCCATGTT KO-107 TMED4 int PAT 2nd GCATGTGTCAGAATTTCTTAAGGC 
KO-132 DAP int S PAT 1st CAGGAAGCTCTGGTGTTCTTGT KO-072 DAP int pA S CGGCCCACTACACTAAAGGA 
KO-126 ZNF207 UA AS GCATGCGAATGGAAAACAG KO-129 ZNF207 UA PAT 2nd AAAGATAGAGACAGCGCCCA 
KO-119 IGF2BP1 UA AS AGAAATGGGGCTGGGACTTA KO-130 IGF2BP1 UA PAT 2nd TTTGTTCTACCCAGCCACGT 
KO-154 MAN1A2 UA AS TCACCGGAGTTAATGGCTTC KO-155 MAN1A2 UA PAT 2nd GAGGATTCAGCAACAGGGTC 
 
3) Primers for plasmid construction 
Sense (5'-3') antisense(5'-3') 
KO-052 Mtr4 SalI S 
TTTGTCGACATGGCGGACGCATTCGGAG
AT 




KO-295 NRDE2  




 3Flag XbaI AS AATTTCTAGACTAATCCTCCAGCAGCA 
KO-380 hnRNPU  
PstI S TTCCCTGCAGATGAGTTCCTCGCCTGTT 
KO-381 hnRNPU  
SalI AS TTTTGTCGACTCAATAATATCCTTGGTGATAA 
KO-382 hnRNPM  
PstI S TTTCCTGCAGATGGCGGCAGGGGTCGA 
KO-383 hnRNPM  
SalI AS TTTTGTCGACTTAAGCGTTTCTATCAATTC 




KO-401 Prp31  
XbaI AS TTTTTCTAGATCAGGTGGACATAAGGCC 





XbaI AS TTTTCTAGATCTTCACTGAATCTCTCCCA 
 
4) siRNAs 
Name Sense (5'-3') antisense(5'-3') 
siMtr4 CAAUUAAGGCUCUGAGUAATT  UUACUCAGAGCCUUAAUUGTT  
siRBM7 GUCAUAUGGUGGAAAAUUUTT AAAUUUUCCACCAUAUGACTT 
siZCCHC8 GAAAUACAACAGAAUAAAATT UUUUAUUCUGUUGUAUUUCTT 
siZCCHC7 CUAAUGAGCUGGUUGAUAATT  UUAUCAACCAGCUCAUUAGTT  













Appendix III. NRDE-2, the human homolog of fission yeast Nrl1, prevents DNA damage 
accumulation in human cells 
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ABSTRACT
The RNA helicase Mtr4 is a versatile protein that is a crucial component of several distinct RNA
surveillance complexes. Here we describe a novel complex that contains Mtr4, but has a role distinct
from any of those previously described. We found that Mtr4 association with the human homolog of
fission yeast Nrl1, NRDE-2, defines a novel function for Mtr4 in the DNA damage response pathway. We
provide biochemical evidence that Mtr4 and NRDE-2 are part of the same complex and show that both
proteins play a role in the DNA damage response by maintaining low DNA double-strand break levels.
Importantly, the DNA damage response function of the Mtr4/NRDE-2 complex does not depend on the
formation of R loops. We show however that NRDE-2 and Mtr4 can affect R-loop signals at a subset of
distinct genes, possibly regulating their expression. Our work not only expands the wide range of Mtr4
functions, but also elucidates an important role of the less characterized human NRDE-2 protein.
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Mtr4 is an RNA helicase that is the centerpiece of several distinct
complexes involved in turnover of specific RNAs [1]. It is part of
exosome adaptor complexes such as TRAMP (Trf4-Air-Mtr4
polyadenylation) and NEXT (nuclear exosome targeting) [2].
We and others recently identified Mtr4 as a master player of
another RNA surveillance complex, Mtr4/ZFC3H1 or PAXT
(poly(A) tail exosome targeting), which plays a role in turnover
of polyadenylated lncRNAs, such as ptRNAs (prematurely ter-
minated RNAs), uaRNAs (upstream antisense RNAs) and
eRNAs (enhancer RNAs) [3,4].
We and others previously identified NRDE-2 (nuclear
RNAi defective-2; also known as C14ORF102) as an Mtr4-
interacting protein in human cells [2,3]. While the function
of human NRDE-2 is unknown, the S. pombe NRDE-2
homolog Nrl1 (NRDE-2 like 1) has been found to interact
with the Mtr4-like protein Mtl1 and with splicing factors
that help the RNAi-dependent assembly of heterochromatin
at loci called HOODs (heterochromatin domains) on certain
specific genes [5,6]. NRDE-2 was first identified in C. ele-
gans as a factor required for RNAi in the nucleus [7].
Interestingly, its association with the RNAi machinery is
necessary for both trimethylation of H3K9 at genomic loci
targeted by siRNAs and also inhibition of transcription
elongation downstream of the siRNA-targeted sequences,
most likely achieved by inducing early transcription termi-
nation. Human NRDE-2 is a ~ 130 kDa protein that con-
tains, like the C. elegans and S. pombe ortholgues, many
Half-A-Tetratricopeptide (HAT) repeats (SMART accession
#: SM00386) [8], usually found in RNA-binding proteins
and often involved in protein-protein interactions [9].
Importantly, Nrl1 has been found to protect the S. pombe
genome from instability by resolving R loops and promoting
DNA repair through homologous recombination (HR) [8]. R
loops are conserved co-transcriptional structures that arise from
hybridization of a nascent RNA with the DNA template, and are
thought to cover ~5% of mammalian genomes [10]. While R
loops function in several important cellular processes, such as
immunoglobulin class switch recombination in activated B cells
[11], mitochondria replication [12,13], protection against epi-
genetic silencing at promoters [10] and transcription termina-
tion [10,14,15], their persistence or formation at inappropriate
locations can lead to mutations, DNA double-strand breaks
(DSBs) and chromosome rearrangements causing genome
instability [16,17]. Indeed, R-loop accumulation has been linked
to many diseases, from cancer to neurological disorders [18,19].
In this study, we have investigated the role of NRDE-2 and an
Mtr4/NRDE-2 complex in human cells. We first conducted co-
immunoprecipitation (co-IP) experiments of FLAG-tagged deri-
vatives of both NRDE-2 and Mtr4 stably expressed in HEK293
cells. We identified common partners that confirm the existence
of a specific Mtr4/NRDE-2 complex that interacts with splicing
factors, similar to its yeast counterpart. We also identified new
interacting proteins, including several involved in chromatin
remodeling/DNA damage response (DDR), associated with the
proteasome, or are cytoskeletal proteins. Importantly, we provide
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evidence that NRDE-2 plays a role in the DDR. However, in
contrast with Nrl1, DSBs that accumulate after NRDE-2 or Mtr4
depletion are not dependent on R-loop accumulation. Finally, we
found that NRDE-2 and Mtr4 siRNA-mediated knockdowns
(KDs) can modestly but significantly affect R-loop profiles at
specific and distinct loci, suggesting an independent connection
of NRDE-2 and Mtr4 with transcriptional regulation through
R-loop formation/resolution.
2. Results
2.1. Identification of human Mtr4/NRDE-2-associated
proteins
With the goal of understanding NRDE-2 function, we first set
out to identify NRDE-2-interacting proteins. NRDE-2 was
previously identified as an Mtr4-interacting protein [2,3];
however, proteins associated with Mtr4/NRDE-2 remain
undetermined. To identify NRDE-2-interacting proteins, we
prepared extracts from HEK293 cells stably producing NRDE-
2-3FLAG with expression equivalent to endogenous NRDE-2
(Fig. S1A). Similar to its S. pombe counterpart [6], NRDE-2-
3FLAG localizes to the nucleus (Fig. S1B). Considering the
possible association of NRDE-2 with insoluble chromatin-
binding proteins, and to avoid obtaining possible indirect
interactions mediated by DNA and/or RNA, we treated the
extracts with Benzonase and RNase A (Fig. S1C). By treating
with Benzonase, strong chromatin-binding proteins, such as
histones, can be efficiently extracted even under physiological
salt concentrations [20]. Nuclease-treated lysates were used
for co-IP with FLAG antibody, and co-IPed proteins were
eluted with 3×FLAG peptide (silver stain; Figure 1(a)) and
subjected to mass spectrometry (MS) (Table S1). As expected,
Mtr4 was detected with the highest peptide counts [2,3,6,8].
This interaction was further validated with another NRDE-2-
3FLAG co-IP experiment performed under the same condi-
tions as the one subjected to MS (Fig. S1D). Interestingly,
despite the high abundance of Mtr4 in the MS analysis, no
exosome subunits were identified. Additionally, no NEXT
(RBM7 and ZCCHC8), TRAMP (PAPD5 and ZCCHC7) or
Mtr4/ZFC3H1 (or PAXT) subunits were detected, confirming
that the Mtr4/NRDE-2 complex is distinct from these com-
plexes. Unlike in C. elegans [7], but similar to S. pombe
[6,8,21], no RNAi factors were obtained.
Next, we wished to determine which NRDE-2-associat-
ing proteins also co-purify with Mtr4. Since Mtr4 exists
in multiple distinct protein complexes, we performed gel













































Figure 1. Identification of NRDE-2-interacting proteins by co-IP and mass spectrometry.
(a) Silver staining of FLAG co-IPs from control and NRDE-2-3FLAG stable HEK293 cell lines used for mass spectrometry. (b) Fractions from Superose 6 gel filtration of
3FLAG-Mtr4-expressing HEK293 cell lysates treated with Benzonase/RNase A were analyzed by WB, using antibodies against proteins shown on the right.
Approximate molecular sizes are indicated at the top and fractions pooled at the bottom. The asterisk indicates a non-specific band. (c) The protein-protein
interaction network among the proteins shared in NRDE-2-3FLAG and 3FLAG-Mtr4 co-IP that are absent in HEK293 control co-IP was constructed using STRING v10.5
(http://string-db.org) with the high confidence setting. Disconnected nodes are not shown in the network.
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Benzonase/RNase A-treated extracts prepared from the
stable HEK293 cell line expressing 3FLAG-Mtr4 [3] were
fractionated by size using a Superose 6 column
(Figure 1(b)), and the NRDE-2-containing fractions
(158–669 kDa) were used for anti-FLAG co-IP followed
by MS. We previously reported that 3FLAG-Mtr4 was
broadly distributed between 158 kDa and void fractions
in RNase A-treated extracts [3]. However, 3FLAG-Mtr4 in
>1 MDa ~ void fractions was absent following Benzonase
treatment (compare Figure 1(b) with Figure 2(b) in [3]).
There were no significant changes in the distribution
patterns of ZCCHC7, ZCCHC8 and NRDE-2 due to
Benzonase (Figure 1(b), see Figure 2(b) in [3]). MS ana-
lysis successfully detected known Mtr4 partners, including
NRDE-2 and exosome subunits (Table S1). Among the
proteins that were not detected in a HEK293 control, 98
were detected in both NRDE-2 and Mtr4 interactomes.
We note that 103 out of 252 (40.8%) of the proteins from
the Benzonase/RNase A-treated 3FLAG-Mtr4 co-IP/MS
overlap with the RNase A only-treated 3FLAG-Mtr4 co-
IP/MS described in our previous work [3], despite the
absence of most of the DNA-associated proteins (presence
of benzonase) in our current analysis.
To gain better insight into the Mtr4/NRDE-2-interacting
proteins, we uploaded the shared proteins to STRING v10.5
database [22] and created high confidence interaction net-
works (Figure 1(c)). The proteins were clustered largely
into four groups: splicing factors, histone/chromatin/
DDR-related proteins, cytoskeletal proteins and proteasome
subunits. The interaction of Mtr4/NRDE-2 with splicing
factors is reminiscent of the fission yeast Mtl1/Nrl1 com-
plex, although an additional conserved protein, Ctr1, stably
interacts with Mtl1/Nrl1 and splicing factors [6,8,21], but
its human homolog CCDC174 was absent in both NRDE-2-
3FLAG and 3FLAG-Mtr4 co-IP/MS analyses. Altogether
these co-IP experiments highlight the existence of a
human Mtr4/NRDE-2 complex distinct from any previously
identified Mtr4 complexes, and which appears to share
several features with the fission yeast complex.
2.2. NRDE-2 prevents DNA damage accumulation
For some time, splicing factors have been linked to genome
stability maintenance through the prevention of R-loop accu-
mulation [23]. Importantly, deletion of Nrl1 in fission yeast
leads to an accumulation of R loops and DSBs [8]. Since we
found NRDE-2 interacting with splicing factors, and to begin
to test whether NRDE-2 is also involved in maintaining gen-
ome stability in human cells, we monitored, by western blot
(WB) and immunofluorescence (IF), levels of γH2AX, a mar-
ker of DSBs, following siRNA-mediated KD of NRDE-2 in
HeLa cells. Strikingly, the IFs, and quantification of γH2AX
signal, showed a drastic increase (~ two-fold relative to con-
trol) of DNA damage in KDed cells compared to non-trans-
fected cells or cells transfected with a control siRNA (NC)
(Figure 2 + Fig. S2). Since NRDE-2 interacts with Mtr4, and
Mtr4 KO in mouse B cells shows an increase in R loops at
certain loci [24], we asked whether Mtr4 KD also leads to
DSBs. Indeed, Mtr4 KD also resulted in a significant increase
in DSBs as shown by the quantification of the γH2AX signal
(Fig. S2). These data suggest that the Mtr4/NRDE-2 complex
is involved in DNA damage prevention or repair.
2.3. DNA damage in NRDE-2 and Mtr4 depleted cells is
R-loop independent
Since Nrl1 and mouse Mtr4 have both been linked to R-loop
metabolism [8,24], we next asked whether the DSBs detected after










































Figure 2. NRDE-2 KD leads to increased DSBs.
(a) γH2AX protein levels in non-transfected HeLa cells (None), cells transfected with an siRNA control (NC) or siNRDE-2 analyzed by WB. U2AF65 is used as a loading
control. (b) γH2AX signal visualized by IFs in HeLa cells as in A. (c) Quantification of images as in B. n = 267 cells, SE is shown.
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NRDE-2 and Mtr4 KDs were caused by an increase in R-loop
levels. To address this, we overexpressed GFP-RNase H1 in HeLa
cells KDed for Mtr4 or NRDE-2 and quantified the γH2AX levels
by WB analysis (Fig. S3). Confirming our IF data, Mtr4 and
NRDE-2 KDs led to an accumulation of DSBs as shown by an
increased γH2AX protein level compared to control cells.
Interestingly, Mtr4 KD led to ~ 4 times more γH2AX than did
NRDE-2 KD, a result that was not apparent by IF (Fig. S2), and
which is discussed below. Importantly, RNase H1 overexpression
did not significantly decrease γH2AX levels in NRDE-2 or Mtr4
KDed cells. To confirm these data, we performed IF to monitor
γH2AX and GFP-RNase H1 signals simultaneously (Figure 3).
The IF images show that γH2AX and high levels of RNase H1
expression can co-exist (see cells with white arrows) and that
consequently there was no statistical difference in γH2AX staining
after NRDE-2 KD between cells expressing RNase-H1 or not, as
calculated by the quantification of the γH2AX signal in the RNase
H1-expressing cells. However, RNase H1 overexpression had a
significant and unexpected effect on DSB accumulation in Mtr4
KDed cells, as the γH2AX signal in these cells actually increased
by 30% after RNase H1 overexpression. While we also detect a
10% increase of the γH2AX signal after RNase H1 overexpression
in NRDE-2 KDed cells, this difference doesn’t appear significant
(Figure 3, left histogram). These data confirm that DNA damage
induced by NRDE-2 and/orMtr4 KDs is not due to accumulation
of R loops.
We also examined a possible connection between R-loop
formation and NRDE-2 and/or Mtr4 more directly.
Specifically, we performed DRIP assays in HeLa cells after
NRDE-2 and Mtr4 KDs, using the S9.6 antibody to IP RNA:
DNA hybrids [25,26]. We examined R-loop formation at
known positive loci, the RPL13A 3ʹ end and the BACT 5ʹ
pause site, as well as an R-loop negative locus, EGR1 [10,14]
(Figure 4(a–c)). While the DRIP assay detected the expected
percentage of input at RPL13A (~10%), BACT (~2%) and
EGR1 (<0.1%) loci in untransfected and siRNA control (NC)
transfected cells [10], R-loop enrichment increased by 20%
compared to control at RPL13A and BACT after NRDE-2
KD. In contrast, R-loop enrichment at the 5ʹ pause site of
BACT did not change after Mtr4 KD, while ~20% less
R-loop signal was detected at RPL13A. Although we only
examined a very limited number of loci, the DRIP data
suggests that while DSB accumulation after NRDE-2 or
Mtr4 KDs is R-loop independent, it is very likely that
NRDE-2 and Mtr4 play minor but significant and indepen-
dent roles in R-loop resolution or formation at specific
genes, possibly regulating their transcription.
Since Mtr4 has recently been shown to regulate lncRNAs
turnover as part of the Mtr4/ZFC3H1 (or PAXT) complex, we
performed NRDE-2 ChIP assays to ask whether NRDE-2
could also play a role at genomic loci including those asso-
ciated with lncRNAs expression. We indeed found that
NRDE-2 binds various loci including eRNA (eRNA17−),
ptRNAs intronic PAS (DAP-PAS and TMED4-PAS),
PROMPT (pro-RBM39) as well as the promoter of CSTF3
(Figure 4(d); note that NRDE-2 and Mtr4 KDs did not sig-
nificantly affect Mtr4 or NRDE-2 protein levels, respectively
(Figure 4(c))). Importantly, NRDE-2 KD led to a weak but
general increase in eRNA17−, ptTMED4, ptDAP, proRBM39
lncRNAs (Fig. S4). CSTF3 mRNA levels also increased sig-
nificantly after NRDE-2 KD (three-fold relative to control),
however CSTF3 ptRNA decreased (Fig. S4). While these data
show some disparity, they indicate that NRDE-2 might func-
tion as a negative regulator of gene expression. While we
could not detect R loops at eRNA17− loci, we were able to














































Figure 3. DSBs induced by NRDE-2 or Mtr4 KDs are R-loop independent.
(a) IF of γH2AX signal in NRDE-2 KDed HeLa cells for 72h and transfected (H1) or
not (no H1) with GFP-RNase H1 for 48h. Signal quantifications are shown at the
bottom. n = 189 cells, SE shown. (b) Quantification of γH2AX signal in Mtr4 KDed
cells expressing GFP-RNase H1 (H1) or not (no H1). n = 78 cells, SE shown. White
arrows show cells expressing GFP-RNase H1 and high level of γH2AX signal.
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TMED4). These did not, however, show significant differences
after NRDE-2 or Mtr4 KD compared to controls (data not
shown), indicating that the potential NRDE-2 negative regu-
lation of eRNA17−, ptDAP and ptTMED4 expression is
R-loop independent. These data indicate that it is very likely
that NRDE-2 plays a role in transcription regulation that in
some cases might involve R-loop resolution or formation
(Figure 5).
3. Discussion
In this study, we investigated the functions and properties
of the conserved human NRDE-2 protein. We identified
several NRDE-2 associated proteins as well as proteins
associated with one of its previously identified partners,
the RNA helicase Mtr4. As strong evidence that NRDE-2
and Mtr4 are core components of a novel NRDE-2/Mtr4
complex, we found that the two proteins share many
interacting factors that can be classified into four main
categories. We identified proteins from the chromatin
remodeling/DDR pathways, splicing factors, cytoskeletal
proteins and proteasome subunits. The association of
NRDE-2 with splicing factors has previously been
observed in fission yeast, where nrl1 deletion is indeed
associated with splicing defects of a subset of genes [6,8].
While it is therefore likely that human NRDE-2 also plays
a role in pre-mRNA splicing we have not investigated this
possibility.
Similar to the nrl1Δ strain, we found that NRDE-2 depleted
cells accumulate DSBs. Because genome instability in nrl1Δ yeast
has been attributed to an increase in R loops [8], we were in fact
very surprised to find that the DSB increase after NRDE-2 or
Mtr4 depletion was R-loop independent. Indeed, overexpression
of RNase H1, which should eliminate R loops, did not reduce
DNA damage after NRDE-2 or Mtr4 KD. On the contrary,





































































Figure 4. R-loop levels at RPL13A, BACT and EGR1 are not affected by NRDE-2 or Mtr4 KD.
(a) DRIP assays were performed in HeLa cell after 72 h of siRNAs transfection. DRIP signal was also measured after RNase H1 treatment (right). (b) DRIP signal was normalized
to the signal in non-transfected cell. Error bars represent the average of two different experiments. SD shown. (c) NRDE-2 and Mtr4 KDs confirmation by WB. None = no
transfection, NC: siRNA control transfection. (D) NRDE-2 ChIP at various loci. ChIP assays were performed in HeLa cell after 72 h of siRNAs transfection. n = 2
872 P. RICHARD ET AL.
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in the Mtr4 KDed cells. This data was however only observed by
IF and its significance is not yet clear. While WBs would seem
likely to be more quantitative than IF, we believe that the stress
level (passage number, harvesting time, etc.) and/or cell cycle
might have a significant impact on DSB accumulation. While we
noticed that γH2AX levels can vary from one experiment to
another, levels were always significantly higher after either
NRDE-2 or Mtr4 KD. Nevertheless, our IF data showed that
under certain circumstances, RNase H1 overexpression can trig-
ger an increase in γH2AX signal in an Mtr4 KD background.
While we know that RNase H1 eliminates R loops, we also
know that its overexpression or inhibition can have other
effects [27], which include changes in gene expression and
inhibition of HR-mediated DSB repair, at least in fission yeast
[28,29]. It is thus possible that RNase H1 overexpression affects
expression of genes involved in the DDR or interferes with
repair in the Mtr4 KD background. The latter scenario implies
that R loops might be required for repair of some of the DSBs
triggered by Mtr4 KD. Another explanation would involve a
role for Mtr4 in RNA-mediated HR repair [30]. While we
cannot eliminate the last two possibilities, we find them unli-
kely because, as discussed below, Mtr4- and NRDE-2-interact-
ing proteins favor a function for the complex in NHEJ rather
than HR. It has however been shown in budding yeast that
RNA can be used as a homologous template to repair DSBs
[31]. Considering this scenario, RNase H1 overexpression
could interfere with the repair process, which could explain
the observed γH2AX signal increase in the Mtr4 KD back-
ground. However, despite the evidence that RNA oligos can
function in repair of DSBs in humans [32], this kind of HR
repair mechanism needs to be investigated more thoroughly.
How might Mtr4/NRDE-2 function in DNA repair? In S.
pombe, it was proposed that the R loops formed in nrl1Δ strains
sequester HR factors that are then no longer available to repair
damage, leading to an increase in DSBs [8]. While Nrl1 has not
been found to interact with HR factors, we found that NRDE-2
and Mtr4 both associated with several DDR factors, including
PARP1, Ku70 and Ku80 as well as many histones and chromatin
remodeling factors. The heterodimer Ku is part of the NHEJ DSB
repair machinery, functioning by recognizing the breaks [33].
PARP1 is involved in numerous aspects of the DDR and functions
in both the NHEJ and HR pathways [34]. Thus, it appears that
while NRDE-2 and Nrl1 both function in the DDR, they likely do
so by distinct mechanisms. We suggest that DSBs occurring after
NRDE-2 and Mtr4 KDs result from a defect in the NHEJ repair
process due to a lack of break recognition by the heterodimer
Ku70/80 and/or PARP1 we found interacting with both proteins
(Figure 5). The interaction with histones and chromatin remodel-
ing factors make perfect sense in that scenario since their presence
and particular organization at DNA damage sites provides the
environment necessary for efficient and proper repair [35].
In C. elegans, NRDE-2 is essential for the nuclear RNAi
pathway, which involves siRNA-directed H3K9me. NRDE-2 is
directed to nascent transcripts through association with an
siRNA-incorporated Argonaut (AGO) protein, NRDE-3, to
introduce H3K9 methylation and block RNAP II elongation
[7]. Although no RNAi factors were identified in the NRDE-2
(Nrl1)-proteomics analysis performed by us (human) and others
(yeast), RNAi factor-directed introduction of H3K9me is
observed in both organisms [15,36]. Notably, there are inter-
connections between R loops and the modification status of
chromatin (reviewed by [37,38]). In human cells, R loops formed
over RNAP II pause-site termination regions induce antisense
transcription and consequent double-stranded RNA generation,
which recruits RNAi factors such as DICER, AGOs, and the
histone methyltransferase G9a to direct H3K9me at transcrip-
tional termination sites [15]. In S. pombe, depletion of Nrl1
selectively abrogates RNAi-dependent heterochromatin assem-
bly by decreasing H3K9me at HOODs [6]. The authors further
suggested that RNAi-mediated heterochromatin assembly is
defined by cryptic introns within HOODs and the spliceosome,
since deletion of the cryptic introns or splicing factors resulted in
reduced H3K9me3 levels [6]. Considering that splicing factor
deficiency causes R-loop stabilization [23], it is possible that
R-loop structures are enriched at specific loci such as HOODs
in Nrl1-depleted cells and that H3K9 methylation is coupled
with their resolution. It is then interesting to speculate that
NRDE-2 is involved in R-loop resolution and H3K9methylation
at transcriptional termination sites, since NRDE-2 KD leads to
an increase of R loops at the 3ʹend of RPL13A and BACT.
Several studies have suggested that changes in NRDE-2
expression could be involved in human health and disease.
Array-based genome-wide copy number aberration analyses
have suggested that NRDE-2 (14q32.11) haploinsufficiency
can be associated with schizophrenia [39] and can be observed
in circulating tumor cells that have been detected in the blood
of patients with metastatic melanoma [40]. Moreover, an
intronic single-nucleotide polymorphism (SNP) in NRDE-2
(refSNP Cluster Report ID: rs4904670) is associated with
reduced lifespan, physiological aging changes, and major dis-
eases like cancer and coronary heart disease [41]. Future
analyses may uncover the possible link between the function
of NRDE-2 and/or Mtr4/NRDE-2 and disease.
We identified here yet another complex containing Mtr4 that
surprisingly has a function distinct from RNA surveillance.
While our data reveal an R-loop independent role of the Mtr4/
NRDE-2 complex in the DDR, each protein seems to individu-
ally (or part of two different complexes) affect R-loop levels at
specific and distinct genes. It will be of great interest in the near
future not only to dissect the molecular mechanisms that allow
the Mtr4/NRDE-2 complex to protect the cell from DNA
damage, but also to understand the independent role each pro-
tein plays at specific genes where R loops form. Our work shows
that Mtr4 has an even broader role than expected from previous
studies. In fact, it is very likely, according to ourMS data, that the
Mtr4/NRDE-2 complex participates inmany other aspects of cell
physiology through its interaction with subunits of the protea-
some and cytoskeleton proteins (Figure 5).
4. Materials and methods
4.1. Gel filtration
Superose 6 gel filtration was performed as previously
described [3] except that cell lysates were treated with
>250 U/mL Benzonase (Sigma: #E1014) and 10 µg/mL
RNase A (Sigma: #R5250) and that eluates were collected
every 5 min (1 mL, flow rate = 0.2 mL/min).
RNA BIOLOGY 873
235
4.2. Co-immunoprecipitation (co-IP) and mass
spectrometry (MS)
co-IP using FLAG antibody and MS analysis were performed as
previously described [3] except that HEK293 and HEK293/
NRDE-2-3FLAG cells were lysed in 20 mM Tris-HCl (pH 8.0),
150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1x protease inhi-
bitor cocktail (Biotools), 10μg/mLRNase A (Sigma: #R5250) and
>250U/mL Benzonase (Sigma: #E1014).
4.3. Immunofluorescence (IF)
γH2AX IF were performed with HeLa cells after siRNAs transfec-
tion at 20 nM with RNAiMAX (Invitrogen: #13778) for 72h,
methanol fixation for 10 mins and permeabilization with acetone
for 1min. FLAG IF in HEK293 cells were performed after fixation
with 4% paraformaldehyde for 10 mins followed by fixation with
0.5% Triton X 100 for 10 mins. γH2AX antibody (Cell signaling
Technology: #2577S) was used at 1:200 and anti-FLAG (Sigma:
#F1804) at 1:250 for 2h. Secondary anti-rabbit Alexa 488
(Invitrogen: #A11008) and anti-mouse Alexa 568 (#A11031) at
1:500 for 1h at RT. Images were acquired using Zeiss LSM 700
confocal microscope and 20x/1.4 and 40x/1.4 oil objectives were
used. Nuclear immunofluorescence signals were analyzed with
ImageJ. 200 ng of GFP-RNase H1 and empty plasmid was trans-
fected with Lipofectamine 2000 (Invitrogen: #11668) 24h after
siRNA transfection for 48h.
4.4. siRNAs transfection and Western Blots
HeLa cells were not transfected (Ctrl) or transfected with an
siRNA control (NC: TTCTCCGAACGTGTCACGT,
GenePharma), siNRDE-2 (GCAAGCAGGUUGAACGCUA),
siNRDE-2#2 (ID: S30064, Cat#: 4,427,037, Thermofisher),
siMtr4 (CAAUUAAGGCUCUGAGUAA, GenePharma) for 72h
at 20 nMwith RNAiMAX (Invitrogen: #13778) prior extracts. The
following antibodies were used: γH2AX (Cell signaling
Technology: #2577S), U2AF65 (Sigma: #U4758), NRDE-2 (pro-
teintech: #24968-I-AP), Mtr4 (Bethyl: #A300-614A), GFP (abm:
#G095), GAPDH (Sigma: #G9545), FLAG (Sigma: #F1804).
Western Blot quantifications were performed using ImageJ.
4.5. DRIP assay and qPCR
DRIP was performed as described in Ginno et al. [26]. Briefly,
HeLa cells transfected with 20 nM siRNAs for 72h were lysed O/N
in SDS and proteinase K. 50 μl of extracted gDNA was then
digested O/N with a cocktail of restriction enzymes at 40 U each
(HindIII/EcoRI/BsrGI/XbaI/SspI). After phenol/chloroform
extraction and EtOH precipitation, 4.4 μg of digested DNA was
treated O/N with 3 μl of Ribonuclease H (NEB, #M0297) as
negative control. Treated and un-treated DNA were IPed O/N at
4°C with 10 μg of S9.6 antibody in binding buffer (10mMNaPO4
pH7.0, 140mMNaCl, 0.5%TritonX-100). Next day, agarose A/G
beads (Pierce #20421) were added for 2 hours. After washes, IPs
were eluted at 55°C for 45min in 250 μl elution buffer (50mMTris
pH 8.0, 10 mM EDTA, 0.5% SDS) supplemented with 7 μl of
Proteinase K at 20 mg/ml. DNA was analyzed by qPCR using the
following primers: RPL13A (3ʹ of the gene): F: AGGTGC
CTTGCTCACAGAGT, R: GGTTGCATTGCCCTCATTAC,
βactin (5ʹ pause site): F: TTACCCAGAGTGCAGGTGTG, R:
CCCCAATAAGCAGGAACAGA, EGR1 (intergenic region
downstream of EGR1): F: GAACGTTCAGCCTCGTTCTC, R:
GGAAGGTGGAAGGAAACACA.
The primers used to detect ptRNAs, full-length mRNA and
proRBM39 after NRDE-2 KD are described in [3]. Primers for
eRNA17- are the same as the ones used for ChIP.
Figure 5. Possible functions of the Mtr4/NRDE-2 complex in various cellular processes.
The role of the Mtr4/NRDE-2 complex in the DDR might involve interaction with the Ku70/80 heterodimer, which recognizes DSBs. Its interaction with PARP1 may
stimulate the activation of the DNA-dependent protein kinase catalytic subunit (DNA-Pkcs), a NHEJ factor that also interacts with the Ku complex. NRDE-2 and Mtr4
appear to have independent roles in transcription regulation. While NRDE-2 can have a negative effect on transcription, it seems to resolve R loops at the 3ʹ end of
certain genes. According to [24], Mtr4 might also promote R-loop resolution, at least in certain circumstances.
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4.6. ChIP assay
A confluent 10 cm dish of HeLa cells were cross-linked in 1%
formaldehyde for 10 minutes at room temperature (RT). Cross-
links were quenched in 125 mM glycine for 5 mins, cells were
rinsed in PBS and then collected by centrifugation (500xg for
5 mins). Cells were collected in 400 μl RIPA buffer (150 mM
NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris.Cl pH8,
5 mM EDTA pH 8) supplemented with PMSF and a protease
inhibitor cocktail (0.2 mM Pepstatin A, 72 μM Leupeptin, 26 μM
Aprotinin) and sonicated (30s x 10 times using a bioruptor
sonicator). Extracts were clarified by centrifugation at 13000xg
for 15 mins. NRDE-2 ChIP was performed O/N at 4°C with 2 μg
of antibody (proteintech: #24968-I-AP) and 20 μl of protein A/G
sepharose (Invitrogen). No antibody control was performed in
parallel. Beads were washed 3x in RIPA buffer without SDS.
Immune complexes were eluted in 0.1M NaHCO3/1%SDS
(15 mins rotation at RT). Cross-links were reversed for 5 hours
at 65°C (250mM NaCl and 1μg RNase A). DNA was purified
using QIAquick PCR purification kit (#28106) from Qiagen.
Generally, 1/50th was used for each q-PCR reaction. The primers
used for DAP int PAS, TMED4 int PAS and proRBM39 detection
are described in [3]. eRNA17- and CSTF3 primers are (F:
GAGCCATGGATGGGTGATAA, R: AACCCATCTTGTC
AGGCAGA) and (F: ACTGATTTGGGGGTGGTTTT, R:
GGCCTCAGCTGATTACAACG), respectively.
Acknowledgments
We thank Robert Crouch for the GFP-RNase H1 plasmid, Frédéric
Chédin and Lionel Sanz for the S9.6 antibody and for their insightful
advices and comments to perform DRIP assay. We also thank Juan
Irizarry-Cole for his help with the IF quantifications.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This work was supported by the Muscular Dystrophy Association [MDA
377780];National Institutes of Health [P41 GM 103533];National





1. Ogami K, Chen Y, Manley JL. RNA surveillance by the nuclear
RNA exosome: mechanisms and significance. Non-Coding RNA.
2018 Mar 11;4(1):8. PubMed Central PMCID: PMC5886371.
2. Lubas M, Christensen MS, Kristiansen MS, et al. Interaction profiling
identifies the human nuclear exosome targeting complex. Mol Cell.
2011 Aug 19;43(4):624–637. PubMed PMID: 21855801.
3. Ogami K, Richard P, Chen Y, et al. An Mtr4/ZFC3H1 complex
facilitates turnover of unstable nuclear RNAs to prevent their
cytoplasmic transport and global translational repression. Genes
Dev. 2017 Jul 21. PubMed PMID: 28733371; PubMed Central
PMCID: PMC5558927. DOI:10.1101/gad.302604.117
4. Meola N, Domanski M, Karadoulama E, et al. Identification of a
nuclear exosome decay pathway for processed transcripts. Mol
Cell. 2016 Nov 3;64(3):520–533. PubMed PMID: 27871484.
5. Yamanaka S, Mehta S, Reyes-Turcu FE, et al. RNAi triggered by
specialized machinery silences developmental genes and retro-
transposons. Nature. 2013 Jan 24;493(7433):557–560. PubMed
PMID: 23151475; PubMed Central PMCID: PMC3554839.
6. Lee NN, Chalamcharla VR, Reyes-Turcu F, et al. Mtr4-like protein
coordinates nuclear RNA processing for heterochromatin assembly
and for telomere maintenance. Cell. 2013 Nov 21;155(5):1061–1074.
PubMed PMID: 24210919; PubMed Central PMCID: PMC3974623.
7. Guang S, Bochner AF, Burkhart KB, et al. Small regulatory RNAs
inhibit RNA polymerase II during the elongation phase of tran-
scription. Nature. 2010 Jun 24;465(7301):1097–1101. PubMed
PMID: 20543824; PubMed Central PMCID: PMC2892551.
8. Aronica L, Kasparek T, Ruchman D, et al. The spliceosome-
associated protein Nrl1 suppresses homologous recombination-
dependent R-loop formation in fission yeast. Nucleic Acids Res.
2016 Feb 29;44(4):1703–1717. PubMed PMID: 26682798; PubMed
Central PMCID: PMC4770224.
9. Preker PJ, Keller W. The HAT helix, a repetitive motif implicated
in RNA processing. Trends Biochem Sci. 1998 Jan;23(1):15–16.
PubMed PMID: 9478129.
10. Sanz LA, Hartono SR, Lim YW, et al. Prevalent, dynamic, and
conserved R-loop structures associate with specific epigenomic
signatures in mammals. Mol Cell. 2016 Jun 29. PubMed PMID:
27373332. DOI:10.1016/j.molcel.2016.05.032
11. Yu K, Chedin F, Hsieh CL, et al. R-loops at immunoglobulin class
switch regions in the chromosomes of stimulated B cells. Nat
Immunol. 2003 May;4(5):442–451. PubMed PMID: 12679812.
12. Xu B, Clayton DA. RNA-DNA hybrid formation at the human
mitochondrial heavy-strand origin ceases at replication start sites:
an implication for RNA-DNA hybrids serving as primers. The
EMBO Journal. 1996 Jun 17;15(12):3135–3143. PubMed PMID:
8670814; PubMed Central PMCID: PMC450256.
13. Pohjoismaki JL, Holmes JB, Wood SR, et al. Mammalian mito-
chondrial DNA replication intermediates are essentially duplex
but contain extensive tracts of RNA/DNA hybrid. J Mol Biol.
2010 Apr 16;397(5):1144–1155. PubMed PMID: 20184890;
PubMed Central PMCID: PMC2857715.
14. Skourti-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin
resolves RNA/DNA hybrids formed at transcriptional pause sites
to promote Xrn2-dependent termination. Mol Cell. 2011 Jun
24;42(6):794–805. PubMed PMID: 21700224; PubMed Central
PMCID: PMC3145960. eng.
15. Skourti-Stathaki K, Kamieniarz-Gdula K, Proudfoot NJ. R-loops
induce repressive chromatin marks over mammalian gene termi-
nators. Nature. 2014 Oct 5. PubMed PMID: 25296254.
DOI:10.1038/nature13787
16. Aguilera A, Garcia-Muse T. R loops: from transcription bypro-
ducts to threats to genome stability. Mol Cell. 2012 Apr 27;46
(2):115–124. PubMed PMID: 22541554; eng.
17. Chan YA, Hieter P, Stirling PC. Mechanisms of genome instability
induced by RNA-processing defects. Trends Genet. 2014 Jun;30
(6):245–253. PubMed PMID: 24794811; PubMed Central PMCID:
PMC4039741.
18. Richard P, Manley JL. R loops and links to human disease. J Mol Biol.
2016 Sep 4. PubMed PMID: 27600412; PubMed Central PMCID:
PMC5478472. DOI:10.1016/j.jmb.2016.08.031
19. Groh M, Gromak N. Out of balance: R-loops in human disease.
PLoS Genet. 2014 Sep;10(9):e1004630. PubMed PMID: 25233079;
PubMed Central PMCID: PMC4169248.
20. Anindya R, Aygun O, Svejstrup JQ. Damage-induced ubiquityla-
tion of human RNA polymerase II by the ubiquitin ligase Nedd4,
but not Cockayne syndrome proteins or BRCA1. Mol Cell. 2007
Nov 9;28(3):386–397. PubMed PMID: 17996703.
21. Zhou Y, Zhu J, Schermann G, et al. The fission yeast MTREC
complex targets CUTs and unspliced pre-mRNAs to the nuclear
exosome. Nat Commun. 2015 May 20;6:7050. PubMed PMID:
25989903; PubMed Central PMCID: PMC4455066.
RNA BIOLOGY 875
237
22. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-
protein interaction networks, integrated over the tree of life. Nucleic
Acids Res. 2015 Jan;43(Database issue):D447–D452. PubMed PMID:
25352553; PubMed Central PMCID: PMC4383874.
23. Li X, Manley JL. Inactivation of the SR protein splicing factor
ASF/SF2 results in genomic instability. Cell. 2005 Aug 12;122
(3):365–378. PubMed PMID: 16096057; eng.
24. Lim J, Giri PK, Kazadi D, et al. Nuclear proximity of Mtr4 to RNA
exosome restricts DNA mutational asymmetry. Cell. 2017 Apr
20;169(3):523–537 e15. PubMed PMID: 28431250; PubMed
Central PMCID: PMC5515252.
25. Boguslawski SJ, Smith DE, Michalak MA, et al. Characterization
of monoclonal antibody to DNA.RNA and its application to
immunodetection of hybrids. J Immunol Methods. 1986 May
1;89(1):123–130. PubMed PMID: 2422282.
26. Ginno PA, Lott PL, Christensen HC, et al. R-loop formation is a
distinctive characteristic of unmethylated human CpG island pro-
moters. Mol Cell. 2012 Mar 30;45(6):814–825. PubMed PMID:
22387027; PubMed Central PMCID: PMC3319272. eng.
27. Vanoosthuyse V. Strengths and weaknesses of the current stra-
tegies to map and characterize R-loops. Non-Coding RNA.
2018;4(2):9.
28. Hartono SR, Malapert A, Legros P, et al. The affinity of the S9.6
antibody for double-stranded RNAs impacts the accurate map-
ping of R-loops in fission yeast. J Mol Biol. 2017 Dec 28. PubMed
PMID: 29289567. DOI:10.1016/j.jmb.2017.12.016
29. Ohle C, Tesorero R, Schermann G, et al. Transient RNA-DNA
hybrids are required for efficient double-strand break repair. Cell.
2016 Nov 3;167(4):1001–1013 e7. PubMed PMID: 27881299.
30. Meers C, Keskin H, Storici F. DNA repair by RNA: templated, or not
templated, that is the question. DNA Repair. 2016 Aug;44:17–21.
PubMed PMID: 27237587; PubMed Central PMCID: PMC4958532.
31. Keskin H, Shen Y, Huang F, et al. Transcript-RNA-templated
DNA recombination and repair. Nature. 2014 Nov 20;515
(7527):436–439. PubMed PMID: 25186730; PubMed Central
PMCID: PMC4899968.
32. Shen Y, Nandi P, Taylor MB, et al. RNA-driven genetic changes in
bacteria and in human cells. Mutat Res. 2011 Dec 1;717(1–2):91–
98. PubMed PMID: 21515292.
33. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radia-
tion-induced DNA double-strand breaks by non-homologous
end-joining. Biochem J. 2009 Feb 1;417:639–650.
34. Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of
PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol
Cell Biol. 2017 Oct;18(10):610–621. PubMed PMID: 28676700.
35. Escargueil AE, Soares DG, Salvador M, et al. What histone code
for DNA repair? Mutat Res. 2008 Mar–Apr;658(3):259–270.
PubMed PMID: 18296106.
36. Holoch D, Moazed D. RNAi in fission yeast finds new targets and
new ways of targeting at the nuclear periphery. Genes Dev. 2012
Apr 15;26(8):741–745. PubMed PMID: 22508721; PubMed
Central PMCID: PMC3337448.
37. Santos-Pereira JM, Aguilera A. R loops: new modulators of gen-
ome dynamics and function. Nat Rev Genet. 2015 Oct;16
(10):583–597. PubMed PMID: 26370899.
38. Chedin F. Nascent connections: R-loops and chromatin pattern-
ing. Trends Genet. 2016 Dec;32(12):828–838. PubMed PMID:
27793359; PubMed Central PMCID: PMC5123964.
39. Maiti S, Kumar KH, Castellani CA, et al. Ontogenetic de novo
copy number variations (CNVs) as a source of genetic individual-
ity: studies on two families with MZD twins for schizophrenia.
PLoS One. 2011 Mar 2;6(3):e17125. PubMed PMID: 21399695;
PubMed Central PMCID: PMC3047561.
40. Chiu CG, Nakamura Y, Chong KK, et al. Genome-wide char-
acterization of circulating tumor cells identifies novel prog-
nostic genomic alterations in systemic melanoma metastasis.
Clin Chem. 2014 Jun;60(6):873–885. PubMed PMID:
24718909.
41. Yashin AI, Wu D, Arbeeva LS, et al. Genetics of aging, health, and
survival: dynamic regulation of human longevity related traits.
Front Genet. 2015;6:122. PubMed PMID: 25918517; PubMed
Central PMCID: PMC4394697.





















































































































































































































































































Table S1. Proteins identified in co-IP/MS analysis 
Protein Name HEK293 NRDE2-3FLAG 3FLAG-Mtr4 
Mtr4  0 (0%) 228 (41.3%) 454 (49.5%) 
NRDE2   0 (0%) 226 (45.7%) 57 (23.1%) 
STK38   0 (0%) 34 (36.8%) 4 (14.6%) 
SPIN1   0 (0%) 25 (39.3%) 50 (67.6%) 
PRPF31   0 (0%) 24 (21.2%) 34 (39.5%) 
CCT3   0 (0%) 23 (42.2%) 32 (40.6%) 
C11orf84   0 (0%) 20 (30.7%) 80 (51.4%) 
TUBB2B   0 (0%) 18 (25.4%) 38 (20.2%) 
TUBB2A   0 (0%) 18 (25.4%) 38 (20.2%) 
TUBB3   0 (0%) 18 (23.3%) 24 (20.9%) 
EEF1A1   0 (0%) 17 (27.7%) 15 (23.4%) 
SPIN2A   0 (0%) 17 (8.1%) 6 (20.2%) 
SPIN2B   0 (0%) 17 (8.1%) 6 (20.2%) 
EEF1A1P5   0 (0%) 16 (22.7%) 15 (23.4%) 
ANKFY1   0 (0%) 14 (9.8%) 55 (37.3%) 
ATP5B  0 (0%) 12 (25.5%) 3 (9.1%) 
TUBB4A   0 (0%) 11 (27.7%) 45 (34.5%) 
XRCC5   0 (0%) 11 (15.7%) 38 (28.7%) 
EEF1A2   0 (0%) 11 (19.0%) 4 (4.1%) 
SPIN3   0 (0%) 10 (12.0%) 19 (29.8%) 
PARP1   0 (0%) 10 (6.4%) 9 (11.7%) 
HNRNPA2B1   0 (0%) 9 (12.2%) 18 (27.5%) 
TUBA4A   0 (0%) 9 (27.2%) 17 (27.2%) 
HIST1H4A   0 (0%) 8 (42.7%) 10 (35.9%) 
STK38L   0 (0%) 8 (13.4%) 2 (8.6%) 
ACTB  0 (0%) 7 (23.7%) 19 (5.9%) 
ACTG1  0 (0%) 7 (23.7%) 19 (5.9%) 
PRDX4   0 (0%) 7 (24.4%) 3 (14.4%) 
PSMC1   0 (0%) 7 (16.4%) 2 (8.2%) 
HNRNPU   0 (0%) 6 (9.9%) 31 (21.8%) 
TUBB6   0 (0%) 6 (11.7%) 28 (8.7%) 
TRIM28   0 (0%) 6 (11.7%) 19 (23.2%) 
NPM1   0 (0%) 6 (16.7%) 3 (18.4%) 
TAB1   0 (0%) 5 (16.1%) 16 (22.6%) 
SFPQ  0 (0%) 5 (5.2%) 15 (12.7%) 
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TUBA8   0 (0%) 5 (15.4%) 7 (21.6%) 
PSMB5   0 (0%) 5 (16.7%) 5 (23.2%) 
TUBB8   0 (0%) 4 (9.9%) 27 (9.0%) 
CLNS1A   0 (0%) 4 (23.2%) 25 (34.6%) 
XRCC6   0 (0%) 4 (8.5%) 10 (19.4%) 
MCM7   0 (0%) 4 (4.7%) 8 (9.9%) 
EEF1D   0 (0%) 4 (18.9%) 6 (26.0%) 
EEF1B2   0 (0%) 4 (37.3%) 5 (16.0%) 
PSMA2   0 (0%) 4 (20.9%) 4 (20.9%) 
Putative tubulin beta chain-like protein  0 (0%) 3 (7.8%) 26 (6.7%) 
Tubulin beta-8 chain-like protein  0 (0%) 3 (6.5%) 26 (5.6%) 
ACTA2  0 (0%) 3 (7.2%) 19 (5.8%) 
NONO   0 (0%) 3 (4.7%) 19 (25.9%) 
ACTA1  0 (0%) 3 (7.2%) 19 (5.8%) 
ACTC1  0 (0%) 3 (7.2%) 19 (5.8%) 
ACTG2  0 (0%) 3 (7.2%) 19 (5.9%) 
POTEE   0 (0%) 3 (3.6%) 16 (1.0%) 
MAP3K7   0 (0%) 3 (4.1%) 9 (11.1%) 
CALU   0 (0%) 3 (13.7%) 7 (34.6%) 
RBM5   0 (0%) 3 (0.9%) 7 (1.2%) 
RIOK1   0 (0%) 3 (8.3%) 6 (12.1%) 
DDB1   0 (0%) 3 (3.0%) 6 (5.3%) 
RBBP4   0 (0%) 3 (6.4%) 5 (12.7%) 
HNRNPF   0 (0%) 3 (8.7%) 5 (8.2%) 
H2AFJ   0 (0%) 3 (7.0%) 4 (20.9%) 
HIST1H2AJ   0 (0%) 3 (7.0%) 4 (21.1%) 
HIST2H2AC   0 (0%) 3 (7.0%) 4 (20.9%) 
PSMA6   0 (0%) 3 (12.2%) 4 (17.9%) 
HIST1H2AH   0 (0%) 3 (7.0%) 4 (21.1%) 
HIST1H2AG   0 (0%) 3 (6.9%) 4 (20.8%) 
HIST2H2AA3   0 (0%) 3 (6.9%) 4 (20.8%) 
HIST1H2AD   0 (0%) 3 (6.9%) 4 (20.8%) 
PSMB1   0 (0%) 3 (19.9%) 4 (29.0%) 
HIST1H2AC   0 (0%) 3 (6.9%) 3 (12.3%) 
H2AFX   0 (0%) 3 (6.3%) 3 (11.2%) 
HIST1H2AB   0 (0%) 3 (6.9%) 3 (12.3%) 
HIST3H2A   0 (0%) 3 (6.9%) 3 (12.3%) 
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HIST1H2AA   0 (0%) 3 (6.9%) 3 (12.2%) 
H2AFZ   0 (0%) 3 (7.0%) 3 (12.5%) 
PSMD2   0 (0%) 3 (4.0%) 3 (2.9%) 
H2AFV   0 (0%) 3 (7.0%) 3 (12.5%) 
PSMD7   0 (0%) 3 (7.4%) 3 (12.0%) 
PSMC4   0 (0%) 3 (9.1%) 2 (6.9%) 
PSMC3   0 (0%) 3 (4.1%) 2 (5.7%) 
HSPD1  0 (0%) 3 (5.9%) 2 (6.3%) 
ILF2   0 (0%) 3 (10.0%) 2 (5.1%) 
ACAP2  0 (0%) 2 (4.6%) 16 (12.7%) 
MATR3   0 (0%) 2 (3.8%) 12 (13.8%) 
MCM3   0 (0%) 2 (2.6%) 11 (17.3%) 
ACLY   0 (0%) 2 (3.9%) 8 (10.1%) 
GANAB   0 (0%) 2 (2.9%) 7 (5.7%) 
PPIL4   0 (0%) 2 (7.1%) 5 (12.4%) 
PSMB3   0 (0%) 2 (16.6%) 5 (32.2%) 
RUVBL2   0 (0%) 2 (7.1%) 5 (16.4%) 
PSMD12   0 (0%) 2 (5.3%) 4 (12.9%) 
PPM1B   0 (0%) 2 (6.5%) 4 (11.1%) 
PSMD11   0 (0%) 2 (2.6%) 3 (8.8%) 
ROCK1   0 (0%) 2 (2.7%) 3 (4.7%) 
PPP2R2A   0 (0%) 2 (3.4%) 3 (13.9%) 
SNRNP200   0 (0%) 2 (1.8%) 3 (1.9%) 
HNRNPH2   0 (0%) 2 (3.8%) 2 (7.6%) 
TUBA4B   0 (0%) 2 (8.7%) 2 (11.6%) 
COPA   0 (0%) 2 (2.4%) 2 (1.8%) 
JPH2   0 (0%) 6 (3.2%)  0 (0%) 
PSMD3   0 (0%) 4 (10.3%)  0 (0%) 
KIF11   0 (0%) 4 (5.5%)  0 (0%) 
MYL6   0 (0%) 4 (16.6%)  0 (0%) 
FLNC   0 (0%) 3 (1.7%)  0 (0%) 
DPH7   0 (0%) 3 (1.5%)  0 (0%) 
SMC1A   0 (0%) 3 (3.2%)  0 (0%) 
TUBB1   0 (0%) 3 (6.4%)  0 (0%) 
ACTBL2   0 (0%) 3 (7.2%)  0 (0%) 
PSMC5   0 (0%) 3 (4.7%)  0 (0%) 
SF3B2   0 (0%) 3 (3.6%)  0 (0%) 
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HIST2H2AB   0 (0%) 3 (6.9%)  0 (0%) 
CSNK2A1   0 (0%) 3 (11.0%)  0 (0%) 
GOLPH3   0 (0%) 2 (3.7%)  0 (0%) 
ATP1A1   0 (0%) 2 (3.8%)  0 (0%) 
EPRS   0 (0%) 2 (1.5%)  0 (0%) 
CSNK2A2   0 (0%) 2 (10.6%)  0 (0%) 
PSMA3   0 (0%) 2 (2.4%)  0 (0%) 
PSMD6   0 (0%) 2 (6.2%)  0 (0%) 
SMC3   0 (0%) 2 (2.1%)  0 (0%) 
BMS1   0 (0%) 2 (1.9%)  0 (0%) 
SHC1   0 (0%)  0 (0%) 112 (1.4%) 
EXOSC10   0 (0%)  0 (0%) 55 (30.4%) 
PABPC1   0 (0%)  0 (0%) 23 (20.3%) 
EXOSC2   0 (0%)  0 (0%) 22 (29.4%) 
PABPC3   0 (0%)  0 (0%) 19 (12.7%) 
ZFC3H1   0 (0%)  0 (0%) 19 (12.4%) 
C1QBP  0 (0%)  0 (0%) 19 (39.7%) 
POTEKP   0 (0%)  0 (0%) 16 (2.9%) 
POTEI   0 (0%)  0 (0%) 16 (1.0%) 
EXOSC6   0 (0%)  0 (0%) 16 (26.8%) 
POTEF   0 (0%)  0 (0%) 16 (1.0%) 
HSP90AA5P   0 (0%)  0 (0%) 15 (4.5%) 
CERS3   0 (0%)  0 (0%) 15 (5.0%) 
EXOSC1   0 (0%)  0 (0%) 14 (29.2%) 
NT5C2   0 (0%)  0 (0%) 14 (15.2%) 
PFKFB3  0 (0%)  0 (0%) 14 (23.8%) 
EXOSC3   0 (0%)  0 (0%) 13 (26.5%) 
ZCCHC8   0 (0%)  0 (0%) 13 (18.1%) 
RCN2   0 (0%)  0 (0%) 12 (37.9%) 
CSHL1   0 (0%)  0 (0%) 11 (3.6%) 
CSH1   0 (0%)  0 (0%) 11 (3.7%) 
GH1   0 (0%)  0 (0%) 11 (3.7%) 
GH2   0 (0%)  0 (0%) 11 (3.7%) 
EXOSC9   0 (0%)  0 (0%) 11 (21.9%) 
IPO8   0 (0%)  0 (0%) 11 (11.8%) 
GTF2I   0 (0%)  0 (0%) 11 (8.2%) 
MTHFD1L  0 (0%)  0 (0%) 10 (14.1%) 
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DDX3X   0 (0%)  0 (0%) 10 (14.0%) 
SRRT   0 (0%)  0 (0%) 9 (13.0%) 
USP15   0 (0%)  0 (0%) 8 (12.5%) 
SNRPD3   0 (0%)  0 (0%) 8 (15.1%) 
ALYREF   0 (0%)  0 (0%) 8 (24.5%) 
IMPDH2   0 (0%)  0 (0%) 8 (12.3%) 
MCM6   0 (0%)  0 (0%) 7 (8.3%) 
JAK1   0 (0%)  0 (0%) 7 (4.9%) 
USP7   0 (0%)  0 (0%) 7 (8.2%) 
EXOSC5   0 (0%)  0 (0%) 7 (22.1%) 
DHX15   0 (0%)  0 (0%) 7 (9.3%) 
EXOSC7   0 (0%)  0 (0%) 7 (32.6%) 
DDX3Y   0 (0%)  0 (0%) 7 (6.8%) 
EXOSC8   0 (0%)  0 (0%) 7 (21.0%) 
CCT6B   0 (0%)  0 (0%) 7 (5.7%) 
PFKFB2  0 (0%)  0 (0%) 6 (6.5%) 
PRMT1   0 (0%)  0 (0%) 6 (19.7%) 
SNRPD2   0 (0%)  0 (0%) 6 (29.7%) 
EXOSC4   0 (0%)  0 (0%) 5 (11.0%) 
NAP1L1   0 (0%)  0 (0%) 5 (19.9%) 
MCM5   0 (0%)  0 (0%) 5 (8.6%) 
PSMA4   0 (0%)  0 (0%) 5 (33.7%) 
PPP2R1A   0 (0%)  0 (0%) 5 (9.5%) 
DDX5   0 (0%)  0 (0%) 5 (7.7%) 
DHX38   0 (0%)  0 (0%) 5 (3.7%) 
YWHAZ   0 (0%)  0 (0%) 5 (20.0%) 
KPNB1   0 (0%)  0 (0%) 5 (6.3%) 
PUF60   0 (0%)  0 (0%) 5 (13.8%) 
YWHAG   0 (0%)  0 (0%) 5 (23.1%) 
EIF3E   0 (0%)  0 (0%) 4 (10.1%) 
NUDT21   0 (0%)  0 (0%) 4 (14.1%) 
SRSF11   0 (0%)  0 (0%) 4 (8.1%) 
PSMA8   0 (0%)  0 (0%) 4 (15.2%) 
KPNA2   0 (0%)  0 (0%) 4 (14.6%) 
LRPPRC  0 (0%)  0 (0%) 4 (5.0%) 
CANX   0 (0%)  0 (0%) 4 (8.8%) 
HNRNPA1   0 (0%)  0 (0%) 4 (11.0%) 
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NCL   0 (0%)  0 (0%) 4 (7.3%) 
SF3B3   0 (0%)  0 (0%) 4 (4.4%) 
HNRNPA1L2   0 (0%)  0 (0%) 4 (12.8%) 
HNRNPA3   0 (0%)  0 (0%) 4 (12.4%) 
TAB2   0 (0%)  0 (0%) 4 (10.0%) 
RBM6   0 (0%)  0 (0%) 4 (0.6%) 
EIF3B   0 (0%)  0 (0%) 4 (8.7%) 
U2AF2   0 (0%)  0 (0%) 4 (9.7%) 
SNRPN   0 (0%)  0 (0%) 4 (15.4%) 
HSPH1   0 (0%)  0 (0%) 4 (5.4%) 
PAICS   0 (0%)  0 (0%) 4 (13.2%) 
YWHAB   0 (0%)  0 (0%) 4 (15.0%) 
SNRPB   0 (0%)  0 (0%) 4 (15.4%) 
PSMA5   0 (0%)  0 (0%) 3 (17.0%) 
PSMB4   0 (0%)  0 (0%) 3 (25.0%) 
HSP90AA2   0 (0%)  0 (0%) 3 (9.3%) 
PPP2CA   0 (0%)  0 (0%) 3 (12.9%) 
SPIN4   0 (0%)  0 (0%) 3 (2.8%) 
HNRNPD   0 (0%)  0 (0%) 3 (7.6%) 
HNRNPR   0 (0%)  0 (0%) 3 (6.2%) 
COPRS   0 (0%)  0 (0%) 3 (15.8%) 
SRP9   0 (0%)  0 (0%) 3 (25.6%) 
TAF4   0 (0%)  0 (0%) 3 (4.1%) 
PABPC1L   0 (0%)  0 (0%) 3 (5.4%) 
RBBP7   0 (0%)  0 (0%) 3 (12.7%) 
YWHAQ   0 (0%)  0 (0%) 3 (7.3%) 
PPP2CB   0 (0%)  0 (0%) 3 (12.9%) 
SMC2   0 (0%)  0 (0%) 3 (3.9%) 
HNRNPDL   0 (0%)  0 (0%) 3 (6.4%) 
PABPC4   0 (0%)  0 (0%) 3 (6.5%) 
YWHAH   0 (0%)  0 (0%) 3 (7.3%) 
2-Sep  0 (0%)  0 (0%) 3 (12.5%) 
PSMD1   0 (0%)  0 (0%) 3 (5.2%) 
PRDX2   0 (0%)  0 (0%) 3 (14.1%) 
MPHOSPH6   0 (0%)  0 (0%) 3 (11.2%) 
SLC25A6   0 (0%)  0 (0%) 3 (11.4%) 
DDX17   0 (0%)  0 (0%) 3 (3.2%) 
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SNRPB2   0 (0%)  0 (0%) 3 (12.0%) 
OAT  0 (0%)  0 (0%) 3 (17.3%) 
SFN   0 (0%)  0 (0%) 3 (7.3%) 
DHX9   0 (0%)  0 (0%) 3 (3.5%) 
HNRNPL   0 (0%)  0 (0%) 3 (4.6%) 
COPB2   0 (0%)  0 (0%) 2 (4.0%) 
KLC1   0 (0%)  0 (0%) 2 (4.7%) 
ACTN4   0 (0%)  0 (0%) 2 (2.5%) 
CKAP5   0 (0%)  0 (0%) 2 (1.8%) 
SF3B14   0 (0%)  0 (0%) 2 (20.8%) 
EIF4A2   0 (0%)  0 (0%) 2 (5.7%) 
RBM7   0 (0%)  0 (0%) 2 (6.8%) 
TTLL12   0 (0%)  0 (0%) 2 (4.0%) 
EIF3A   0 (0%)  0 (0%) 2 (1.9%) 
SNRNPE   0 (0%)  0 (0%) 2 (17.1%) 
SRP14   0 (0%)  0 (0%) 2 (17.6%) 
CPVL   0 (0%)  0 (0%) 2 (3.2%) 
GAPDH   0 (0%)  0 (0%) 2 (12.8%) 
TBC1D4   0 (0%)  0 (0%) 2 (2.0%) 
SPAG9   0 (0%)  0 (0%) 2 (2.4%) 
SNRPA   0 (0%)  0 (0%) 2 (2.8%) 
PHGDH   0 (0%)  0 (0%) 2 (1.5%) 
SLC25A5   0 (0%)  0 (0%) 2 (7.0%) 
HNRNPM   0 (0%)  0 (0%) 2 (4.7%) 
AP3B1   0 (0%)  0 (0%) 2 (2.7%) 
KLC2   0 (0%)  0 (0%) 2 (6.9%) 
PSMD14   0 (0%)  0 (0%) 2 (12.6%) 
RPS7   0 (0%)  0 (0%) 2 (5.7%) 
SRPK1   0 (0%)  0 (0%) 2 (6.1%) 
PPIB   0 (0%)  0 (0%) 2 (11.6%) 
SNRPG   0 (0%)  0 (0%) 2 (17.1%) 
SNRPE   0 (0%)  0 (0%) 2 (13.0%) 
EEF2   0 (0%)  0 (0%) 2 (4.4%) 
EIF4A1   0 (0%)  0 (0%) 2 (5.7%) 
CPSF6   0 (0%)  0 (0%) 2 (5.1%) 
XPO1   0 (0%)  0 (0%) 2 (2.8%) 
SHMT2  0 (0%)  0 (0%) 2 (6.9%) 
249
ROCK2   0 (0%)  0 (0%) 2 (1.9%) 
HSPA4L   0 (0%)  0 (0%) 2 (3.6%) 
G3BP1   0 (0%)  0 (0%) 2 (5.6%) 
HNRNPA0   0 (0%)  0 (0%) 2 (6.6%) 
HBB   0 (0%)  0 (0%) 2 (19.7%) 
ACTN1   0 (0%)  0 (0%) 2 (2.6%) 
ARHGEF10   0 (0%)  0 (0%) 2 (2.2%) 
PRSS3P2   0 (0%)  0 (0%) 2 (10.1%) 
COPB1   0 (0%)  0 (0%) 2 (3.0%) 
HDAC2   0 (0%)  0 (0%) 2 (6.4%) 
KHSRP   0 (0%)  0 (0%) 2 (3.1%) 
ARCN1   0 (0%)  0 (0%) 2 (4.5%) 
DDX6   0 (0%)  0 (0%) 2 (5.4%) 
SNRNP70   0 (0%)  0 (0%) 2 (5.0%) 
STIP1   0 (0%)  0 (0%) 2 (5.5%) 
GART   0 (0%)  0 (0%) 2 (2.4%) 
ATP5C1  0 (0%)  0 (0%) 2 (8.4%) 
EIF3L   0 (0%)  0 (0%) 2 (4.8%) 
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